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Abstract  
 
This study reports the development of a new molecular scaffold based on human Chaperonin 
10 (hCpn10), for the development of protein-based new molecular entities (NMEs) of 
diagnostic and therapeutic potential. The aims were to establish the fundamental basis of a 
molecular design for the scaffold, to enable the display of non-native peptides with binding 
activity to selected targets, while maintaining structural integrity and native heptameric 
conformation. 
 
Recently there has been much global interest in developing NMEs of protein and peptide 
origin, as therapeutic agents and diagnostic reagents. A class of NMEs are based on 
molecular scaffolds, whereby peptides with binding activity to a given target are displayed on 
a protein backbone or scaffold. The molecular scaffold provides a rigid folding unit which 
spatially brings together several exposed peptide loops, forming an extended interface that 
ensures tight binding of the target. Monoclonal antibodies (mAbs) are in essence molecular 
scaffolds, whereby complementarity determining regions, otherwise known as CDR peptide 
loops, extend from a framework and contact antigen. mAbs have been widely utilised in the 
life sciences and biopharmaceutical industries for the development of diagnostic probes and 
biologic medicines, respectively. However the current patent landscape surrounding mAbs is 
complex and commercialisation of newly developed antibodies can be hampered by licensing 
agreements and royalty stacking.  
 
Molecular scaffolds are an alternative to antibodies, and some of the scaffolds in 
development include lipocalins, fibronectin domain, DARPins consensus repeat domain and 
avimers, to name a few. hCpn10 is a homo-oligomer composed of seven subunits. Each 
hCpn10 monomer is composed of a β-barrel core structure that is flanked by two flexible 
loops, known as the β-hairpin and mobile loop. It is proposed the mobile could be substituted 
with peptides and so increase the apparent affinity to a given target compared to that of naked 
peptides, due to avidity conferred by the heptameric structure. This study focussed on 
assessing the properties of hCpn10 and determining whether this molecule could be utilised 
as a scaffold for the development of NMEs that have binding activity to selected targets.  
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In the first example of the utility of hCpn10 as a molecular scaffold, the E-76 peptide, which 
binds to Factor VIIa (FVIIa) of the extrinsic coagulation cascade pathway, was substituted 
into the mobile loop region of hCpn10 creating a NME designated CE76 with anticoagulant 
activity. Anticoagulants prevent blood from clotting and have clinical applications associated 
with coronary heart disease and stroke. Common anticoagulants include heparin, warfarin, 
and dicoumarol. Although these compounds have proved beneficial they are not without 
complications and side effects. An NME has been created through display of the E-76 peptide 
on the hCpn10 scaffold, creating the highly avid CE76, which binds FVIIa with sub-
nanomolar affinity.  
 
Prior to creation of CE76 NME, molecular dynamic (MD) simulation studies were conducted 
in order to optimise linkers at the N- and C-junctures of the mobile loop, so as to optimise 
mobile loop orientation and conserve native-like heptamer formation. Simulation studies 
revealed that inserting proline residues at both ends of the mobile loop region stabilized the 
new CE76 variants (named CE76P1) and facilitated heptamer assembly. Characterisation by 
size exclusion chromatography confirmed CE76P1 formed a stable heptamer, and bound 
specifically to the exosite of FVIIa, and subsequently inhibited the activation of Factor X 
(IC50 1.5 nM). CE76P1 prologed the extrinsic pathway 4-fold higher than E-76 alone, while 
not affecting the intrinsic coagulation cascade as determined by prothrombin time (PT) and 
thromboelastography (TEG) assays. CE76P1 has the potential to be a new biologic drug with 
potent anticoagulant properties.  
 
The utility of hCpn10 as a molecular scaffold was further assessed by incorporating P7 
peptide into the mobile loop, creating a NME designated CP7. P7 peptide binds to CD44, 
which is overexpressed in cancers of the breast, colon, prostate and brain. Binding studies 
revealed that CP7 bound specifically to recombinant CD44 (KD 1.32 nM), while no binding 
was detected to surface protein CD24. Immunofluorescence imaging and flow cytometry 
studies showed increased binding activity of CP7 to breast adenocarcinoma MDA-MB-486 
cells compared to P7 peptide alone. Further expression studies using peptides that bind 
VEGFR and FGFR, were incorporated into hCpn10 scaffold also resulted in correct assembly 
of heptamer. 
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Based on these studies associated with the incorporation of selected peptides into the hCpn10 
scaffold, it is evident that hCpn10 can be utilised as a molecular scaffold for the developing 
of NMEs with therapeutic and diagnostic potential. The demonstration that human Cpn10 is a 
useful molecular scaffold for the creation of NMEs in a “beyond antibody” approach offers 
the opportunity to create new intellectual property in the area of biologic medicines and 
bioanalytical reagents/diagnostics. 
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Chapter 1.  Engineering the Next-Generation of Non-Antibody 
Molecular Scaffolds 
 
 
1.1 General introduction 
 
Therapeutic agents and diagnostic reagents are a crucial component of the commercial 
activities of the Life Sciences and Biopharmaceutical industries. Monoclonal antibodies 
(mAbs) are the fastest growing class of biologic medicines, while mAbs are used extensively 
as components in various forms of diagnostic tests and immunologically-based assays, and as 
analytical reagents. mAbs immobilised on resins and matrices are also used for purifying 
recombinant protein biologics, and at the laboratory scale for purifying proteins of interest 
from tissue lysates or cell culture supernatants. The reason why mAbs are key products of 
these industries is that they are able to bind potentially to any molecular entity that exists in 
nature, including macromolecular structures, small organic molecules and some materials. 
The basic design of an antibody facilitates peptide loops to extend from the antibody scaffold 
and make contact with a target surface, resulting in binding. 
 
Although mAbs are versatile molecular entities and have evolved to have exquisite specificity 
as nature’s preferred scaffold, there are other molecular entities beyond antibodies that are 
able to bind specifically to a target, in a similar fashion to the manner that antibodies bind to 
their target. These molecular scaffolds or macrocycles bind to their target through the 
physicochemical interaction of a peptide loop or peptide domain with another surface, 
resulting in binding of the two entities. As with antibodies the weak molecular forces involve 
salt bridges and ionic interactions, hydrophobic interactions and van der Waals forces, and 
the overall binding strength is a summation of the number and nature of these 
physicochemical interactions, and the strength of each individual interaction. 
 
Antibodies have been the cornerstone of the success of the Life Sciences and 
Biopharmaceutical industries. As antibodies are a crucial part of the immune system and are 
nature’s preferred scaffold, the following paragraphs will incorporate descriptions of the 
immune system, antibody structure and antibody production. The similarity and differences 
between antibodies and other molecular scaffolds will be compared and contrasted, and the 
structures of various molecular scaffolds will be described. 
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The novel human chaperonin 10 (hCpn10) scaffold, the subject of the research described in 
this thesis, is introduced and proposed as a new molecular scaffold with application in the 
therapeutic and diagnostic areas. The hypothesis put forward in this thesis is that the mobile 
loop of hCpn10 can be substituted with non-hCpn10 peptide sequence, and that new 
molecular entities (NME) can be created with binding specificity to specific targets. It is also 
hypothesised that peptide substitution will not hinder the assembly of hCpn10 heptamer from 
monomer. The hypothesis is tested through the creation of several NMEs based on hCpn10 
and demonstration of binding to the target. The NMEs created in this research have both 
therapeutic and diagnostic value, and the process of intellectual property protection is now 
underway.  
 
1.1.1 The immune system, antibodies and antibody structure 
 
The immune system, a network of cells, tissues and organs, is the body’s defence against 
infections and diseases. It responds to pathogens and other foreign bodies by producing 
antibodies, which binds to various molecules with high affinity and specificity. Antibodies 
are a naturally occurring molecular scaffold that are produced and secreted by B-cells of the 
acquired immune system. The specificity of an antibody towards a foreign molecule is made 
possible through immunoglobulin gene rearrangement in hematopoietic stem cells to give rise 
to the B-cell lineage. Subsequently, antibodies with the highest affinity towards an antigen 
are naturally selected by the immune system for clonal expansion and propagation in larger 
numbers (Janeway et al., 2001). Antibodies are either monoclonal or polyclonal depending on 
the recognition of epitope per antigen. Monoclonal antibodies (mAbs) are derived from a 
single B-cell clone with specificity towards a single antigenic determinant (Birch and 
Onakunle, 2005), while polyclonal antibodies are derived from multiple clones of B-cells that 
produce antibodies binding to different epitopes on single antigen (Burry, 2010). 
 
Antibodies have complex structures composed of two heavy and two light chains linked by 
disulphide bonds. This in turn gives rise to a quaternary structure that closely resembles a Y 
shape (Figure 1.1). The structure of the antibody can be further subdivided into two major 
regions, namely, the Fc (Fragment, crystallisable) region and the Fab (Fragment, antigen-
binding) region. The Fc region, which forms part of the heavy chain, has an effector function 
whereby the complement system and/or antibody dependent cytotoxicity can be initiated. The 
Fab region or the antigen binding site, which has both heavy and light chains, is responsible 
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for interacting with the foreign antigen. The antigen binding site is composed of six 
complementarity determining regions (CDRs), with three CDRs in both the heavy and light 
chains. Interaction with the antigen is dependent on all six CDRs working in synergy. The 
CDRs within both chains are interconnected by eight β-strands that serve as a scaffold for the 
CDR regions. Of all sequence within the variable domain, the CDRs have the highest 
sequence diversity which is developed through cycles of somatic mutation and clonal 
expansion (Marks, 2009, Skerra, 2000a, Tramontano and Lesk, 1992). In comparison to 
CDR1 and CDR2, CDR3 has the longest average peptide length, the largest contact surface 
and is frequently the greatest contributor towards antigen binding (Rees et al., 1994).  
 
 
Figure ‎1.1  Structural and schematic representations of an antibody 
Structure of a mouse IgG1 (PDB ID 1IGY). The heavy chain is shown in blue, light chain in green 
and glycosylation in orange in both representations of the antibody. (A) A ribbon representation of the 
secondary structure of the antibody. (B) A space-filled model representation of the same molecule. 
(C) An enlargement of the variable domain shown in ribbon representation of the β-sheet framework 
and antigen binding CDR1, 2 and 3 loops. Figure adapted from AbsoluteAntibody (2014).  
 
1.1.2 Monoclonal antibodies (mAbs) and the biopharmaceutical 
industry 
 
mAbs are the largest class of biologics, and are able to treat a wide variety of diseases 
indications including chronic conditions such as cancer and inflammatory disease, and also 
infectious disease.  mAbs may be produced through conventional hybridoma technology, or 
through recombinant DNA methodologies that include antibody engineering, phage display 
A.                                    B.                                            
                                                                                       C.  
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and transgenic mouse technologies. A number of mAbs have already been approved for 
cancer therapy and for the treatment of some autoimmune and infectious diseases with 
varying degrees of success. Examples of these mAbs are Herceptin
®
 (trastuzumab) for breast 
and lung cancer treatment (Nakamura et al., 2005) and Avastin
®
 (Bevacizumab) for the 
inhibition of angiogenesis in non-small cell lung cancer (Cohen et al., 2007). In some cases 
due to their large size and complex molecular structure, mAbs, have some limitations as 
therapeutic agents. Furthermore, the cost of discovery to actual usage of novel mAbs is quite 
high, exceeding $US 1.2 billion (Nelson and Reichert, 2009, Steinmeyer and McCormick, 
2008). This is because mAbs are manufactured by biopharmaceutical companies using large 
scale mammalian cell culture aiming for a high gross margins of between 80-85 %, in order 
to recoup the high cost of mAb development of $US 300-500 million per annum over a 
significant period of time (7-10 years). Therapeutic mAbs cost around $US 2,000-10,000 per 
treatment with an annual cost of $US 20,000-100,000 per patient being treated for serious 
illness (Hassett and Elkin, 2013, Samaranayake et al., 2009). 
 
In addition to having a structure of two sets of heavy and light chains stabilised through 
disulphide bonds, complete, full length mAbs are glycosylated, which is critical for its 
functionality and therefore, can only be expressed and purified from mammalian systems 
such as Chinese hamster ovary (CHO) or Human Embryonic Kidney (HEK) cells, or in 
yeasts such as Pichia pastoris. As previously mentioned, large scale manufacturing of mAbs 
using eukaryotic expression systems incurs high costs and is labour intensive (Steinmeyer 
and McCormick, 2008). In addition, the therapeutic efficacy of mAbs can be limited in some 
cases due to their relatively large size, (≥ 150 kDa) since full length mAbs cannot penetrate 
deep into the tissues or into solid tumours. Moreover, antibodies cannot target critical 
intracellular molecules that are implicated in uninhibited cancer cell proliferation (Beck et al., 
2008). Regarding thermodynamic stability, mAbs are sensitive to higher temperatures and 
require optimum storage conditions whereby temperatures below 4 °C are ideal in order to 
retain therapeutic efficacy (Gebauer and Skerra, 2009). Importantly, acquiring intellectual 
property (IP) protection for new mAbs is complicated by the relatively large number of 
patents that have already been granted (Beck et al., 2008, Kontermann, 2010). Therefore, it is 
important to look beyond conventional antibodies for the development of new molecular 
entities (NMEs) with target binding capabilities that are not only scalable for production of 
kilogram quantities, but also provide opportunities for a robust IP portfolio. 
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1.1.3 Non-antibody molecular scaffolds 
 
For the past 15-20 years, researchers have been developing alternative binding entities using 
different antibody and non-antibody scaffolds. Antibody-derived scaffolds are beyond the 
scope of this study and have been reviewed elsewhere (Holliger and Hudson, 2005, Nelson 
and Reichert, 2009, DS, 2012). Through advancements in recombinant DNA technology, 
next generation biologics have been derived from endogenous protein scaffolds and have 
been modified in such a manner that they possess the antigen binding properties of 
conventional mAbs but with the added advantage in some cases of lower cost of production 
and thermal stability.  
 
Non-antibody scaffolds are defined by Binz et al. (2005), as “a framework that can carry 
altered amino acid or sequence insertions that confer on protein variants different functions, 
usually for binding specific targets”. The ideal molecular scaffold must retain the properties 
of conventional mAbs, i.e. target specificity and affinity, and secondly, have a higher degree 
of structural stability with a lower molecular weight (<100 kDa). This is particularly 
important in the field of oncology for example, since an enhancement of the tissue 
penetrating properties of the molecular scaffold ensures a higher therapeutic efficacy against 
solid tumours. From a commercial perspective, non-antibody scaffolds have the potential to 
generate new IP that will not be hindered by the current complex landscape in the 
development of conventional mAbs. 
 
More than 50 non-antibody derived proteins have already been identified as alternative 
scaffolds for various basic and applied research applications in the field of biopharmaceutical 
development (Wurch et al., 2012, Lofblom et al., 2011, Gebauer and Skerra, 2009, Nuttall 
and Walsh, 2008, Gill and Damle, 2006). The antibody’s genetic engineering platforms have 
facilitated further design and development of such molecular scaffolds and there are currently 
many more platforms used for the research and development of such alternative-binding 
molecules. 
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Two most commonly used protein engineering platforms are the combinatorial and rational 
engineering approaches, summarised in Table 1.1. Utilising either of these two platforms, 
naturally occurring proteins can be genetically engineered to specifically recognize and bind 
to a potential target though modification of the binding site (Kontermann, 2010, Wurch et al., 
2012, Gebauer and Skerra, 2009). Table 1.1 shows that for each engineering platform, there 
are various possible locations of engineered binding-sites, associated screening/selection 
methodologies and selected examples for each scaffold platform technology. 
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Table ‎1.1  Non-antibody scaffold platform 
 Engineering Platform Engineering Site(s) Selection Method(s) Scaffold Example(s) Reference(s) 
I. Combinatorial Engineering Approaches: 
 Flat surface randomisation  α-helices   Phage display. Affibody (Protein Z) (Nord et al., 1997) 
 
Loop randomisation  Loop(s) 
Phage display;  
mRNA display; &  
Yeast two-hybrid display. 
10
FN3 (Fibronectin)  
(Koide et al., 1998, Xu 
et al., 2002, Hackel et 
al., 2008) 
 Cavity randomisation  β-barrel  Phage display, & 
Ribosome display. 
Anticalin (Lipocalin)  (Beste et al., 1999, Liu 
et al., 2012) 
 Multiple-sites randomisation  β-hairpin & α-helices  Ribosome display. DARPins (Ankyrin repeat)  (Binz et al., 2004) 
 Random peptide insertion  Random sites Flagellin fusion; & 
Yeast two-hybrid display. 
Aptamers (Thioredoxin)  
(Lu et al., 1995, Colas 
et al., 1996) 
 Error-prone PCR Undefined position(s)  Yeast two-hybrid. PDZ domain (Schneider et al., 1999) 
II. Rational Engineering Approaches: 
 Grafting Loop  Traditional ELISA assays, 
SPR measurements , & etc. 
Neocarzinostatin (NCS)  (Nicaise et al., 2004) 
 
 Loop Computational modelling. 
CE76FVIIa 
CP7CD44 
Unpublished/ 
Chapters 4 & 5 
 “De novo” Rational design De novo binding-site Automated design procedures. Ribose-binding protein (RBP) (Looger et al., 2003) 
  De novo α-helices Computational strategies (Fe4S4)-Cluster protein (Grzyb et al., 2010) 
  De novo α-helices & 
β-barrel 
De Novo protein Computational 
strategy 
Top7 (Kuhlman et al., 2003) 
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1.2 Alternative molecular scaffolds 
 
While mAbs have been spectacularly successful in the clinic, there is much global research 
activity at present associated with the discovery of NMEs based on conferring functionality 
within a protein scaffold, whereby binding domains can be engineered within loop structures 
or flat surfaces, for example, without interrupting the folding or structural integrity of the 
protein scaffold. These surface exposed residues can be utilised as binding entities towards 
various antigens and possess different secondary structures such as α-helical bundles, β-
strands configurations or spatial loops. These sites can be modified by a variety of protein 
engineering strategies without significantly affecting the core protein framework (Table 1.1). 
There are a number of molecular scaffolds in various stages of clinical development and are 
described in Tables 1.2 to 1.4. These scaffolds are not only diverse in size, topology and 
modes of interaction but they also demonstrate the properties critical to designing proteins 
with synthetic binding-sites to be used in a variety of applications (Figure 1.2). Non-antibody 
based scaffolds for use in therapeutics and diagnostics will serve as an alternative to naturally 
occurring antibodies and potentially overcome some of the structural limitations of mAbs.  
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Figure ‎1.2  Non-antibody molecular scaffolds 
Schematic representations of protein backbones used as scaffolds for generating protein-binding 
agents: (A) α-helix bundle, Affibody (PDB ID. 2B89); (B) α-helix bundle & β-barrel, Aptamer (PDB 
ID. 1TXX); (C) Loop, Kuntiz (PDB ID. 4DTG); (D) β-sandwich & loop, Fibronectin (FN3) (PDB 
ID. 1TTG); (E) β-barrel bundle & loop, Neocarzinostatin (PDB ID. 2G0K); (F) β-barrel & loop, 
Anticalin (PDB ID. 1LNM) of lipocalin; (G) bundle & loop, Avimer (PDB ID. 1LDL); and (H) α-
helix bundle & β-turn repeat unit, DARPin (PDB ID. 2BKK) of ankyrin repeat protein. These are 
examples of molecular based-scaffold; however, they differ from each other in terms of size, topology 
and modes of interaction with target protein/antigen. All molecular structures are shown in ribbon 
representation and were modelled using UCSF Chimera1.5.3. 
  
G.                               H. 
D.                                                             F. 
A.                      B.                                             C. 
                      E.                                           
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The general design principle in engineering protein scaffolds is to introduce residue(s)/ 
peptide sequence(s) with a specific function(s) into a specific region of the protein scaffold 
without compromising protein folding and overall stability (Skerra, 2007a, Skerra, 2000a, 
Mathonet and Fastrez, 2004). It has been observed that many molecular entities exist 
whereby for example, certain endogenous loop structures can be replaced with non-native 
peptide sequence. This provides an opportunity to develop NMEs using these non-antibody 
based scaffolds. Ideally, the non-antibody molecular scaffold should be small, robust and 
economical when scaled in prokaryotic expression systems.  
 
Despite the favourable outcomes expected in utilising non-antibody scaffolds for therapeutic 
or diagnostic purposes, only a few such biological entities have either reached clinical trials 
(Table 1.2). As an example, Ecallantide (a DX-88 derived from the kuntiz domain), which is 
a kallikrein inhibitor, is the first non-antibody, scaffold-based biologic to be approved by the 
US Food and Drug Administration (FDA) in 2009 for the treatment of acute hereditary 
angioedema (HAE) and the prevention of blood loss in cardiothoracic surgery (Bernstein and 
Moellman, 2012). The success of Ecallantide demonstrates that non-antibody scaffolds can 
be used in the treatment of various diseases. Others are being investigated for their 
application as in vivo/in vitro diagnostic agents for various diseases (Table 1.3). A number of 
molecular scaffolds have been extensively studied for their use in a wide range of 
biotechnological applications (Table 1.4), including affibodies, fibronectin, lipocalin, 
ankyrin, kunitz domain and others. In the following sections, each of these non-antibody 
scaffolds isare described in detail. 
 
1.2.1 Protein A (Affibody) 
 
Affibodies are derived from the Staphylococcus aureus protein A which is known to bind to 
the Fc domain of immunoglobulins (Nord et al., 1997). Affibodies consist of three α-helices 
with no disulfide linkage and have the capacity to display reversible folding (Figure 1.2). 
Affibodies have been developed through combinatorial protein design and selected via phage 
display for a range of therapeutic applications such as tumour targeting (Friedman et al., 
2008). Affibody ZHER, for example, is a high affinity affibody that binds to the cell surface of 
human epidermal growth factor receptor 2 (HER2) and is now undergoing Phase I clinical 
trial for the treatment of breast cancer (Wikman et al., 2004) (Table 1.2). Affibodies have 
also shown promise as in vitro diagnostic reagents and for tumour imaging for detecting 
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positive HER2 expression (Nilsson and Tolmachev, 2007) (Table 1.3). As summarised in 
Table 1.4, Affibodies have also been utilised in bio-purifications (Nord et al., 2000) and as 
analytical reagents (Karlstrom and Nygren, 2001). 
 
1.2.2 Fibronectin (Monobody) 
 
Fibronectin type III (FN3), derived from the tenth FN type III domain in human fibronectin 
(
10
FN3) (Koide and Koide, 2007, Koide et al., 1998) has an antibody-like structure that 
displays CDR-like loops (Figure 1.2). In contrast to antibodies, FN3 does not rely on 
disulfide cross-linking for folding, and thus has a higher thermodynamic stability (Koide et 
al., 1998). The use of 
10
FN3, alternatively known as a Monobody or Adnectine, was first 
proposed as a scaffold as it has the combined features of having a small size and high 
structural stability, all of which are favourable properties for an NME intended for 
therapeutic use (Bloom and Calabro, 2009). A library of diverse Monobodies have been 
developed through combinatorial engineering approaches, whereby individual binding clones 
can be isolated through various selection strategies such as phage, mRNA, or yeast displays 
approaches (Table 1.1). Overall, due to its structural stability combined with the absence of 
disulfides, fibronectin is speculated to have similar binding capabilities as that of 
conventional antibodies, and can therefore be applied to cellular targeting (Table 1.2), 
(Getmanova et al., 2006, Karatan et al., 2004, Koide et al., 2002). Monobodies have been 
successfully applied to the treatment of cancer.; Ffor example, a Monobody reactive to 
vascular endothelial growth factor receptor 2 (VEGFR2), has been used to inhibit 
angiogenesis in tumours (Table 1.2), (Getmanova et al., 2006). 
 
1.2.3 Lipocalin (Anticalin) 
 
The Anticalin scaffold is derived from the lipocalin family proteins of various species such as 
humans and insects (Skerra, 2000b, Skerra, 2001, Beste et al., 1999). The term Anticalin is 
derived from the combination of antibody and lipocalin (Beste et al., 1999). Anticalins 
consist of a β-barrel core that is stabilized by disulfide bridges with an interconnection of two 
to three mobile loops (Figure 1.2) (Beste et al., 1999). Lipocalins typically bind to small 
molecules, such as water-insoluble vitamin A, pheromones and odorants for example, 
(Schlehuber et al., 2000), through their β-barrel surface or through the mobile loop regions. 
Anticalins, on the other hand, are designed to bind with high affinity and specificity to 
various antigens through loop-substituted peptides (Table 1.1). Anticalin libraries have been 
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developed where peptides with wide sequence diversity were introduced within the mobile 
loops of the β-strands and potential binders were selected via phage or ribosomal display 
technologies (Table 1.1), (Schlehuber and Skerra, 2002). As shown in Table 1.2, Anticalins 
have been developed for a number of uses such as an antidote for overdose of digoxigenin 
(Schlehuber et al., 2000), an immunomodulator by targeting cytotoxic T-lymphocyte antigen-
4 (CTLA-4) and thus, blocking cells signalling (Schlehuber and Skerra, 2005) and as an 
antagonist for vascular endothelial growth factor (VEGF) for cancer treatment (Skerra, 2008). 
Anticalins, have also been proposed as in vivo/in vitro diagnostic agents (Table 1.3), as well 
as being utilised as reagents in various biomedical research field settings (Table 1.4). 
 
1.2.4 Designed Ankyrin Repeat Protein (DARPin) 
 
DARPins are another class of molecular scaffolds created by fusing the ankyrin repeat 
sequence of multiple α-helices and β-turns (Figure 1.2), (Forrer et al., 2003). DARPins have 
the unique capability of forming large surface interaction interfaces by adjusting the number 
of the ankyrin repeats (Table 1.1). DARPins have a high thermodynamic stability and 
reversible folding capacity, thus they have been successfully used to develop a library of 
high-affinity binders against a range of targets (Table 1.2), (Stumpp et al., 2008, Binz et al., 
2004, Mosavi et al., 2004). DARPins can be expressed at high levels as functional and 
soluble proteins using bacterial expression systems (Stumpp et al., 2008). Conjugated-
DARPins have also been designed to bind to intracellular and extracellular targets (Stumpp et 
al., 2008). Therapeutic applications of high affinity DARPins include targeting maltose 
binding protein (MBP) (Binz et al., 2004), caspase-2 (Schweizer et al., 2007), intracellular 
proteinase (Kawe et al., 2006), human epidermal growth factor 2 (EGF2) and HER2 (Zahnd 
et al., 2007) (Table 1.2). Also, anti-idiotypic IgE-DARPins have been developed as vaccine 
candidates (Table 1.2), (Vogel et al., 2007). Moreover, DARPins have been utilised for in 
vivo/in vitro detection of HER2 expression in breast cancer (Table 1.3). The unique structural 
properties of DARPins have been utilised in their co-crystallisation with unstable proteins 
and subsequent determination of protein structure by X-ray crystallography (Table 1.4). 
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1.2.5 Kuntiz Domain 
 
The Kuntiz Domains are another class of non-antibody scaffold based on human serine 
protease inhibitors that have been engineered as an alternative scaffold for a variety of 
important protease targets (Figure 1.2), (Dennis and Lazarus, 1994b, Dennis and Lazarus, 
1994a, Nixon and Wood, 2006). An LACI-D1 is a Kuntiz Domain-derivative based on 
domain-1 of human lipoprotein-associated coagulation inhibitor, and is the first non-antibody 
scaffold derivative approved by FDA for medical applications in the USA; LACI-D1 (or DX-
88/ Escallantide) is approved for treatment of acute HAE as a potent inhibitor of the plasma 
kallikrein, and also used for prevention of blood loss in cardiothoracic surgery (Table 1.2), 
(Lehmann, 2008, Lunn and Banta, 2011). DX-1000 is another example of a Kunitz Domain 
derivative based on tissue factor pathway inhibitor (TFPI). This biologic drug is currently 
being studied in animal models for blocking the growth of breast cancer and preventing 
metastasis by inhibiting plasminogen activation (Table 1.2). 
 
1.2.6 Avimers 
 
Avimer molecules (named from Avidity and multimer) are another example of a protein 
scaffold. Avimers are derived from the multivalent low density lipoprotein receptor class A 
(LDLR-A), (Figure 1.2). An avimer is capable of neutralising interleukin-6 (IL-6) and has 
been developed for the treatment of Crohn’s disease (Table 1.2), (Silverman et al., 2005). 
Recently, the anti-IL6 Avimer was trialled (Phase I) for safety and toxicity studies 
(Table 1.2). 
 
1.2.7 Neocarzinostatin (NCS) 
 
Neocarzinostatin (NCS) is a small protein and member of endiyne-chromoprotein family with 
a well-defined hydrophobic β-barrel core connected with two loops structurally equivalent to 
CDR1 & CDR3 of immunoglobulin (Figure 1.2), (Nicaise et al., 2004). NCS was developed 
as a molecular scaffold by grafting an immunoglobulin-CDR3 sequence to one of the NCS 
loops (Table 1.1). The scaffold NCS-CDR3 specifically bound with high affinity to hen egg 
white lysozyme and has been exploited for future drug and biologic development (Nicaise et 
al., 2004). 
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Table ‎1.2  Non-antibody molecular scaffolds utilised for therapeutic applications 
Scaffold 
Name  
Scaffold 
Format  
Target Application(s)/ description(s)  Clinical 
Trial Phase 
Reference(s) 
ZHER2:342 Affibody HER2 
Radioimmunotherapy (RIT); 
177Lu-labeled HER2-Specific Affibody
®
 
For treatment of disseminated tumours with a high level of 
HER2 expression on breast, ovary, and urinary bladder. 
1 
 
(Tolmachev et 
al., 2007) 
ZCD25  Affibody 
IL-2Rα/CD25  
 
Affibody
® 
binding to interlekin-2 (IL-2) receptor α subunit 
(known as CD25) used for prevention of organ rejection or 
autoimmune disease. Also, as therapeutic depletion of CD25
+
 
cells in T-cell leukemia. 
-- 
(Gronwall et al., 
2008) 
Zgp120 Affibody HIV-I gp120 
Treatment for HIV-I through virus neutralization, inhibiting 
attachment or entry. 
-- 
(Wikman et al., 
2006) 
ZAB Affibody β-Amyloid 
Slow down plaque formation for Alzheimer patients, by bind 
to amyloid-beta (Aβ) peptide and reduce amyloid plaque 
formation. 
-- (Gronwall et al., 
2007) 
Monobody 
10
FN3 VEGFR-2 
Anti-angiogenesis 
For treatment of non-Hodgkin’s lymphoma.  
Antagonists of human VEGFR2. 
1 (Getmanova et 
al., 2006). 
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Scaffold 
Name  
Scaffold 
Format  
Target Application(s)/ description(s)  Clinical 
Trial Phase 
Reference(s) 
Adnectin
™
  
CT-322  
10
FN3 VEGFR-2 
Glioblastoma, Non-small-cell lung carcinoma (NSCLC) 
VEGFR-2 inhibitor 
Treatment of glioblastoma multiforme, colorectal cancer, 
pancreatic cancer, and non-small cell lung cancer.  
2 
(Dineen et al., 
2008, Mamluk et 
al., 2010) 
Anticalin 
(FluA) 
Lipocalin Fluorescein  
Antidote 
Engineered lipocalin, from bilin-binding protein (BBP), 
against small molecules and target proteins coupled with 
fluorescein as a nonradioactive label 
-- (Beste et al., 
1999). 
Anticalin  
(DigA) 
Lipocalin  Digoxigenin  
Antidote 
Engineered lipocalin, from BBP, for binding to Digoxigenin 
group, for overdoses or poisons.  
-- (Schlehuber et 
al., 2000) 
Anticalin 
(Lcn2) 
Lipocalin  
Radioimmunotherapy (RIT), Metal-chelator 
Used in RIT, and used as radionuclide-chelate capturing (e.g. 
Y3
+
-DTPA), preventing the release of free metal ion and 
preventing kidney toxicity. 
-- (Kim et al., 2009) 
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Scaffold 
Name  
Scaffold 
Format  
Target Application(s)/ description(s)  Clinical 
Trial Phase 
Reference(s) 
Anticalin 
(PRS-050) 
Lipocalin VEGF 
Angiogenesis inhibitor, oncology 
A potential treatment for certain solid tumors, act as inhibitor 
of tumor angiogenesis, by neutralizes human VEGF. 
1 (Skerra, 2007b) 
Anticalin 
(PRS-010) 
Lipocalin CTLA-4 
Cancer immunotherapy, blocking CTLA-4, a receptor with 
attenuating function expressed on activated T cells, and 
stimulating the cellular immune response. 
Pre-
clinical 
(Schonfeld et al., 
2009) 
TF7I-C 
Kuntiz 
domain  
TF-FVIIa 
Anticoagulant 
Derived from β-amyloid protein precursor inhibitor (APPI), 
used as potent inhibitors of the active site of the human 
TF.FVIIa complex. 
-- (Dennis and 
Lazarus, 1994b). 
Escallantide 
(DX-88) 
Kuntiz 
domain  
Plasma kallikrein 
Kallikrein inhibitor 
Approved for treating acute HAE as potent inhibitor of the 
plasma kallikrein. Also, for prevention of blood loss in 
cardiothoracic surgery. It is derived from human lipoprotein-
associated coagulation inhibitor (LACI). 
FDA 
approved 
(2009) 
 
(Lehmann, 2008, 
Lunn and Banta, 
2011) 
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Scaffold 
Name  
Scaffold 
Format  
Target Application(s)/ description(s)  Clinical 
Trial Phase 
Reference(s) 
DX-1000 
Kuntiz 
domain  
Plasmin (pln) 
Anticancer and plasmin inhibitor 
Blocking breast cancer growth and metastasis by inhibiting 
plasminogen activation. It is derived from tissue factor 
pathway inhibitor (TFPI). 
Pre-
clinical 
(Devy et al., 
2007) 
EPIhNE4 
(DX-890) 
Kuntiz 
domain  
Neutrophil elastase 
(HNE). 
Proteolysis-resistant inhibitor 
Anti-inflammatory drug for cystic fibrosis. It is derived from 
the light chain (bikunin) of the human protease inhibitor, 
inter-α-trypsin inhibitor. 
-- (Attucci et al., 
2006) 
CD4-
DARPin 
DARPins CD4 
Microbicide 
Blocking mucosal HIV transmission, by specifically bind to 
the cellular CD4 receptor, the main entry receptor of HIV. 
-- (Schweizer et al., 
2008) 
DARPin DARPins IgE & IgE receptor 
Anti-idiotypic antibody, regulators of immune responses, 
inhibits mast cell degeneration by blocking IgE and IgE 
receptor. 
Potential vaccine, used to induce an anti-IgE response 
preventing the binding of IgE to FcεRI and the degranulation 
of effector cells implicating in allergic disease.  
-- (Vogel et al., 
2007) 
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Scaffold 
Name  
Scaffold 
Format  
Target Application(s)/ description(s)  Clinical 
Trial Phase 
Reference(s) 
DARPin G3 DARPins HER2 
Anti-HER2, for HER2-overexpressing cancers e.g. breast and 
ovarian cancers.  
Pre-
clinical 
(Zahnd et al., 
2010) 
MP0112 DARPins 
VEGF-A, 
VEGFR-1 
Ophthalmologic, AMD, DME 
Ophthalmological diseases, against VEGR cellular receptors, 
as a possible treatment for various ophthalmologic disease 
indications 
2 (Campochiaro et 
al., 2013) 
C326 
(AMG-220) 
C426 
C2810 
C65 
C2 
 
Avimer 
Interleukin-6 
cMet,  
CD28,  
CD40L, &  
BAFF 
Anti-IL6 Neutralizes IL-6 (a pro-inflammatory cytokine) for 
treating Crohn’s disease. 
Different designed Avimers bind to and antagonise for: cMet, 
CD28, CD40L and BAFF.  
1 
Completed 
-- 
(Tawara et al., 
2011, Silverman 
et al., 2005) 
CE76FVIIa Cpn10 FVII/FVIIa 
Anticoagulant, act as Factor X activity inhibitor by blocking 
the extrinsic-dependent TF-FVIIa complex.  
Designed based on human Cpn10. 
-- Unpublished/ 
Chapter 4 
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Table ‎1.3  Non-antibody molecular scaffolds utilised for diagnostic applications 
Scaffold Name  For  Application(s)   Description(s) Reference(s) 
Affibodies     
ZHER2 In vivo Tumor imaging/ 
localization 
HER2 expression in breast 
and ovarian cancer.  
In phase (I) clinical trial for 
breast cancer imaging. 
 
(Orlova et al., 
2006, 
Tolmachev et 
al., 2007, 
Wikman et al., 
2004) 
ZEGFR  In vivo Tumor imaging/ 
localization 
Imaging of expression of 
EGFR-1 carcinoma. 
(Friedman et 
al., 2008) 
ZTNF-α:185  In vivo Inflammatory imaging  Binding to human tumor 
necrosis factor α (TNF-α), 
aids in the diagnosis and 
staging of patients.  
(Jonsson et al., 
2009) 
ZCD25  In vitro Medical imaging  Visualizing of over expression 
of IL-2α/CD25 in organ 
rejections, autoimmune 
diseases and T-cell 
malignancies.  
(Gronwall et 
al., 2008) 
ZTaq In vitro Protein microarrays Taq DNA polymerase and 
human IgA. 
(Renberg et 
al., 2007) 
Anticalins      
Lcn2 In vivo Imaging  Radioimmunodiagnosis (RID) (Kim et al., 
2009) 
DigA16 In vivo/  
in vitro 
Detector reagent For studying digoxigenin-
binding function and 
enzymatic activity. 
(Schlehuber et 
al., 2000) 
 
CTLA-4 
specific   
In vitro Immunocytochemicals
staining 
Immunological reagent for 
cytotoxic T lymphocyte-
associated antigen (CTLA)-4. 
(Schlehuber 
and Skerra, 
2005) 
DARPins In vivo   Tumor imaging/ 
localization 
HER2 imaging of breast 
cancer patients 
(Stumpp et al., 
2008) 
 
In vitro/ 
In vivo 
Tumor imaging/    
stage detections 
HER2 expression state of 
breast and colon carcinoma 
(Zahnd et al., 
2007) 
PDZ domain In vivo/ 
in vitro  
Discovery reagent  For peptide C-terminus 
recognitions of drugs & for 
studying protease activities. 
(Ferrer et al., 
2005) 
 
In vitro Detector For time-resolved 
fluorescence resonance energy 
transfer (TR-RET) method. 
(Ferrer et al., 
2002) 
CP7CD44 In vitro/  
in vivo 
Tumor imaging/ 
localization 
Targeting CD44 
overexpression in breast, 
colon, & prostate cancer. 
Designed based on human 
Cpn10.    
Unpublished/ 
Chapter 5 
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Table ‎1.4  Non-antibody molecular scaffolds utilised for bio-research applications 
Scaffold  Application(s) Relevance(s)  Reference(s) 
Affibodies Microarray 
detection 
Protein capturing in microarray, of Taq 
DNA polymerase, human IgA, IgE, IgG, 
TNFα, and insulin. 
(Renberg et al., 
2007, Nord et 
al., 2001, 
Ronnmark et al., 
2002, Gronwall 
et al., 2007)  
Biopurification & 
Bioseparation 
Affinity chromatography capturing 
recombinant human Factor VIII from CHO 
superannuant, apolioprtoein A from 
fermentation media, Taq DNA polymerase 
or recombinant human IgA from bacterial 
lysate, and human β-amyloid peptide from 
human body fluid. 
FN3 Biopurification  Purify the active estrogens receptor (ER) 
from lysate mixture containing misfolded 
receptors.  
(Huang et al., 
2006, Karatan et 
al., 2004) 
 
Affinity reagent  Used in immunoprecipitation experiments 
for c-Src from murine fibroblast cell 
extracts. 
 Research 
diagnostic  
Valuable tool for studying intercellular 
protein functions, due to expression inside 
cells. 
Anticalins 
(DigA/ FluA) 
Bioanalytics  Fusion with alkaline phosphatase (reporter 
enzyme). 
(Schlehuber et 
al., 2000, Beste 
et al., 1999) 
 
Biochemical 
reagent 
For the detection of biomolecules coupled 
with a nonradioactive label e.g. fluorescein 
DARPins Protein 
crystallography 
Facilitate crystallisation studies of; trimeric 
AcrB (a multidrug exporter in E. coli); & 
human polo-like kinase 1 (Plk-1) proteins, a 
well validated drug target in cancer therapy; 
the E. coli maltose binding protein (MBP); 
and two eukaryotic mitogen-activated 
protein kinases (MAPKs). 
(Sennhauser et 
al., 2007, 
Bandeiras et al., 
2008, Binz et 
al., 2004, 
Schweizer et al., 
2007) 
(AR) Biopurification  Facilitate purification of MBP and MAPKs. 
(AR-F8) Discovery tool Specific caspase inhibitors useful for the 
validation of pathways, for the discovery of 
unknown interactions, and for the 
identification of novel intracellular targets.   
PDZ domain Peptide detector  For studying protease activities  (Ferrer et al., 
2005) 
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1.3 Chaperone proteins 
 
Molecular chaperones are proteins which facilitate the correct folding, assembly, transport 
and degradation of other proteins in vivo (Macario and de Macario, 2007, Ranson et al., 1998, 
Hartl and Hayer-Hartl, 2002). Chaperonin 10 (Cpn10), heat shock protein 10 (Hsp10), or 
GroES in E. coli is a member of the chaperone family. Cpn10 is an essential mitochondrial 
protein that binds with its cognate partner chaperonin 60 (Cpn60, Hsp60 or GroEL), and in 
the presence of Mg
2+/ATP, the complex forms a “barrel” type structure, in which unfolded or 
degraded proteins are refolded (Hartman et al., 1992, Hartl and Hayer-Hartl, 2002). 
 
It has been generally accepted that proteins have fixed cellular localisations. However, recent 
studies have shown that proteins can serve a variety of functions, depending on which 
organelle these proteins are localised. The identification of a protein outside of its known 
functional zone in cellular preparations was once thought to be due to rupturing of cells 
and/or cell organelles. It is now known that proteins translocate between intracellular and 
extracellular compartments. For example, chaperone proteins such as Cpn10, Hsp70 and 
Hsp90, which are known to conventionally localise in various organelles for chaperone 
activity, have now been shown to exist in extracellular locations (Butler and Overall, 2009). 
 
1.3.1 Human Chaperonin 10 
 
Human Cpn10 (hCpn10) is located within the mitochondrial membrane and is functionally 
associated with the correct folding of proteins that enter the mitochondria from the cytosol 
(Hartl and Hayer-Hartl, 2002). hCpn10 expression is up-regulated in several diseases that are 
associated with protein-misfolding (Slavotinek and Biesecker, 2001, Ranford et al., 2000). In 
addition to its traditional chaperone activity, hCpn10 has been found to have anti-
inflammatory properties. The initial identification of hCpn10 in the serum of pregnant 
women led to the hypothesis that hCpn10 possessed immunosuppressive properties 
(Cavanagh, 1996). More recently, recombinant hCpn10 (XToll) has been tested in clinical 
trials (completed Phase II) for the treatment of various diseases associated with inflammation 
including rheumatoid arthritis (RA), psoriasis (van Eden, 2008) and multiple sclerosis (MS) 
(Broadley et al., 2009). 
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1.3.2 Chaperonin 10 structure and features 
 
The Cpn10 structure is highly conserved across all species despite the fact that hCpn10, for 
example, has only 30 % sequence homology with GroES (Taneja and Mande, 1999, Ranford 
et al., 2000, Perham and Wittung-Stafshede, 2007) (Chapter 3). As shown in Figure 1.3, the 
quaternary structure of hCpn10 is a heptameric fold (70 kDa) with seven identical monomers, 
where each monomer (10 kDa) consists of a rigid hydrophobic β-barrel core, a β-hairpin roof 
loop, and a mobile loop extending below the plane of the molecule (Higurashi et al., 2003, 
Lin et al., 2004, Guidry et al., 2000). hCpn10 monomers, like most of the members of the 
Cpn10 family, assemble into a heptameric structure through interactions between the β-barrel 
interfaces of each monomers, whereby the C-terminus of one monomer binds to the N-
terminus of an adjacent monomer via strong hydrogen bonds (Sakane et al., 2007, Sakane et 
al., 2004). Heptameric hCpn10 subsequently forms a complex with Cpn60 for full chaperone 
functionality (Figure 1.3). The oligomeric Cpn10 protein is one of a few proteins that can 
fold reversibly in vitro (Perham and Wittung-Stafshede, 2007), which is an important aspect 
in molecular folding and protein assembly.  
 
The flexible “mobile” loop (Ala21-Gly38) of hCpn10 consisting of 18 residues 
(AAETVTKGGIMLPEKSQG), is an unstructured region that is critical for binding to Cpn60 
(Richardson et al., 2001, Lin et al., 2004) (Figure 1.3). The mobile loop within Cpn10 is 
highly flexible but its movements are restricted when Cpn10 is bound to Cpn60 (Higurashi et 
al., 2003). The structure of the hCpn10 delta mobile loop (∆L-Cpn10) was solved to a 
resolution of 2 angstrom units (unpublished data). Although mutations within the loop can 
substantially reduce the binding affinity of Cpn10 towards Cpn60 (Lin et al., 2004), it does 
not affect the assembly of Cpn10 into a heptamer (Sakane et al., 2007) (Chapters 3 to 5). 
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Figure ‎1.3  Three-dimensional model of human Chaperonin complex (Cpn10/Cpn60) 
Schematic representation of protein backbones of human Chaperonin complex (Cpn10/Cpn60) taken 
from various angles. (A) Side view of chaperonin complex, showing Cpn10 (cyan) in complex with 
Cpn60 (magenta); (B) Top view of chaperonin complex, showing the dome-shaped Cpn10; (C) Top 
view of heptamer hCpn10 (70 kDa); (D) Side view of heptamer hCpn10; and (E) Side view of 
monomer hCpn10, shows the roof β-hairpins and the Cpn60-binding mobile loop extending outward 
from the lower edge of the hydrophobic β-barrel core. The hCpn10 models were generated by 
homology modelling using the chaperonin complex from Thermus Thermophilus (PDB ID. 1WE3) as 
a template (detailed in Chapter 3). All molecular structures are shown in ribbon representations and 
prepared using PyMOL software. 
  
N 
C 
β-hairpin 
Roof loop 
Hydrophobic      
β-barrel core 
A. B. 
C. 
Mobile 
loop 
D. E. 
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1.4 Scope of this thesis – hCpn10 as a novel molecular scaffold 
 
Provided that introducing mutations within the mobile loop does not compromise the 
assembly of hCpn10 into a heptamer, the question arises as to whether hCpn10 can be utilised 
as an alternative molecular scaffold to display various peptides (Table 1.1). The tertiary 
structure of hCpn10 (monomer) is a rigid unit (anti-parallel β-barrel) consisting of a 
hydrophobic core (Figure 1.3). As with other molecular scaffolds, the loops form an extended 
interface that facilitates the binding of the molecular scaffold to the target molecule. In such 
loops, residues can be substituted or extended with a functional peptide domain that may vary 
in peptide sequence and length (Chapter 3). 
 
In this study, hCpn10 is proposed as a novel molecular scaffold since it bears many ideal 
features of a scaffold wherein the mobile loop can be substituted with variant and non-native 
peptide sequences. As shown in Figure 1.3, the mobile loop lies below the plane of the ring of 
the heptameric structure and removal of this region does not compromise the assembly of 
hCpn10 monomers into the heptameric structure (Chapters 3 to 5). Thus one of the criteria for 
a molecular scaffold has been satisfied, whereby the mobile loop is an independent domain of 
hCpn10 which appears to not play a role in the assembly of the β-barrel monomer and the 
three dimensional conformation of heptameric hCpn10. In addition to the mobile loop, 
hCpn10 also possesses a roof loop at the apex of the molecule. The β-hairpin roof loop also 
presents a potential domain for amino acid randomization. The N- and C- termini also present 
opportunities for further fusion of protein domains. 
 
The research described in this thesis aims to develop hCpn10 as a new molecular scaffold by 
demonstrating its utility through the creation of hCpn10 variants with specific functionality. 
This will be achieved by engineering protein sequences into the mobile loop region of native 
hCpn10, as similarly performed for the NCS scaffold (Section 1.2.7.). Importantly, a versatile 
molecular scaffold protein should constitute a stable conformation fold that is capable of 
displaying a multitude of loop structures or amino-acid sequences in a particular surface 
region (Skerra, 2000a). By definition, the features and properties of the hCpn10 molecule 
have shown that it is an ideal molecular scaffold candidate due to the rigid structure of the 
hydrophobic β-barrel core and the spatially separated mobile loop domain (Chapters 3 to 5). 
Furthermore, hCpn10 does not require post-translation modification (e.g. glycosylation) and 
can therefore be expressed as a soluble protein at high level using low cost prokaryotic 
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expression systems. Importantly, the quaternary structure of hCpn10 provides for higher 
binding avidity, with seven loops extending below the plane of the heptameric ring structure, 
which is an important aspect for the development of highly avid therapeutic agents (Chapter 
4). Furthermore, the development of hCpn10 variants with new functionality offers an 
opportunity to create a platform for the development of a new class of NMEs based on 
hCpn10. 
 
1.5 Potential applications for a hCpn10-based molecular scaffold 
 
Several properties of hCpn10 meet the requirements of an ideal molecular scaffold, namely, 
small size (70 kDa), thermal stability and high expression level (30-40 % total cell protein) of 
soluble hCpn10 in E. coli production systems. Most importantly, removal of the mobile loop 
does not compromise assembly of the hCpn10 heptamer. Several potential applications for 
the hCpn10 molecular scaffold are summarised below:  
 
 Biologics: NMEs that can bind to validated and new, potential disease targets. 
 
 Vaccines: The hCpn10 scaffold could be loaded with major antigenic determinants of 
viral origin to elicit a broad polyclonal antibody response. For example, the display of 
DENV1, DENV2, DENV3 or DENV4 epitopes on scaffold-based hCpn10 for 
neutralizing antibodies and vaccine development against dengue virus (Mahler et al. 
Unpublished).  
 
 Multispecific Binding Entities: Analogous to bispecific antibodies, peptides with 
specificity towards two (or more) targets could be expressed within the hCpn10 
molecular scaffold. These peptides could be genetically engineered into the roof loop 
and mobile loop creating a bi (or tri etc)-specific-hCpn10-based NMEs. Such 
approaches could, for example, cross link receptors on cancer cells with cytotoxic T-
cells. 
 
 Phage Display Systems: Expression of the hCpn10 monomer in a phagemid vector, 
fused to the gene 3 could allow for the display of peptides within a hCpn10 monomer 
on filamentous phage library. By randomising the ~18 amino acids within the mobile 
loop, a library of diverse peptides could be screened for binders against specific targets 
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using a method known as “biopanning” in phage display technology (Mahler et al. 
unpublished data). 
 
 In Vivo Decoys: Expressing multiple peptides (derived from receptors or soluble 
factors) on the hCpn10 scaffold may act as decoys in vivo, and have potential 
application in autoimmune diseases. 
 
 Recombinant Peptide Production: hCpn10 can be expressed at high levels in low cost 
prokaryotic systems such as E. coli (~30-40 % of total cell protein). Under such 
circumstances, cleavage sites can be engineered at the N- and C-termini of the mobile 
loop whereby the recombinant protein can be extracted via protease digestion. This 
could provide a more cost effective method for peptide production for recombinant 
protein production.  
 
1.6 Monovalent versus multivalent scaffolds 
 
Binding affinity is one of the most crucial protein attributes for its successful engineering for 
therapeutic or diagnostic purposes. Non-antibody scaffolds, in some instances, have 
monovalent display of peptides, whereas antibodies are naturally bivalent and therefore, have 
a higher binding avidity towards a target antigen. In order to address this issue, various 
approaches have been tested to develop non-antibody scaffolds with multiple binding sites. 
For example, the Affibody (ZHER) has been engineered to contain two binding sites and thus 
create avidity that is comparable to that of a typical antibody. ZHER has been developed 
against HER2, which is overexpressed in breast cancer and studies have shown that the 
bivalent nature of ZHER has contributed to a ten-fold decrease in the dissociation constant 
(KD) and thus demonstrates a higher binding avidity relative to its monovalent counterpart 
(Steffen et al., 2005, Wikman et al., 2006).  
 
Another approach is to create an NME, where a known scaffold is fused to a multidomain 
molecule. In this way, fusing αVβ3, which binds to FN3, to a pentamerisation domain, 
significantly increased the avidity towards the target and reduced the dissociation rate of 
integrin binding (Duan et al., 2007, Zhang et al., 2004).  
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Further strategies have been adopted to increase the avidity of non-antibody scaffolds. A 
multiple binding domain was developed by linking a number of monomeric avimers that bind 
to different IL-6 epitopes (Silverman et al., 2005). This approach was determined via protein 
modelling and studies have demonstrated that the avidity of this molecule had increased 
significantly. Non antibody-scaffolds have been developed principally in the context of their 
required applications; for example, Monobody (
10
FN3) was used as an anti-angiogenic 
therapy, which only required a ratio of 1:1 monobody-antigen binding (Getmanova et al., 
2006).  
 
However, in the field of oncology, polyvalent biologic molecules are needed in order to 
effectively destroy cancer tissues. This is important because antibodies that typically bind to 
cancer cells can initiate the effector function and destroy the tumour cells (Vasudev and 
Reynolds, 2014, Carter, 2001). For this reason many approaches have been taken in order to 
create multivalent scaffolds, either by protein fusion (Zhang et al., 2004), conjugating certain 
molecules to antibodies or creating polyvalent antibody-fragments (Carter and Senter, 2008). 
Such strategies would superimpose and complement the molecular scaffold functions.  
 
Unlike previous examples, because of the molecular structure nature of the heptameric 
hCpn10 neither fusions nor conjugations are required. The structural features of hCpn10 are 
capable of forming bispecific properties through simultaneously grafting functional peptides 
in both roof and mobile loops, as previously described. Thus, the scaffold based on hCpn10 
has no limitation and is relevant to be used in any medical fields upon request  
 
In addition, hCpn10 is an endogenous protein with natural multivalent properties and 
therefore, engineering additional bindings sites is not required (see section 1.5). It is practical 
to graft high affinity binding peptide sequences within the mobile or roof loop in hCpn10 and 
still retain its overall tertiary and quaternary structure (Chapter 3). This in turn will lead to the 
development of new biologics with a higher affinity towards a particular target.  
 
1.7 Limitations of molecular scaffolds 
 
A major disadvantage of many protein scaffolds, particularly those that are proposed as 
therapeutic or in vivo diagnostic agents, is their capacity to elicit an immune response. For 
example, Affibodies which are derived from the S. aureus protein A have the potential to 
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generate an immune response after being administered to patients multiple times. 
Nevertheless, Affibodies such as ZHER2 have been successfully used to image HER2 positive 
breast tumours in patients, as a single administration of ZHER2 for imaging purposes s would 
not stimulate a strong immune response.  
 
Ideally a molecular scaffold should be of human origin to ensure a lower probability of 
eliciting an immune response (Li and Zhu, 2010, Samaranayake et al., 2009). However, there 
will be some limitations in the overall efficacy of these molecular scaffold proteins as 
therapeutic or diagnostic agents due to the host immune response, which ultimately results in 
neutralising the biologics. Nevertheless, the successful use of recombinant hCpn10 (XToll) in 
phase II clinical trials (i.e. completion of immunogenicity and toxicity studies of phase I) 
(van Eden, 2008), demonstrates the high tolerance of host immune systems to rhCpn10 (with 
≤ 20 % mutations).  
 
An additional limitation of molecular scaffolds, beyond their capability as neutralising 
agents, is the lack of a capacity to initiate the effector function of the innate immune system, 
mediated through the Fc portion of endogenous antibodies. Molecular scaffolds could be 
fused with an Fc fragment or other effector molecules, in order to facilitate the required 
therapeutic functions (Wu and Sun, 2014, Liu et al., 2012).  
 
Another limiting factor in the use of alternative molecular scaffolds is the rapid metabolic 
clearance rates of these biologics, due to their size, by the renal system. Normally, small 
proteins (≤ 60 kDa) are rapidly cleared from the serum and thus have shorter half-lives (< 1 
hr) (Vugmeyster et al., 2012, Wu and Sun, 2014, Nord et al., 1997). However, these 
limitations can be overcome by increasing the molecular size of the biologics, which 
subsequently increases the serum half-life. Alternatively, the protein is modified through 
PEGylation, fusion to serum albumin, attachment to an antibody or antibody fragments, or 
other such methodologies (Nilsson and Tolmachev, 2007, Bernstein and Moellman, 2012, Xu 
et al., 2002). However, Cpn10 (70 kDa) has a half-life of up to 7 hrs (van Eden, 2008), which 
benefits short-term treatments and minimises the requirement of multiple dose 
administrations. Strategies such as PEGylation could be used to increase serum half-life if 
required. 
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In summary, hCpn10 is an ideal molecule for development as a molecular scaffold.  NMEs 
based on hCpn10 molecular scaffold have the potential to exhibit ideal binding kinetics and 
parameters (ka, kd and KD) to the target, display high potency, elicit minimal immunogenicity, 
have stability within a formulation, display ideal pharmacokinetics and show favourable 
bioprocess economics. Such attributes and qualities can be either inherent within the 
properties of a molecular scaffold or can be incorporated throughout the drug development 
process. hCpn10 inherently possesses ideal properties that fulfil many of the requirements for 
a molecular scaffold, and through appropriate production bioprocesses and formulation, has 
the potential to create a new class of NMEs for both diagnostic and therapeutic applications. 
 
1.8 Hypothesis on which the research reported in this thesis is based  
 
As previously stated, the hypothesis put forward in this thesis poses a number of leading 
questions regarding the suitability of hCpn10 as a molecular scaffold. These are as follows: 
 
 Can the mobile loop of hCpn10 be substituted with non-hCpn10 peptide sequence, and 
can NMEs be created with binding specificity to specific targets?   
 
 Will peptide substitution hinder the assembly of hCpn10 into heptamer from monomer?   
 
1.9 Structure of the thesis 
 
The general materials and methodologies used in these studies are detailed in Chapter 2. The 
establishment of fundamental basis for choosing hCpn10 as a molecular scaffold and 
optimisation of the molecular scaffold based-hCpn10 using dual computational and 
experimental approaches are detailed in Chapter 3. Application of the concept of using 
scaffold based-hCpn10 for therapeutic purposes is described in Chapter 4 with an example, 
supported with in vitro assays. A second proof of concept example NME based on hCpn10, 
as a diagnostic is provided in Chapter 5 with detailed analytical analyses. Chapter 6 discusses 
preliminary results of two hCpn10-based candidates with anti-angiogenic properties for 
cancer treatment. Finaly, Chapter 7 summarizes the outcomes of the study followed by 
recommendations for future directions of using scaffold based-hCpn10 for many applications.  
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Chapter 2.  General Materials and Methods  
 
 
2.1 Materials 
 
Table 2.1 details the materials used in this research and their manufacturers/suppliers. 
 
Table ‎2.1  List of materials for the research study 
Item(s) From 
  
DNA Oligonucleotides:  
Target constructs (Table 2.2) GeneArt
®
 Gene Synthesis 
DNA Primers (Table 2.8)  Sigma-Aldrich
®
  
  
E.coli strains:  
OneShot
®
 Top10 cells Invitrogen
™
  
α-select cells  Bioline™ 
XL1-Blue cells Stratagene 
 
BL21(DE3) T7 Expression LysY/I
q 
cells  New England BioLabs
® 
(NEB) 
  
Media:  
Peptone from Casein Becton Dickinson Co. (BD
™
) 
Yeast Extract BD
™
 
LB Agar Bio-Rad
™
 Laboratories  
  
Antibiotics and chemical reagent:   
Ampicillin (sodium salt) Fisher BioReagents
® 
Kanamycin (sulphate) Fisher BioReagents
® 
Isopropyl-1-thio-β-D-galactopyranoside (IPTG) Bioline™ 
  
Enzymes, Enzyme Buffers, and PCR reagents:  
EcoRI, BamHI Roche
™
 
NcoI, NotI, NdeI, XbaI NEB 
NEB Enzyme Buffer 1, 2, 3, 4 NEB 
DNase I Invitrogen
™
 
cOmplete ULTRA multiple proteases Tablets  Roche
™
 
Calf intestinal alkaline phophatase (CIAP) Invitrogen
™ 
AccuPrime
™
 Taq DNA Polymerase High Fidelity life technology
™
  
PCR Master Mix (2x)  Promega
™
 
  
Antibodies:  
Monoclonal Anti-6xHis HRP-Conjugated Abcam
®
 
Mouse Monoclonal Anti-Human Cpn10 Abcam
® 
  
Molecular weight standards and dye:  
HyperLadder
™ 
100 pb Bioline
™
 
GeneRuler
™ 
1 kb DNA Ladder Fisher Scientific
™
 
SeeBule
® 
Plus2 prestained protein standard  Invitrogen
™
 
BioRad
™
 Gel filtration standard Bio-Rad
™
 Laboratories 
SimplyBlue
™
 SafeStain (Coomassie
® 
G-250) Invitrogen
™
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Item(s) From 
Kits:  
PureLink
® 
Quick Plasmid Miniprep Kit Invitrogen
™
  
QIAEX-II
® 
Gel Extraction Kit  QIAGEN
™
 
Rapid DNA Ligation Kit  Roche
™
 
Pierce
™ 
Bicinchoninic acid (BCA) Assay Kit Thermo
™
 Scientific 
  
Columns and gel:  
HisTrap
™
FF crude, HisTrap
™
FF, HisTrap
™
HP 1-5 mL GE Healthcare
™
 
HiTrap
™
SP FF, HiTrap Capto
™
S 1-5 mL  GE Healthcare
™
 
Superdex
™
75 GF columns GE Healthcare
™
 
Superdex
™
200 GF columns GE Healthcare
™
 
HiTrap
™
 Desalting, HiPrep
™ 
26/10 Desalting columns GE Healthcare
™
 
SnakeSkin
® 
Dialysis Tubing Thermo
™
 Scientific 
TSK G3000SWXL SE-HPLC column  Tosoh
™
 Bioscience 
Guard column (7.8mm) Tosoh
™
 Bioscience 
4-12% NuPAGE
®
 Bis-Tris gel 12, 15 and 17-wells Invitrogen
™
 
 
2.2 Wild-type hCpn10 and designed variants 
 
The hCpn10 and its variants are listed in Table 2.2 with their corresponding binding targets 
and amino acid (AA) sizes. AA sequences are described in more detail in Appendix 1. 
 
Table ‎2.2  Wild-type hCpn10 protein and its variants and their amino acids size 
  
No. Construct term Binding Target(s) AA Size 
1.  hCpn10 Cpn60 102 
2.  ∆L-Cpn10 -- 86 
3.  ∆Roof-Cpn10 -- 90 
4.  β-barrel (∆L-∆Roof-Cpn10)  -- 78 
5.  FH-Cpn10 Cpn60 726 
6.  CE76 FVII/FVIIa 102 
7.  CE76P1 FVII/FVIIa 108 
8.  CE76P2 FVII/FVIIa 106 
9.  CE76E5 FVII/FVIIa 112 
10.  FH-CE76 FVII/FVIIa 726 
11.  CPMyc 9E10 96 
12.  CPMycP1 9E10 102 
13.  CP7CD44-P1 CD44 104 
14.  CP11bFGF-P1 bFGF 102 
15.  CR2VEGF-P2 VEGF1 111 
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2.3 Cells culture medium 
 
The various culture media used for certain applications are described in Table 2.3. 
 
Table ‎2.3  Media preparation applied for bacterial growth 
Media Compositions Application(s) 
Luria broth (LB) 1 % Peptone from Casein; 0.5 % Yeast 
Extract; and 1 % NaCl) per L of MiliQ water, 
autoclaved at 121 °C (250 °F), for 20-60 min, 
at 15 psi. 
For plasmid growth 
amplification. 
Super Optimal Broth 
with Catabolite 
repression (SOC)  
 
10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 
mM MgSO4, 2 % Peptone from Casein; and 
0.5 % Yeast Extract) per L of MiliQ water, 
autoclaved at 121 °C (250 °F), for 20-60 min, 
at 15 psi.  
A 20 mM glucose filtered sterilizes by (0.22 
µm) and added post-autoclaving. 
To obtain maximal 
transformation 
efficiency of E. coli. 
Terrific broth (TB) 1.2 % Peptone from Casein; 2.4 % Yeast 
Extract; 72 mM K2HPO4, 17 mM KH2PO4 and 
0.4 % glycerol) per L of MiliQ water, 
autoclaved at 121 °C (250 °F), for 20-60 min, 
at 15 psi. 
For small to lab-scale 
protein expressions  
(from 5 - 5000 mL). 
Defined media (DM) Solution 1: KH2PO4 (16.6 g/L), (NH4)2HPO4 (4 
g/L), Citric Acid (2.1 g/L). Solution 2: 
Glycerol (25 g/L), MgSO4.H2O (1.5 g/L). 
Solution 3: Iron(III) citrate hydrate (75 
mg/mL), Boric acid (3.8 mg/mL), MnCl2.4H2O 
(18.8 mg/mL), EDTA (10.5 mg/mL), 
CuCl2.6H2O (1.9 mg/mL), Na2MoO4.22H2O 
(3.1 mg/mL), CoCl2.6H2O (3.1 mg/mL), Zinc 
acetate dihydrate  (10 mg/mL). Solution 4: 
Thiamine HCL (2 mg/mL).  
All solutions sterilized by autoclaving (as 
above) or 0.22 µm filtering.  
For large and  single-
batch cultivation  
(from 4 - 7 L).  
 
Note: Only mixed 
(solution 1 to 4) prior 
to expression and 
under sanitizes 
conditions with final 
pH of 6.7, adjust with 
NH3 (27 %).   
 
2.4 Buffer system 
 
2.4.1 Buffer preparation 
 
The choice of buffers (Table 2.4) was based on the nature and the pH suitability for target 
protein. This depends on pre-screening test for determining the stability of each target protein 
with respect to pH and the buffering compound. It also depends on the suitability of 
purification procedures. This was crucial to avoid loss of time and protein caused by an 
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additional step of buffer exchange. In addition, the lysis buffer should be compatible with the 
first chromatography step. It was necessary to improve the stability of the target protein and 
to keep the protein active in solution by including additives (e.g. salts, stabilizer, solubiliser, 
anti-oxidant agent, etc). Also, a cocktail of protease inhibitors was added to the lysis buffer to 
control the undesirable proteolysis effect during cells disruptions. 
 
Table ‎2.4  Commonly applied buffers with stabilizing components and optimum pH value  
Buffer Name Components pH 
Lysis (+) 50 mM Tris-HCl, 150 mM NaCl, 1 mM DTT or 0.05 % 
BME, 5 % glycerol, 1 mM EDTA, 1 tablet/10mL cOmplete 
ULTRA (proteases cocktail), 1 µg/mL DNaseI, 0.1 % Triton 
X-100. 
7.6 
Lysis (-)  50 mM Tris-HCl, 150 mM NaCl, 10 mM Imidazole. 7.6 
PBS  8.1 mM Na2HPO4, 1.8 mM KH2PO4, 2.7 mM KCl, 137 
mM NaCl,  
7.4 
PBST PBS, 0.1 % (v/v) Tween 20. 7.4  
TBS 25 mM Tris-HCl, 2.7 mM KCl, 137 mM NaCl. 7.6 
TBST TBS, 0.1 % (v/v) Tween 20. 7.6 
IB Washing  100 mM Phosphate, 1 M Urea, 1 % Trion X-100 7.4 
IB Denaturation  100 mM Phosphate, 150 mM NaCl, 8 M Urea, 2 
mM DTT or 0.5 % BME 
7.4 
IMAC Biding buffer I 20 mM Phosphate, 0.5 M NaCl, 20-40 mM imidazole, 0.01 
% BME. 
7.6 
IMAC Biding buffer II 50 mM Tris, 150 mM NaCl, 20 mM Imidazole 8.0 
IMAC Biding buffer III 100 mM Phosphate, 150 mM NaCl, 0.05 % BME, 8 M 
Urea, 10 mM Imidazole 
7.8 
IMAC Elusion buffer I 20 mM Phosphate, 0.5 M NaCl, 0.5 M imidazole, 0.01 % 
BME 
7.6 
IMAC Elusion buffer II 50 mM Tris-HCl, 150 mM NaCl, 0.5 M Imidazole 8.0 
IMAC Elusion buffer III 100 mM Phosphate, 150 mM NaCl, 0.05 % BME, 8 M 
Urea, 0.5 M Imidazole 
7.8 
Exchange Buffer I 20mM Phosphate, 150mM NaCl 7.8 
Exchange Buffer II 50 mM Tris, 150 mM NaCl  8.0 
Exchange Buffer III 100mM Sodium Acetate, 150 mM NaCl 5.5 
Refolding (4-0)  100 mM Phosphate, 150 mM NaCl, 4 M Urea, 
0.05 % BME.  
 100 mM Phosphate, 150 mM NaCl, 2 M Urea, 
0.05 % BME. 
 100 mM Phosphate, 150 mM NaCl, 1 M Urea, 
0.05 % BME. 
 100 mM Phosphate, 150 mM NaCl, 0 M Urea, 
0.05 % BME.  
7.4 
IEX Biding buffer  50 mM Sodium Acetate  5.5 
IEX Elution buffer  50 mM Sodium Acetate, 1 M NaCl 5.5 
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Buffer Name Components pH 
GF Running Buffer I 100 mM Phosphate, 150 mM NaCl, 1 mM DTT 7.6 
GF Running Buffer II 50 mM Tris, 150 mM NaCl, 1 mM DTT 8.0 
GF Running Buffer III 100 mM Sodium Acetate, 150 mM NaCl, 1 mM DTT 5.5 
SE- Mobile Phase I 0.1 M Phosphate, 0.2 M NaCl  7.8 
SE- Mobile Phase II 100 mM Sodium Acetate, 150 mM NaCl 5.5 
* All buffers were sterilised by filteration (0.45 µm or 0.22 µm filter), prior to applications. 
** PBS – Phosphate buffered saline, TBS – Tris buffered saline, IB – inclusion bodies, IMAC –
Immobilized metal ion affinity chromatography, IEX – Ion exchange chromatography, GF – Gel 
filtration chromatography, SE – Size-exclusion HPLC. 
 
2.4.2 Antibiotics 
 
Table ‎2.5  Applied antibiotics in stock and working concentrations.  
Antibiotic  Stock Concentration* Working Concentration 
Ampicillin (Amp) 100 mg/mL 100 µg/mL 
Kanamycin (Kan) 30 mg/mL 30 µg/mL 
*Filter sterilized (0.22 µm), aliquots stored in 1 mL (-20 °C). 
 
2.5 Standard molecular techniques 
 
2.5.1 Preparation of plasmids: growth, extraction and purification 
 
2.5.1.1 Transformation into competent E. coli cells 
 
DNA sequences encoding target proteins (Table 2.2) were designed in silico and synthesised 
with codon optimisation for expression in E. coli. The lyophilised DNA received from 
GeneArt
®
 Gene Synthesis was transformed into E. coli OneShot
®
 Top10 competent cells 
(Invitrogen
™
) for plasmid DNA transmission. Approximately 2 µL of each plasmid DNA 
(pGA-Script/Protein X) was added to a 50 µL of Top10 cells. Cells and DNA were incubated 
on ice for 30 min before heat-shocked at 42 °C for 30 sec. The heat-shocked cells containing 
plasmid DNA were placed back onto ice for 5 min before addition of 950 µL of SOC medium 
and allowed to recover at 37 °C with shaking for 1 hr. Approximately 50 µL (of 1:100 
dilution) of recovered culture were plated onto an LB-Agar/(Amp 100 µg/mL) plate for 
selection. The plate was incubated overnight at 37 °C. 
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2.5.1.2 Small-scale plasmid preparation and DNA purification 
(MiniPrep) 
 
A single colony from LB-Agar/Amp plate was used to inoculate 5 mL LB/Amp (37 °C, 
220 rpm). A PureLink
® 
Quick Plasmid Miniprep Kits were used for plasmid DNA extractions 
per the manufacturer’s instructions. In brief, a 1.5 mL from overnight LB culture was pelleted 
at 14000xg for 5min. Pellets were resuspended in 250 µL PureLink
®
Resuspension buffer 
(50 mM Tris-HCl, pH 8.0; 10 mM EDTA) with RNase A (20 mg/mL) and denatured with 
250 µL PureLink
®
Lysis buffer (200 mM NaOH, 1 % w/v SDS), mixed gently and incubated 
for 5 min at room temperature (RT). A 350 µL PureLink
®
Precipitation buffer was added for 
precipitating protein contaminants by vortex mixing and pelleted by 14000xg for 10 min. 
After plasmid DNA was bound to spin the column, the supernatant was discarded. A 500 µL 
Wash buffer, containing 100 % ethanol was added, incubated for 1 min, then discarded after 
centrifugation at 12000xg for 1 min. DNA plasmid was recovered from adding 75 µL 
TE buffer (10 mM Tris-HCl, pH 8.0; 0.1 mM EDTA), incubated for 1 min, 12000xg for 2 
min at room temperature. Plasmid DNA concentrations were determined and stored in 
aliquots at -20 °C. 
 
2.5.1.3 Quantification of nucleic acid concentration and purity 
determination 
 
Quantification of DNA recovered from miniprep was determined by using NanoDrop1000 
spectrophotometer (Thermo
™
 Scientific) and calculated from Equation 2.1. 
 
              
               
    
        Equation  2.1 
 
Based on the standard DNA formula a 50 µg/mL of DNA (at OD260) is 1 unit and DF is the 
dilution factor of sample. The purity of DNA sample was measured relative to ration of 
OD280 to OD260, whereby pure DNA has ratio of 1.8-2.0, and a spectrophotometer path length 
of 1 cm. The approximate concentrations of the DNA samples were 0.1-0.5 µg/µL. 
 
The size and purity of plasmid DNA was visualized by agarose gel electrophoresis. A 1-5 µL 
of undigested and/or restrictions enzyme digested DNA was run in parallel with molecular 
weight standard, as detailed in Section 2.5.4. 
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2.5.2 Primer designs 
 
Polymerase Chain Reaction (PCR) and sequencing of oligonucleotide primers was designed 
with enrichment of GC content (>50 %) and ended at the 3' termini with a G or C. 
Appropriate restriction enzyme sites were included at the 5' termini for PCR cloning primers, 
and extra nucleotides were incorporated for optimal cleavage according to restriction 
enzymes (NdeI/NdeI/NotI and EcoRI/BamHI/XbaI) and followed manufacturer’s 
instructions. The primer oligonucleotides resuspended in MilliQ water to concentration of 
1 µg/µL, and diluted into a working concentration of 100 ng/µL. 
 
Table ‎2.6  Oligonucleotide primers used for PCR and DNA sequencing 
Primer bp Sequence (5’- 3’) bp Size 
Cpn10_NcoI_For GGTACCCCATGGCGGGCCAG 20 
Nde1_Cpn10_For GAGATATACATATGGCGGGCCAGGCGTTTCG 31 
Cpn10_His6_ EcoRI_Rev 
CTGGGCAAATATGTGGATCATCATCACCATCA
CCATTAAGAATTCGAGCTC 
Reverse Complement: 
GAGCTCGAATTCTTAATGGTGATGGTGATGAT
GATCCACATATTTGCCCAG 
51 
Cpn10_G4His6_EcoRI_ Rev 
CTGGGCAAATATGTGGATGGTGGAGGTGGACA
TCATCACCATCACCATTAAGAATTCGAGCTC 
Reverse Complement: 
GAGCTCGAATTCTTAATGGTGATGGTGATGAT
GTCCACCTCCACCATCCACATATTTGCCCAG 
63 
T7_pET30a_For AGTTATTGCTCAGCGGTGGCAGC 23 
T7_pET30a_Rev 
CCACGCCGAAACAAGCGCTC 
Reverse Complement: 
GAGCGCTTGTTTCGGCGTGG 
20 
* Bold blue: Start codon.  Bold red: Stop codon. 
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2.5.3 Restriction enzymes digestions 
 
Appropriate restriction enzymes were applied for digestion of cloning and/or expression 
plasmids following manufacturer’s instructions. Approximately 1 µg DNA (plasmid and/or 
PCR product) was mixed with appropriate concentration of restriction enzymes 0.5 µL 
NdeI/NdeI/NotI, 0.5 µL EcoRI/BamHI/XbaI, 2.5 µL NEB Buffer-4, MilliQ water was added 
to reach a final volume of 25 µL, and incubated at 37 °C for 2 hrs (incubation time varied 
based on restriction enzyme efficiency and buffer components). DNA digestions were 
determined by visualizing DNA bands with 1 µL loading dye, loaded into agarose gel 
electrophoresis. 
 
2.5.4 Agarose gel electrophoresis 
 
All nucleic acids in this study were visualised using a standard ethidium bromide stained 
agarose gel electrophoresis. For visualisation and/or separation of DNA: a fresh preparation 
of 1-2 % (w/v) agarose gel in 1x Tris-Acetate-EDTA (TAE) buffer was mixed with 2 µL 
UltraPure
™ 
Ethidium bromide (10mg/mL, Invitrogen
™
). Then approximately 1-4 µL DNA 
samples loaded with 1 µL DNA-loading dye, electrophoresed at 90 V for 35 min or until it 
achieved an appropriate DNA separation size determined by molecular weight marker 
HyperLadder
™ 
100 bp (Bioline
™
) or GeneRuler
™
1 kb DNA Ladder (Fisher Scientific
™
), were 
run in parallel. Better separation and visualization occurred by using 1.5 % (w/v) agarose 
gels.  
 
2.5.5 General DNA amplification, insertion and sequencing 
 
2.5.5.1 Polymerase chain reaction  
 
PCR reactions consisted of purified DNA (from Miniprep, used as template) ~10 ng (0.1 pg – 
200 ng); 5 µL AccuPrime
™
 10x reaction buffer of: (600 mM Tris-SO4 (pH 8.9), 180 mM 
(NH4)2SO4, 20 mM MgSO4, 2 mM dGTP, 2 mM dATP, 2 mM dTTP, 2 mM dCTP, 
thermostable AccuPrime
™
 protein, 10 % glycerol); Cpn10_For_Primer (0.1 μM); 
Cpn10_Revr_Primer (0.1 μM); 0.4 µL Taq Polymerase, Accuprime™ Taq of: (rTaq DNA 
polymerase, Pyrococcus species GB-D polymerase, and Platinum
®
 Taq Antibody); and 
MilliQ water to 50 µL. A negative control with template DNA replaced with MilliQ water 
was always included. DNA samples were amplified using Veriti Thermal Cycler (life 
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technologies™), following optimized PCR conditions protocol: initial denaturation at 94 °C 
for 5 min; denaturation at 94 °C for 30 sec, annealing at 55 °C for 1 min, extension at 72 °C 
for 1 min, for 30 cycles; and a final extension at 72 °C for 10 min. PCR products were 
visualised by agarose gel electrophoreses and stored at 4 °C (Appendix 2). 
 
2.5.5.2 Enzymes digestions of DNA/PCR product 
 
Digestion of plasmid and PCR products were performed simultaneously in separate tubes 
following manufacturer standard protocol. Restriction enzymes in Table 2.9 were also 
applied for such digestions. Approximately 1 µg DNA (plasmid and/or PCR product) mixed 
with appropriate concentration of restriction enzymes 0.5 µL NcoI, 0.5µL EcoRI, 2.5 µL 
NEB Buffer and MilliQ water was added to final volume of 25 µL and incubated at 37 °C for 
2 hrs (incubation time may vary based on restriction enzyme efficiency and buffer 
components). Vector plasmid was dephosphorylated by 1 µL of calf intestinal alkaline 
phophatase (CIAP) incubated for further 1 hr as per recommendation (Invitrogen
™
). Digested 
and undigested products (of plasmid and PCR) were visualized as DNA bands with 1 µL 
loading dye, separated by agarose gel electrophoresis (see Section 2.5.4). 
 
2.5.5.3 Ligation of DNA fragments 
 
Digested DNA was extracted from agarose gels using QIAEX-II
® 
Gel Extraction Kit 
(QIAGEN
™
). In brief, a 60 µL Buffer QG (3:1 ratio to sample) of DNA digestion mixtures or 
fragments from agarose gel sliced was incubated at 50 °C for 10 min, following all 
manufacturer instructions but excluding optional steps. Final clean DNA fragment was eluted 
from QIAquick column by 50 µL EB
®
 buffer (10 mM Tris·Cl, pH 8.5) or TE
®
 buffer (10 mM 
Tris-HCl, pH 8.0; 0.1 mM EDTA). The sample were then stored at 4 °C. 
 
Rapid DNA Ligation Kit (Roche
™
) was applied for insert/vector DNA ligations following 
standard protocol. A molar ratio of vector DNA (Figure 2.1) to insert DNA is (1:5 or 1:2), 
a 2 µL digested vector, mixed with 10 µL insert, 5 µL T4 DNA ligation buffer (2x), 1 µL 
Dilution buffer (5x), 0.4 µL T4 DNA ligase was incubated for 30 min, at RT. Controls of 
ligations were performed simultaneously, with excluding insert DNA fragment or vector. 
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Figure ‎2.1  Expression vector maps of pPL550 and pET30a(+) used in this study 
 
2.5.6 Transformations and positive colony identifications 
 
Ligated products (i.e. expression plasmid with DNA fragments - encoding targeted proteins) 
were transformed into competent cells as previously described in Section 2.5.1.1 with minor 
modifications. Approximately 5 µL of ligated product was added to a 50 µL of E. coli 
competent Top10 cells (Invitrogen
™) or α-select cells (Bioline™), incubated on ice for 30 min 
before heat-shock at 42 °C for 15-45 sec (based on recommendations). The cells were heat-
shocked and were placed back onto ice for 5 min. Final cells were mixed with 950 µL of 
SOC medium and allowed to recover at 37 °C with shaking for 1 hr. Approximately 50-80 µL 
(of 5:100 or 1:100 diluted, respectively) of recovered culture were plated onto an LB-
Agar/(Kanamycin 30 µg/mL) or LB-Agar/(Ampicillin 100 µg/mL) plate for selection. Plate 
was incubated overnight at 37 °C. 
 
Random choosing of colonies for DNA sequence confirmation was done using colony PCR 
and visualised by gel electrophoresis. Following plasmid preparation procedures in Section 
2.5.1.2, positive colonies were grown individually in 5 mL LB/Kan or LB/Amp media 
culture, shaking overnight at 37 °C, whereby, DNA sequencing were performed on pure 
plasmid DNA extracted from miniprep. 
 
pPL550 cpn10-4xPro
4462 bp
cpn10-4xPro
AmpR
BamHI (4181)
Eco RI (1)
Nde I (4188) Xba I (5)
pET30a cpn10-4xPro
5545 bp
lac operator
kan sequence
lac I
cpn10-4xPro
T7 promoter
His tag
f1 origin
ColE1 pBR322
T7 terminator
Eco RI (5179)
Nde I (5456)
Not I (5153)
Xba I (5494)
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Figure ‎2.2  E. coli α-select cells with expression vector (pET30a-X) encoding target proteins 
Examples of LB-Agar/Kan with colonies grown from successfully transformed E. coli α-select cells 
with expression vector (pET30a-X) encoding target proteins. Randomly selected colonies were 
numbered, picked and applied for cPCR and DNA sequencing. 
 
2.5.6.1 Colony PCR (cPCR) 
 
Individual colonies (Figure 2.2) picked onto a sterile pipette tip were added into PCR reaction 
mixtures of 6.5 µL PCR Master Mix (2x) (Promega
™
, containing 50 units/mL of Taq DNA 
polymerase, reaction buffer (pH 8.5), 400 μM dATP, 400 μM dGTP, 400 μM dCTP, 400 μM 
dTTP, 3 mM MgCl2), 0.5 µL T7_For_Primer (1 µM); 0.5 µL T7_Revr_Primer (1 µM); and 
MilliQ water to 12 µL. A negative control with no colony added was always included. 
Samples were amplified using Veriti Thermal Cycler (life technologies
™
), following 
optimized cPCR conditions protocol: initial denaturation at 94 °C for 10 min; denaturation at 
94 °C for 30 sec, annealing at 60 °C for 30 sec, extension at 72 °C for 1 min, for 25 cycles; 
and a final extension at 72 °C for 8 min. cPCR products were visualised by agarose gel 
electrophoreses and was stored at 4 °C (Appendix 2). 
 
2.5.6.2 Nucleotide sequencing 
 
Nucleotide sequencing was performed for purified plasmid DNA (miniprep) using ABI 
Prism
®
 BigDye
™
 terminator (PE Applied Biosystems) as per manufacturer recommendations. 
Sample was prepared: as 1-5 µL (equivalent to 50-100 ng of >2000 bp) of pure plasmid 
DNA, was added to 1 µL (0.1 µM) primer (F or R), mixed with 8 µL ABI Prism
®
, and MilliQ 
water to 20 µL. Samples were electrophoresed and scanned by Australian Genome Research 
Facility (agrf), University of Queensland. 
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Software tool VectorNTI was used for plasmid sequence analysis and mapping. Multiple 
sequence alignments were performed using online BLAST tool (NCBI, 2014). DNA/Protein 
sequence translation were performed online using ExPASy Bioinformatics Resource Portal 
(ExPASy, 2014a). 
 
2.5.6.3 Transformation into E. coli BL21(DE3)/E. coli XL1-Blue 
expression strains 
 
E. coli BL21 (DE3) T7 Expression LysY/I
q 
competent cells (New England BioLabs
®
) were 
transformed with plasmid (pET30a-Insert-X-ligated) following a recommended 
transformations protocol. Similarly, E. coli XL1-Blue competent cells (Stratagene) was 
transformed with expression vector (pPL550-Insert-X-ligated). In brief, a 50 µL aliquot of 
competent cells was thawed in ice and incubated with 1-5 µL plasmid DNA (approximate 
100-500 ng) for 30 min in ice. Normally, 1 µL of supercoiled plasmids and 5 µL of ligated 
products. Mixtures were heat-shocked at 42 °C for 10 sec (or more upon requirement but 
with maximum of 45 sec), and re-incubated in ice for further 5 min. A 950 µL of SOC 
(sterilised) broth was added to transformed cells, incubated with shaking for 1 hr at 37 °C. 
50-80 µL of mixture (5:100 dilutions, respectively, allow individual colonies to grow) were 
spread onto LB-agar plate with appropriate antibiotic (Kan or Amp), incubated for overnight 
at 37 °C. Freshly grown colonies were applied for inoculation expression cultures and/or 
preparation of 15-25 % (v/v) glycerol stock (-80 °C) for future expression. 
 
2.6 Protein expression 
 
2.6.1 Expression from E. coli XL1-Blue-pPL550 
 
2.6.1.1 E. coli culture growth and protein expression (≤ 1000 mL) 
 
Following schematic procedures below (Figure 2.3), a single colony of E. coli XL1-Blue-
pPL550 encoding recombinant proteins (Table 2.2) of hCpn10 or CE76, was used to 
inoculate 5 mL LB media with 100 µg/mL Amp, and incubated overnight at 37 °C, shaking at 
200 rpm. A dilution (1:100) of overnight culture was used to inoculate 50 or 100 mL LB or 
TB media flask containing 100 µg/mL Amp, and continued to be grown at 37 °C, 220 rpm 
shaking, until OD600 reached an approximate 0.5-0.7. Protein expression was induced by 
increasing the temperature to 42 °C and continued for further 3-4 hrs. A negative induction 
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was performed for each protein by keeping temperature at 37 °C. The cell density at OD600 
was measured at hourly intervals for pre- and post-inductions. E. coli cells were harvested by 
centrifugation at 5000xg at 4 °C for 30 min. Then, cell pellets were frozen and stored at -20 
°C prior to cell lysis. 
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Figure ‎2.3  Scheme for recombinant protein expressions  
The scheme applied for quick expression screening trials and for scaling up processes for recombanint 
proteins examined in this study. Different expression media were used: LB; Luria broth, TB; Terrific 
broth, and DM; Defined media (detailed in Table 2.3).  
SDS-PAGE Analysis  
Soluble/ insoluble protein  
Cells harvest & Protein purifications 
Post-induction  
Post-induction  
Post-induction  
Post-induction  
Strain activation 
Biomass 
Expression conditions screening: 
media, °C, rpm, IPTG, etc. 
For Scale-Up   
For Scale-Up   
Large-Scale  
 
5 L, 20-42 °C, 300-600 
rpm, TB or DM   
Lab-Scale 
  
1 L, 26/37 °C, 
220 rpm, TB    
Small-Scale           
 
50mL, 26/37 °C,  
220 rpm, TB 
5 mL, 37 °C, 220 rpm, TB  
 
      1:100 inoculation 
 
100 mL, 37 °C, 220 rpm 
     1:100 inoculation   
Glycerol stock   
50 mL, 37 °C, 220 rpm   
    1:100 inoculation   
 
5 or 10 mL  
50 /100mL,  
37 °C,   
220 rpm, LB 
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2.6.1.2 Scale-up E. coli culture growth and protein expression (≥ 4 L) 
 
A single colony of E. coli XL1-Blue-pPL550 containing recombinant proteins of hCpn10 or 
its variant CE76 (Table 2.2), was used to inoculate a 5 mL LB media with Amp 100 µg/mL 
for overnight at 37 °C and then shaking at 200 rpm. A dilution (1:100) of overnight culture 
was used to inoculate 100 mL TB media containing 100 µg/mL Amp, and continued to grow 
at 37 °C, 220 rpm shaking, until OD600 reached an approximate 1. Following schematic 
procedures in Figure 2.3, a second dilution (1:100) of 100 mL culture was used for 
inoculating 5 L culture medium of DM or TB media in a 7 L Applikon bioreactor (Applikon
®
 
Biotechnology). DM medium was the best for use due to the high enrichments of media and 
ability to control cultural conditions (Temperature, DO2 %, stirrer speed, and pH). However, 
TB broth was also used as a cheaper option. 5 L of freshly made DM was pre-warmed to 
37 °C, and then inoculated. The inoculated cell cultures continued to grow with appropriate 
antibiotic at 37 °C, 400-600 rpm, DO2 (40-60 %), and pH 6.7. At 0.5-0.7 OD600, targeted 
protein was expressed by increasing temperature to 42 °C, and continued for 4 hrs. The cell 
density at OD600 was measured at hourly intervals, and for pre- and post-induction. Due to the 
cost of overall large-scale production, the negative induction was performed simultaneously 
only on 100 mL cell cultures (shaking flask) by keeping temperature at 37 °C. Finally, E. coli 
cells were harvested by centrifugation at 5000xg at 4 °C for 30 min. Then, cell pellets were 
stored at -20 °C prior to cell lysis, as detailed in Section 2.7.1. 
 
2.6.1.3 Measurement of Cell Density (OD600) 
 
Samples from cell culture were collected and celldensities measured at 600 nm (OD600) using 
UV-Vis SpectraMax Plus
384
 Spectrophotometer. Samples were collected and measured at 
hourly intervals of cell culture growth as well as samples of pre- and post-inductions. In brief, 
a 1 mL of cell culture was diluted 1:1 to 1:100 in culture medium, and measured at 600 nm 
(blanked by same dilution media). The optical densities for all samples were analysed by 
SoftMax
®
Pro statistical software, and OD600 plotted against time in hour. 
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2.6.2 Protein expression from E. coli BL21(DE3)-pET30a 
 
2.6.2.1 E. coli culture growth screening (Expression trials of recombinant 
proteins) 
 
A single colony of E. coli BL21(DE3)-pET30a plate or glycerol stock (stored at -80 °C) 
containing recombinant proteins of hCpn10 and/or CE76 was used to inoculate 5 mL LB or 
TB media, containing 30 µg/mL Kan, shaken at 200 rpm overnight at 37 °C. A dilution 
(1:100) of overnight culture was used to inoculate 500 mL LB or TB media containing Kan 
and was incubated at 37 °C, 220 rpm shaking, until OD600 reached an approximate 0.6-0.8. 
The culture flask was divided into 10 mL cultures of non-induced culture (control) and 
multiple induced cultures at 20, 26, 30, and 37 °C. Protein expression was induced by adding 
IPTG to final concentrations of 0.1, 0.4, 1.0 mM, and continued for 3 hrs, 4 hrs, or overnight 
(approximately 14 hrs). To monitor protein expressions over time, a 100 µL (2x) of cell 
culture were collected at initiation, then at hourly intervals up to 4 hrs post-induction, then 
after overnight incubation and OD600 measured, as described in Section 2.6.1.3. Samples 
were centrifuged at top speed 16000xg for 5 min, supernatants discarded and cell pellets 
stored at -20 °C for SDS-PAGE analysis.  
 
The above experiments were performed over different time frames based on whether the 
culture medium used was LB or TB as well as depending on induction conditions. These 
experiments were thought to be necessary for determining the optimum conditions for 
scalable expressions. 
 
2.6.2.2 Small-scale protein expressions (≥ 100 mL) 
 
A single colony of E. coli BL21(DE3)-pET30a encoding recombinant proteins from 
Table 2.2, was inoculated into 10 mL TB, containing 30 µg/mL Kan, shaking at 200 rpm for 
overnight at 37 °C. A dilution (1:100) of overnight culture was used to inoculate 100 mL TB 
media containing 30 µg/mL Kan, and was incubated at 37 °C, 220 rpm shaking, until OD600 
reached 0.6-0.8. The culture flask was divided equally into two, as induced culture and non-
induced culture (control). Protein expression was induced by adding IPTG to final 
concentrations of 0.4 mM, and continued for further 4 hrs, at reduced temperature of 26 °C. 
1 mL samples were collected for cell density (OD600) pre- and post-induction, centrifuged at 
16000xg for 5 min, and cell pellets stored at -20 °C for SDS-PAGE analysis. Final culture 
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cells were harvested by centrifugation at 5000xg at 4 °C for 30 min. Then, cell pellets were 
stored at -20 °C prior to cell lysis (Appendix 2). 
 
2.6.2.3 Large scale protein expressions (≥ 1L) 
 
Large scale (≥ 1L ) protein expression was carried out as described in Section 2.6.1.2 above, 
except that 100 mL TB-culture was used to inoculate 1 L of TB medium, containing 
appropriate antibiotic. The 1 L TB culture continued to grow in a well ventilated 2.5 L 
baffled flask (from Tunair™) at 37 °C, and shaking 220 rpm, until OD600 reached 0.6-0.8. 
Cultures were set to the optimal conditions and induced with final concentration of 0.4 mM 
IPTG, at reduced temperature of 26 °C. After incubation for 3-4 hrs, the cells were harvested 
by centrifugation at 5000xg, at 4 °C, for 30 min. Cells pellets were resuspended in Lysis 
buffer (Table 2.4), and stored frozen at -20 °C. 
 
Table ‎2.7  Recombinant protein constructs, plasmid, E. coli stains and applied expression 
conditions 
Construct Plasmid E.coli strain Induction conditions* 
hCpn10 
∆L-Cpn10 
∆Roof-Cpn10 
β-barrel   
 
CE76 
6xHis-CE76 
pPL550 XL1-Blue Inducer: increase temp to 42 °C 
Time: 3, 4 hrs 
Culture medium: LB, TB, DM 
Culture size: 5, 50, 100, 1000, 5000 mL 
CE76 
CE76P1 
CE76P2 
CE76E5 
 
CPMyc 
CPMycP1 
 
CP7CD44-P1 
 
CP11bFGF-P1 
 
CR2-VEGF1-P2 
pET30a BL21 (DE3) Inducer: 0.1, 0.4, 1.0 (mM) IPTG  
Temperature:  20, 26, 30 or 37 °C 
Time: 3, 4, overnight (14) hrs 
Culture medium: LB, TB, DM 
Culture size: 10, 50, 100, 400, 1000 mL 
FH-Cpn10 
 
FH-CE76 
 
pET30a BL21 (DE3) Inducer: 0.4 (mM) IPTG  
Temperature:  26 °C 
Time:  4 hrs 
Culture medium: TB 
Culture size: 100, 400 mL 
* Bold highlight the best conditions applied. 
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Figure ‎2.4  Steps in the sample protein preparations and purification  
Scheme illustrates the processes applied for purification of each recombinant protein (Table 2.2). For 
a moderate purity of < 95 %, recombinant proteins were captured by affinity chromatography (IMAC) 
for removing bulk impurties, and/or followed by intermediate purification by ion exchange 
chromatography (IEX) for further isolation, removing impurities and concentrating of target proteins. 
For higher level of purity ≥ 95 %, the recombinant proteins were polished by gel-filtration 
chromatography (GF). 
  
Protein Purification Processes 
YES  
YES  
YES  
YES  
YES  
NO 
NO 
NO 
NO 
YES  
YES  
YES  
YES  
YES  
Soluble protein 
  
Insoluble protein 
(inclusion bodies)  
 Filtered 0.45µm 
Capture by IMAC 
Protein 
Refolding 
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(solubilisation) 
Intermediate purification 
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Protein Analysis and Characterisation  
(in vitro/ in vivo)  
ELISA, MALDI-TOF, Octet, FACS, etc 
Desalting/ 
Buffer  
exchange  
Protein stability & 
Buffer screening   
Purified 
proteins   
YES  
Protein Extraction: cell lysis, extractions, & 
clarifications. 
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2.7 Recombinant proteins extraction and purification 
 
2.7.1 Cell lysates for protein in native conditions 
 
Harvested cell pellets following Figure 2.4, were cell pellets thawed at ≤ 4 °C and 
resuspended in Lysis buffer (Table 2.4) of 5 mL buffer per 1 mg of wet cell pellets. For small 
scale cell culture (≤ 50 mL), 1 mg/mL freshly made lysozyme and 5 µg/mL DNaseI were 
added to Lysis buffer and incubated for 1-2 hrs at ≤ 4 °C. For lab scale cell culture (≤ 100 
mL), cells were resuspended in Lysis buffer (5 mL/1mg), with 5 µg/mL DNaseI, and 
sonicated on ice by 10 sec (5x) bursts at 200 W and cooling period of 10 sec between each 
round. For large scale cell cultures (> 100 mL), cells were resuspended in a pre-chilled Lysis 
buffer (5 mL/mg), and cells ruptured using a high pressure homogenizer at single pass of 
15000 psi or 3x passes of 5000 psi (350 bar) with a cooling period of 5 min between each 
round. The approach of cell lysis and disruptions were based on culturel size and detailed are 
in Table 2.8. 
 
Table ‎2.8  Common processes applied for E. coli intracellular recombinant protein extractions 
Extraction process Potency Usage and comment(s) 
Enzymatic digestions  -
Cell lysis- 
Gentle Small scale only (≤ 50 mL). 
Cell wall digested by osmotic disruption. 
Disadvantage:  
 Low product yield. 
 May Combined with mechanical disruption. 
Ultra sonication  Moderate  Small to Lab-scale (50-100 mL). 
Microscale high-pressure sound waves cause disruption by 
shear forces and cavitations. 
Disadvantages: 
 Release of nucleic acid causing viscosity problem. 
 Required to be pre- and post- chill. 
Homogeniser 
(EmulsiFlex-C5) 
Vigorous Lab to Large-scale (100-1000 mL), capacity 1-5 L/hr. 
Cells forced through small orifice at very high pressure; and 
shear force disrupts cells 
500-30000psi/3.5-207MPa. 
Disadvantage: 
 Proteases release. 
Homogeniser  
(AVP-1000)  
Vigorous Large-scale (≥ 1 L), capacity 22 L/hr. 
Cells forced through small orifice at very high pressure; 
shear force disrupts cells. 
Up to 1000 bar/14,500 psi. 
Disadvantage:  
 Proteases release. 
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Cell lysates were then centrifuged at a maximum speed (16000xg) at 4 °C for ≥ 30 min to 
separate cell debris and produce clear supernatants which contained soluble proteins 
including target recombinants. Protease inhibitor cocktails tablet (1/10 mL) was added to 
protect target proteins from any proteolytic activities, and it was then stored at 4 °C. 
 
2.7.2 General recombinant proteins purification under native 
conditions 
 
Chromatography purification were performed following cell lysis. Different purification 
schemes are illustrated in Figure 2.5. The purification schemes were based the on proteins 
state i.e. in native or in denatured form. Protein samples and buffers were pre-filtered with 
0.45 μm and 0.22 μm, respectively. In every purification step, samples were retained for 
SDS-PAGE analysis. 
 
 
Figure ‎2.5  Affinity chromatography of CE76E5  
Representation chromatogm illustrating procedure of His-tagged CE76E5 capturing and stepwise 
elusion using IMAC-Elution buffer: (20 mM Phosphate, 0.5 M NaCl, 0.5 M imidazole, 0.01 % BME).  
 
2.7.2.1 His-tagged protein purification -affinity chromatography 
(Capture) 
 
Following the purification scheme (Figure 2.4), the affinity purification method was first used 
for capturing His-tagged protein. Clarified lysate was loaded onto HisTrap
™
FF crude or 
HisTrap
™
HP (5 mL column, GE Healthcare) which was pre-equilibrated with 5 column 
volumes (CV) of IMAC Binding buffer (Table 2.4), using an ÄKTA prime plus FPLC 
System (GE Healthcare), with a flow rate of 5 mL/min at RT. After loading, the column was 
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washed with 10 CV Binding Buffer to remove contaminants and unwanted proteins 
(Figure 2.5). Finally, His-tagged proteins were eluted gradually or stepwise to 100 % using 
IMAC Elution buffer (Table 2.4). Eluted fractions were collected, pooled, and stored at 4 °C. 
1-5 µL samples of pre-load, wash, and elution fractions were added to 5 µL (4x) Sample 
Buffer of sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), 
containing 2 µL (10x) Reducing agent (1 M DTT), and loaded in 4-12 % SDS-PAGE for gel 
analysis. The eluted fractions were pooled, concentrated, and buffer exchanged with suitable 
functional/storage buffer. A further purification of recombinant proteins by ion exchange 
chromatography and/or gel-filtration chromatography was performed as required and is 
detailed below. 
 
2.7.2.2 Ion exchange chromatography (intermediate purification) 
 
A pool of target protein (with pI > 7) was further purified by ion exchange chromatography 
(IEX) as an intermediate purification step by using 1 mL cation-IEX column of HiTrap
™
SP 
FF or HiTrap Capto
™
S (GE Healthcare), using an ÄKTA prime plus FPLC System (GE 
Healthcare). The column was equilibrated with IEX Binding buffer: 50 mM Sodium Acetate 
(pH 5.5) (Table 2.4). The pooled sample (from Section 2.7.2.1) was pre-diluted (1:2) or 
buffer exchanged in no-salt buffer before loading onto equilibrated column. Samples were 
loaded at a flow rate of 1 mL/min at RT and eluted using a linear gradient with IEX Elusion 
buffer: 50 mM Sodium Acetate (pH 5.5), 1.0 M NaCl, at 0–1 M NaCl run over 10 CV (10 
mL). Purified protein factions were retained for SDS-PAGE analysis, and then were pooled 
and buffer exchanged with suitable storage buffer and stored at 4 °C.  
 
2.7.2.3 Gel filtration chromatography (polishing) 
 
A pool of protein fragments were further purified (as required) by gel filtration (GF) 
chromatography using Superdex
™ 
75 or Superdex
™ 
200 prep grade gel filtration column (GE 
Healthcare) using FPLC Systems: ÄKTA prime plus (GE Healthcare) or ÄKTA Explorer 
(Amersham Pharmacia). Protein samples and GF Running buffers (Table 2.4) were filtered 
prior to loading with 0.45 μm and 0.22 μm, respectively. The proteins obtained from either 
IMAC or IEX were first buffer exchanged using HiTrap
™
 Desalting (5 mL column, GE 
Healthcare) or HiPrep
™ 
26/10 Desalting (53 mL column, GE Healthcare) with same running 
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buffer and concentrated prior to loading. The SEC column was pre-equilibrated with 5 CV of 
the same buffer. 
 
For  hCpn10 and other variants, the column was pre-equilibrated and run in GF Running 
buffer I (100 mM Phosphate (pH 7.6), 150mM NaCl, 1 mM DTT) or GF Running buffer II 
(50 mM Tris (pH 8.0), 150mM NaCl, 1 mM DTT) at a flow rate of 1 mL/min at RT. For 
CE76 construct and its variants (CE76P1, CE76P2, and CE76E5) the column was pre-
equilibrated and run in GF Running buffer III (100 mM Sodium Acetate (pH 5.5), 150 mM 
NaCl, 1 mM DTT) at the same flow rate and condition. The purified protein fractions were 
collected separately and samples were retained for SDS-PAGE analysis. Protein fractions 
and/or pool were used for further investigations. 
 
2.7.3 Recombinant proteins extraction, purification, and refolding 
(non-native) 
 
2.7.3.1 Cell lysate and inclusion bodies preparations (under denaturing 
conditions) 
 
For dissolving and extracting proteins from insoluble fractions, i.e. inclusion bodies (IB) 
(Figure 2.6), the cells were harvested by centrifugation at 5000xg and stored at -20 °C. The 
harvested cell pellets were thawed overnight on ice at 4 °C, and resuspended in Lysis buffer: 
50 mM Tris (pH 7.6), 150 mM NaCl, 0.1 % Triton X-100, 1 µg/mL DNaseI, 1 mM DTT, 
1 tablet/10mL cOmplete ULTRA (Table 2.4) in a ratio of 5:1 (5 mL/gm) as described in 
Section 2.7.1. Cell pellets were vortexed until they were completely dissolved or placed on 
platform rocker for 1-2 hrs. A combination with mechanical disruption methods (Table 2.8) 
was also applied in some instances. Soluble fractions were separated from insoluble factions 
by centrifugation at 5000xg for 10 min at 4 °C. Pellets were then washed with IB Washing 
buffer: 100 mM phosphate (pH 7.4), 1 M Urea, 1 % Triton X-100 (Table 2.4), and 
centrifuged at maximum speed of 16000xg for 30 min at 4 °C. Pellets were then resuspended 
in IB Denaturation buffer: 100 mM phosphate (pH 7.4), 150 mM NaCl, 8 M Urea, 2 mM 
DTT or 0.5 % BME (Table 2.4), with stirring or shaking for 1-2 hrs at RT, to dissolve the 
inclusion bodies, and were then clarified by centrifugation at maximum speed of 16000xg for 
30 min at 4 °C. The clarified supernatants containing the denatured proteins were then ready 
to be loaded onto a column compatible with chaotropic agent (e.g. 8M Urea) for protein 
purifications. SDS-PAGE analysis was performed by mixing 1-5 µL of denatured lysate, 
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supernatant, and purified denatured protein fractions, with 5 µL Sample Buffer (4x), diluted 
with MilliQ water to 15 µL, heated at 70 °C for 10 min, and then loaded onto SDS-PAGE 
gels. 
 
 
 
Figure ‎2.6  Inclusion bodies (IB) developed during protein expression of FH-CE76 in BL21 
E.coli. 
Images of the E. coli cells with IBs (dark aggregates) post-expression of FH-CE76. (A) E. coli cells 
examined under light microscopy, black bar shows scale of 50 and 10 µm, respectively. (B) E. coli 
cells examined under electronic microscopy, while bar shows scale of 2 and 1 µm, respectively. 
 
2.7.3.2 His-tagged protein purification under denatured conditions 
(capture) 
 
This affinity purification method is similar to Section 2.7.2.1 above with modification for 
His-tagged proteins in denatured conditions. The dissolved inclusion bodies containing the 
His-tagged FH-CE76 protein were loaded onto HisTrap
™
 FF crude or HisTrap
™
 FF (5 mL 
column, GE Healthcare), that was pre-equilibrated with 5 CV IMAC Binding buffer III: 100 
mM Phosphate (pH 7.8), 150 mM NaCl, 0.05 % BME, 8 M Urea, 10 mM Imidazole (Table 
2.4), with a flow rate of 1-5 mL/min, at RT. The column was washed with 5 CV of IMAC 
binding buffer III for removal of contaminants and unwanted proteins, followed by a stepwise 
A. 
 
 
 
 
B. 
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wash of 5 % of IMAC Elution Buffer III: 100 mM Phosphate, 150 mM NaCl, 0.05 % BME, 
8 M Urea, 0.5 M Imidazole (Table 2.4). The His-tagged FH-CE76 fragments were eluted 
from the column (in 5 CV) by 100 % stepwise application of IMAC Elution buffer III 
(Table 2.4). Prior to protein refolding processes, the eluted fractions were collected, pooled, 
and stored at 4 °C. Samples (1-5 µL) of pre-load, wash, and elution fractions were mixed 
with 5 µL Sample buffer (4x), and then loaded into 4-12 % SDS-PAGE gels for analysis. 
 
2.7.3.3 Refolding of denatured proteins 
 
A quick screening test was performed to find the optimum buffering components and 
conditions. A set of multiple buffering systems with different salt concentrations, pH, 
reducing agents, non-ionic detergents, stabilizers, in a total of 190 µL/well were loaded into a 
96-well flat plate. A 10 µL sample of dissolved protein (concentrated ≥1 mg/ml) was added, 
and set to shake in a platform rocker for 1-2 hrs at 4 °C. Protein aggregation was determined 
following the methods of Burgess (2009) and Tresaugues et al. (2004) by measuring the 
absorbance at 320 and 390 nm, respectively (Burgess, 2009; Tresaugues et al., 2004). Low 
absorbances suggested low levels of protein aggregation and determined the buffer of choice 
used for refolding. 
 
The refolding of denatured proteins was performed in multiple dialysis steps in the optimal 
buffer (from above) at 4 °C. Proteins (from Section 2.7.3.2) were loaded into a SnakeSkin
® 
Dialysis Tubing (Thermo
™
 Scientific), with 7 kDa or 10 kDa molecular weight cut-off 
(MWCO) and dialysed against 100 mM Phosphate (pH 7.6) or 50 mM Tris (pH 8.0), 100/150 
mM NaCl, 5/10 % glycerol, 1 mM DTT, and 4M urea, for 3-4 hrs at 4 °C. The concentration 
of Urea was gradually reduced from dialysis buffer during each buffer exchange steps to final 
concentration of 0 M (from: 4, 2, 1 to 0 M Urea). Protein was kept in a fresh dialysis buffer 
(of 0 M Urea) overnight at 4 °C prior to polishing by GF purification (if required), as 
described in Section 2.7.2.3. 
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2.8 Protein analysis and characterisation 
 
2.8.1 Detection of recombinant proteins by SDS-PAGE 
 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a standard 
method for detecting protein expression, purifications, degradations and the formation of 
multimers. 1-5 µL protein samples, mixed with 5 µL LDS Sample buffer (4x) NuPAGE
®
, 
containing 2 µL Reducing agent (10x) 1 M dithiothreitol (DTT) for reduced samples and/or 2 
µL MilliQ water for nonreduced samples and MilliQ water were added to 15 µL. Samples 
were mixed and denatured by heating at 70 °C for 10 min or 90 °C for 5 min. For analysis, 
the denatured samples were loaded onto precast 4-12 % NuPAGE
®
 Bis-Tris mini gels, 
electrophoresed for 35 min (or longer based on proteins size and required separation) at 200 
V, run in NuPAGE
® 
MES running buffer system form Invitrogen
™
. A 5 µL SeeBlue
®
Plus2 
prestained standard (Invitrogen
™
) was run in parallel with samples for molecular weight 
determination. Following electrophoresis, the gel was washed 3x in MilliQ water for 5 min. 
Proteins were visualised by staining the gel in 50 mL SimplyBlue
™
 SafeStain (Coomassie
®
G-
250, Invitrogen
™
) and placed on a platform rocker with gentle shaking for 1-2 hrs. Since 
SimplyBlue
™ 
Safe Stain is a non-hazardous stain and does not require methanol or acetic acid 
fixatives, therefore, gels were only destained in MilliQ water for ≥ 2hrs or until protein bands 
were visible. The gel images were captured using a Bio-Rad Molecular Imager
®
Gel Doc
™
 
XR
+
 System and analysed by Image Lab
™ 
ChemiDoc MP Software. 
 
2.8.2 Detection of purified His-tag proteins by western blot 
 
Post-electrophoresis SDS-PAGE gels were placed with a polyvinylidene fluoride (PVDF) 
transfer membrane, and covered in each side with three pieces of pre-soaked filter in Transfer 
buffer: (25 mM Tris, 192 mM glycine, 0.1 % (w/v) SDS, 20 % (v/v) methanol). Protein bands 
were transferred to PVDF membrane, using a mini-cell apparatus (Invitrogen
™
) for 60 min, at 
30 V at RT. The PVDF membrane was then incubated in 10 mL Blocking buffer PBST-M: 
(PBS; 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.8 mM KH2PO4 (pH 7.4), 0.1 % 
(v/v) Tween-20, 5 % (w/v) skim milk) in orbital shaker for 1 hr at 4 °C. The membrane was 
washed (3x for 10 min) in PBST buffer: (PBS, 0.1 % (v/v) Tween-20), at RT. The washed 
membrane was incubated with 5 µL (1:5000 dilutions in 25 mL PBST) HRP-Mouse Anti-
6xHis (50 µg/mL), for 1 hr at 25 °C in orbital shaker. The membrane was washed with PBST 
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(2x for 15 min) at RT, and 1x wash with PBS for 5 min. The membrane was then drained and 
target proteins were visualized using SuperSignal West Pico Chemiluminescent Substrate 
(Thermo
™
 Scientific) by incubating with 2 mL detection substrate for 3-5 min and then 
excess reagent was drained. Membrane was exposed to Kodak BioMax X-ray film (Kodak
™
) 
in the dark room and processed using Konica SRX-101A film processor (KonicaMinolta
™ 
Healthcare) for 1, 2, 5, 10, 30, and 60 sec. 
 
2.8.3 Protein quantification by spectrophotometric and BCA protein 
assays 
 
Sample protein concentration was measured using a UV-visible NanoDrop1000 
spectrophotometer (Thermo
™
 Scientific) with appropriate sample dilutions with same buffer 
used as blank. The concentration was measured at 280 nm absorbance according to the Beer-
Lambert Equation (2.2) using extinction coefficients (ε) listed in Table 2.10. A is absorbance 
at 280 nm, ε is molar absorptivity (L. mol-1 cm-1), l is path length (1 cm), C is concentration 
(mol. L
-1
) or 100 mg/mL. The ε of proteins were calculated from amino acid sequences using 
ProtParam (online program) by ExPASy proteomics server (ExPASy, 2014b). The protein 
concentrations were then determined from rearranged Equations 2.3 and Equation 2.4. 
 
                Equation ‎2.2 
 
      
         
        
       Equation ‎2.3 
 
            
    
     
        Equation ‎2.4 
 
Table ‎2.9  Proteins molecular weight and molar extinction coefficients 
Protein Mwt (Da) ε (M-1 cm-1 ) Alternative ε (M-1 cm-1 ) 
hCpn10 75626.3 31290  
∆L-Cpn10 63930.0 31290  
∆Roof-Cpn10 67238.2 31290  
∆L-∆Roof-Cpn10 57924.2 31290  
FH-Cpn10 76653.5 31290  
CE76 78901.0 80220  81095 for non-reduced Cys 
CE76P1 82250.9 80220  81095 for non-reduced Cys 
CE76P2 81620.3  80220  81095 for non-reduced Cys 
CE76E5 86399.1 80220  81095 for non-reduced Cys 
FH- CE76 79140.8 80220  81095 for non-reduced Cys 
57 
 
Protein Mwt (Da) ε (M-1 cm-1 ) Alternative ε (M-1 cm-1 ) 
CPMyc 73014.2 31290  
CPMycP1 76364.0 31290  
CP11-bFGF-P1 74535.4 31290  
CP7-CD44-P1 77900.0 31290  
CR2-VFGF-P2 84691.0 31290  
 
Protein concentrations were also measured at 562 nm for samples (from cell lysate, 
purification, refolding, concentration, etc), using the Pierce
™ 
Bicinchoninic acid (BCA) assay 
(Pierce
™
 BCA Assay Kit, Thermo
™
 Scientific), in flat-bottom 96-well plate, following the 
manufacturers protocol. 20 µL samples diluted by a factor of 4 or in diluted net of 1:10 to 
1:100 (to give absorbance values within assay range) in duplicate or triplicate was mixed with 
180 µL BCA reagent mixture per well. 20 µL of bovine serum albumin (BSA) protein 
standard of known concentration (1 mg/mL) made in serial dilution by factor of 4 (in 
duplicate) was also mixed with 180 µL BCA reagent mixture per well, incubated at 37 °C for 
30 min. Samples were read by UV-Vis SpectraMax Plus
384
 Spectrophotometer plate reader at 
A562. Sample concentrations were then interpolated from BSA standard curve (Figure 2.7). 
 
 
Figure ‎2.7  BSA standard curve 
The standard curve of BSA used to determine unknown protein concentrations using Pierce
™ 
BCA 
assay in 96-well plate after incubation for 30 min in 37 °C, and then measured at 562 nm. 
 
2.8.4 Identification of protein by MALDI-TOF MS 
 
Verification of correct protein expressions and purifications, sample purity and protein 
primary molecular weights in dalton (Da) were determined by using matrix assisted laser 
desorption ionization (MALDI) coupled to time of flight (TOF) mass spectrometer (MS) for 
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accurate mass measurement analyses. The peptide fingerprints used to determine structural 
information and protein maps were generated by injecting samples onto a Prominence Nano-
LC system (Shimadzu
™
 Scientific) using a flow rate of 30 µL/min and desalted on an Agilent 
C18 trap (0.3 x 5 mm, 5 um, Agilent
™
 Technologies) for 3 min, followed by separation on a 
Vydac
®
 Everest
®
 C18 (300 A, 5um, 150 mm x 150 um) column at a flow rate of 1 µL/min. A 
gradient of 10-60 % of mobile-phase B (80 % acetonitrile (AcN)/ 0.1 % Formic acid (FA)) 
for 30 min over mobile-phase A (1 % AcN/ 0.1 % FA) was used to separate peptides. Eluted 
peptides were directly analysed on a Triple TOF
®
 5600 system (ABSciex
™
) using a 
NanoSpray
®
 III interface (ABSciex
™
). Gas and voltage settings were adjusted as required. 
MS TOF scan across m/z 350-1800 was performed for 0.5 sec followed by information 
dependent acquisition of the top 20 peptides across m/z 50-1800 per second. 
 
Data was converted to mgf format and searched in MASCOT accessed via the Australian 
Proteomics Computational Facility (APCF). Data was searched in SwissProt against all 
species using trypsin as enzyme, mis-cleavages, MS tolerance of 0.5 Da, MS/MS tolerance of 
0.2 Da. Carbamidomethylation (cys, fixed) and oxidation (met, variable) modifications were 
also included.  
 
Molecular weight analyses of protein samples were also characterized and determined by 
MALDI-TOF MS. The intact protein mass was fitted exactly with the theoretical Mwt 
calculated from the amino acid sequence using ExPASy proteomics server (ExPASy, 2014b), 
or within ±1-2 Da variations due to the intact protein molecule modifications and/or 
heterogeneity. 
 
2.8.5 Characterisation of protein molecular mass and native 
configuration by SE-HPLC 
 
Sample molecular weights in their native state (in full homogeneity), and soluble aggregates 
were further investigated using analytical size exclusion (SE) high performance liquid 
chromatography (HPLC) with a TSK column (TSK G3000SWXL, Tosoh
™
 Bioscience) and 
Agilent 1200 Series HPLC System (Agilent
™
 Technologies). Protein samples and all SE 
Running buffers (Table 2.6) were filtered (0.22 µm) prior to loading onto TSK column. A 
guard column (Guard column (7.8 mm), Tosoh
™
 Bioscience) was placed ahead of the SE-
HPLC TSK column and the whole system was pre-equilibrated with SE mobile phase I: 0.1 
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M Phosphate buffer (pH 7.8), 0.2 M sodium chloride, or by SE mobile phase II: 100 mM 
Sodium Acetate (pH 5.5), 150 mM sodium chloride. A maximum of 100 µL sample/injection 
(total of 1 mg/mL) were analysed at a flow rate of 0.8 mL/min (≤ 70 bar), at 25 °C. A 10 µL 
BioRad
™
 Gel filtration standard (Bio-Rad
™
 Laboratories), was applied for determining 
apparent molecular weight of target recombinant proteins from a standard curve of proteins 
of known size (Figure 2.8). 
 
 
Figure ‎2.8  Determination of apparent molecular mass of unknown proteins 
Determination of apparent molecular mass of known Mwt proteins by SE-HPLC using TSK-
G3000SWXL column, used to calculated apparent molecular mass of native hCpn10 and its variants 
by comparing with the migration length of reference proteins. The column was calibrated with 
BioRad
™ 
reference proteins: Thyroglobulin (670 kDa); Ovalbumin (44 kDa); γ-Globulin (158 kDa); 
Myoglobin (17 kDa); and Vitamin B12 (1.35 kDa); respectively. 
 
2.8.6 Determination of storage buffer and protein stability by 
spectrophotometry 
 
A screening test was performed to find optimum buffering components and conditions for 
each protein constructs (Table 2.2). This was done by adding a 10 µL sample of purified and 
dissolved protein (concentrated ≥ 1 mg/ml) to a set of 190 µL/well of multiple buffering 
systems (Tables 2.4 and 2.5) with different concentrations of salts (NaCl, KCl), pH, reducing 
agents (DTT, BME), non-ionic detergents (Trition X-100), stabilizers (glycerol), loaded into 
96-well flat plate, and set to shake a platform rocker for 1-2 hrs, at 4 °C. Protein aggregates 
were then determined by following the methods of Burgess (2009) and Tresaugues et al. 
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(2004) by measuring the absorbance at 320 and 390 nm, respectively (Burgess, 2009; 
Tresaugues, et al., 2004), using UV-Vis SpectraMax Plus
384
 Spectrophotometer. Buffers with 
low protein aggregates (determined by low UV absorbance) were selected as the appropriate 
buffer system with additive concentrations used for buffer exchange and protein storage. 
 
Protein solubilities, stabilities, and degradations were also illustrated by SE-HPLC (similar to 
Section 2.8.5), whereby protein samples were monitored in multiple storage conditions at (-
20, 4, 25, and 37 °C) over different periods of time: (day, week, and month). In brief, a ≤ 100 
µL sample (equivalent to 1 mg/mL) with the same SE mobile phase (Table 2.4) were injected 
onto a SE-TSK column (Tosoh
™
 Bioscience) at a flow rate of 0.8 mL/min (≤ 70 bar), was 
heated at 25 °C. A molecular weight standard was run in parallel by injecting 10 µL of 
BioRad
™
 GF standard, and absorbance measured at 280 nm using Agilent
™
 1200 Series 
HPLC System. Stacked comparison of SE-HPLC chromatograms was used to determine 
changes for each sample. 
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Chapter 3.  Designing a Novel Molecular Scaffold based on 
Chaperonin 10: Experimental and Computational 
Approaches 
 
 
3.1 Introduction  
 
Binding entities based on molecular scaffolds will have increasing application as therapeutic 
and diagnostic agents in the future. There are more than ten non-antibody-based products 
based on molecular scaffolds currently in clinical trials, and there is at least one that has been 
approved for therapeutic and/or diagnostic applications (Chapter 1). Non-antibody molecular 
scaffolds can be modified where a particular region of the molecule, typically a flexible loop, 
can be replaced with a polypeptide that will bind to a particular antigen. In essence the 
scaffold has been modified in a manner that mimics the binding functionality of conventional 
mAbs. However the antibody scaffold is the product of an evolutionary process that enables 
varying peptide sequence to be inserted within the CDRs without impacting the structural 
integrity and the correct folding of the antibody molecule. In the case where a peptide loop 
with specific functionality within a molecular scaffold is replaced with a non-native 
sequence, optimal display of the peptide loop and/or structural integrity (i.e. folding and three 
dimensional conformation) of the molecular scaffold cannot be guaranteed. The research 
described in this chapter is associated with experimental and computational approaches to 
assessing the impact of various hCpn10 mobile loop substitutions on the structural integrity 
of the hCpn10 molecular scaffold. Strategies to overcome an unfavourable impact on stability 
as a result of peptide substitution are described.   
 
Human chaperonin 10 (hCpn10), otherwise known as Heat shock protein 10 (Hsp10), is an 
essential mitochondrial chaperone protein that assists in the folding of post-translational 
polypeptides (Hartman et al., 1992, Pilkington and Walker, 1993, Martin et al., 1993, Hartl 
and Hayer-Hartl, 2002). As shown in Figures 3.1 and 3.2, Cpn10 is structurally conserved 
across many species despite minor sequence homology (Hunt et al., 1996, Xu et al., 1997, 
Roberts et al., 1999, Numoto et al., 2005, Luke et al., 2005b, Luke et al., 2005a). It also has 
the capacity to form a heptameric ring under physiological conditions (Higurashi et al., 2003, 
Sakane et al., 2004, Perham and Wittung-Stafshede, 2007). The Cpn10 heptamer has seven 
identical monomers (10 kDa) that consist of a hydrophobic β-barrel core, a β-hairpin roof 
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loop and a mobile loop extending below the core of the molecule (Landry et al., 1997). 
Cpn10 is a very stable structure. A study by Sakane et al (2004) demonstrated that the 
introduction of Ala-mutations of Ile3 and Val95 residues (i.e. central residues within anti-
parallel β-strand pairing) did not affect structural stability. The unfolding-refolding 
characteristics of hCpn10 are similar to GroES (i.e. Cpn10 derived from E. coli) after 
denaturation using various concentrations of guanidine hydrochloride (GdnHCl) at 25 °C 
(Sakane et al., 2004). 
 
The mobile loop within Cpn10 monomers is highly flexible and exhibits a variety of 
structural conformations due to the lack of a defined secondary structure (Richardson et al., 
2001, Lin et al., 2004). However this mobility is restricted when the Cpn10 heptamer 
interacts with its cognate partner Cpn60/GroEL (Richardson et al., 2001). Similar to other 
molecular scaffolds (as discussed in Chapter 1), the mobile loop forms an extended interface 
that can bind to the target molecule. The mobile loop of hCpn10 consists of 18 residues, as 
described in Table 3.1. In this study, the removal of the mobile loop (ΔL-Cpn10), the removal 
of β-hairpin roof loop (∆Rf-Cpn10) or the removal of both regions ∆Rf-ΔL-Cpn10 (i.e. 
leaving an isolated β-barrel) did not affect the assembly of hCpn10 into a heptamer. 
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Figure ‎3.1  Three-dimensional representation of Cpn10 from different species 
3D representations of protein backbones (side and top view) of Cpn10 from various species: (A) 
Thermus thermophilus (PDB ID. 1WNR); (B) Escherichia coli BL21 (PDB ID. 3ZPZ); (C) 
Mycobacterium tuberculosis (PDB ID. 1HX5); (D) Escherichia coli K-12 (PDB ID. 3WVL); and (E) 
Mycobacterium tuberculosis in tetradecamer (PDB ID 1P3H). All protein structures shown in ribbon 
representations and modelled by PyMOL using crystallographic solved structures available in 
RCSB Protein Data Bank (RCSB-PDB, 2010).  
A. 
 
 
 
B. 
 
 
 
C. 
 
 
 
D. 
 
 
 
E. 
 
Side view                                             Top view 
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                                  Mobile loop                   β-roof loop 
                    SUI                                                                 75                SUI 
human      -AGQAFRKFLPLFDRVLVERSAAETVTKGGIMLPEKSQGKVLQATVVAVGSGSKGKG-GE-IQPVSVKVGDKVLLPE-YGGTKVVL--DDKDYFLFRDGDILGKYVD 
mouse      -AGQAFRKFLPLFDRVLVERSAAETVTKGGIMLPEKSQGKVLQATVVAVGSGGKGKS-GE-IEPVSVKVGDKVLLPE-YGGTKVVL--DDKDYFLFRDSDILGKYVD 
chicken    MAGKAFRKFLPLFDRVLVERCAAETVTKGGIMIPEKAQGKVLQATVVAVGSGARGKD-GE-IHPVSVKVGEKVLLPE-YGGTKIVL--EDKDYYLFRDGDILGKYLD 
Frog       MAVRAFKKFVPLFDRVLVERLAAETVTKGGIMLPEKSQGKVLQATVVAVGDGSRGKT-GD-IQPVSVKVGEKILLPE-YGGTKVVL--DDKEYFLFRDGDILGKYID 
Zebrafish    MQAFRKFLPMFDRVLVERLAAETVSRGGIMIPEKSQAKVLQATVVAVGPGSTNKD-GK-VIPVCVKVGDKVLLPE-YGGTKVML--EDKDYFLFRDADILGKYVD 
Fly         MAAAIKKIIPMLDRILIQRAEALTKTKGGIVLPEKAVGKVLEGTVLAVGPGTRNASTGN-HIPIGVKEGDRVLLPE-FGGTKVNLEGDQKELFLFRESDILAK-LE 
Yeast    MSTLLKSAKSIVPLMDRVLVQRIKAQAKTASGLYLPEKNVEKLNQAEVVAVGPGFTDAN-GN-KVVPQVKVGDQVLIPQ-FGGSTIKLGNDDE-VILFRDAEILAKIAKD 
Plant          MMKRLIPTFNRILVQRVIQPAKTESGILLPEKSS-KLNSGKVIAVGPGSRDKD-GK-LIPVSVKEGDTVLLPE-YGGTQVKL--GENEYHLFRDEDVLGTLHED 
C.e MFLTAVRRSSNVLKTFKPLYDRVLVERVAAETKTKGGIMLPEKSQGKVLEATVVSAGAGLRNEK-GE-LVALTVKPGDRVLLPE-YGGTKVVV—-EDKEYSIFRESDLLGVFH 
M.mazei          MIVKPIGERVLLKHQKKEEVTKGGIYIPESARQEKKEGIVVAVG---TFED-GK-ELPL--KKDDHVIYGG-YQADEIEI--DDEKYIFVDFKDILATVVEE 
M.tuber       MAKVNIKPLEDKILVQANEAETTTASGLVIPDTAKEKPQEGTVVAVGPGRWDED-GEKRIPLDVAEGDTVIYSK-YGGTEIKY--NGEEYLILSARDVLAVVSK 
E.coli           MNIRPLHDRVIVKRKEVETKSAGGIVLTGSAAAKSTRGEVLAVGNGRILEN-GE-VKPLDVKVGDIVIFNDGYGVKSEKI--DNEEVLIMSESDILAIVEA 
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Human           Homo sapiens                  P61604 (CH10_HUMAN) 
Mouse           Mus musculus                  Q64433 (CH10_MOUSE) 
Chicken         Gallus gallus                 O42283 (O42283_CHICK) 
Frog            Xenopus tropicalis            Q6DDD2 (Q6DDD2_XENTR)  
Zebrafish       Brachydanio rerio             Q6IQI7 (Q6IQI7_BRARE)  
Fly             Drosophila melanogaster       Q9VU35 (Q9VU35_DROME)  
Yeast           Saccharomyces cerevisiae      P38910 (CH10_YEAST) 
Plant           Arabidopsis thaliana          P34893 (CH10_ARATH) 
C.elegans       Caenorhabditis elegans        Q965Q1 (Q965Q1_CAEEL) 
M.mazei         Methanosarcina mazei          Q8PW07 (CH10_METMA)  
M.tuberculosis  Mycobacterium tuberculosis    P9WPE4 (CH10_MYCTU) 
E.coli  K12     Escherichia coli              P0A6F9 (CH10_ECOLI) 
 
DE (-) acidic 
KR (+) basic 
RKE  residues with long side-chains involved in GroES subunit-subunit interactions 
SUI  subunit interface core 
V    GroES residues involved in hydrophobic core 
 
Figure ‎3.2  Sequence alignment of Cpn10 derived from various species 
Sequence data illustrates an approximate 30 % homology of human Cpn10/Hsp10 and E. coli GroES, Cpn10 sequence alignment was obtained from 
UniRef/UniPotKB provided by UniPort online database (UniProt, 2010). 
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Table 3.1 shows the peptides used as substitutes for the native mobile loop of hCpn10 in this 
study. They are further characterised based on their sequence, length, isoelectric point (pI), 
target and biological activity. 
 
Table ‎3.1  Peptides as substitutes for native mobile loop of human Cpn10 
Peptide  Loop sequence  #AA pI Target  Biological activity  Reference(s) 
hCpn10  AAETVTKGGIMLPEKSQG  18 8.91 Cpn60  - Protein folding  
(Landry et al., 
1997) 
ΔL-Cpn10 AG 2 8.91 --    n/a -- 
E76  ALCDDPRVDRWYCQFVEG  18 7.21 
FVII/ 
FVIIa  
- Anticoagulant  
(Dennis et al., 
2000) 
Myc  EQKLISEEDL  10 6.65 9E10  
- Protein localization,  
- ELISA,  
- Protein purification  
(Hilpert et al., 
2001) 
P7  PFNLPLPSRPLLR  13 9.52 CD44  - Diagnostic probe  
(Park et al., 
2012) 
P11  PLLQATLGGGS  11 8.98 bFGF  - Anti-Angiogenic  
(Wu et al., 
2010) 
VEGF1 ITMQIMRIKPHQGQHIGEMSF 21 8.76 
EGFR/
HER1 
- Anti-Angiogenic 
(Vicari et al., 
2011) 
 
 
Based on the flexibility of the mobile loop region and the observation that deletion of mobile 
loop does not affect hCpn10 assembly, this study investigated the use of hCpn10 as a 
molecular scaffold with the aim of developing NMEs capable of binding to targets through 
the insertion of various functional polypeptide domains at the mobile loop site (Table 3.1). 
Substitution with different peptides may compromise the assembly of hCpn10 into a 
heptamer through molecular interactions of amino acids within the mobile loop with those at 
the interface of the β-barrel that mediate heptamer assembly. For example there may be 
physicochemical interactions between loop and β-barrel charged amino acids (salt bridges) or 
hydrophobic residues. Therefore, molecular simulations were conducted in order to 
investigate the dynamics of assembly of hCpn10 heptamer with different peptides and to 
investigate how disruption of heptamer formation through loop peptide steric hindrance could 
occur. Protein engineering strategies that might avoid loop peptide, β-barrel interface 
interactions were also investigated to prevent aggregation and ensure that hCpn10 variant 
forms stable heptamers. 
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Traditional methods of assessing protein stability and 3D structure include X-ray 
crystallography (Roberts et al., 1999, Higurashi et al., 2003, Tereshko et al., 2008, Nandi et 
al., 2012), nuclear magnetic resonance (NMR) (Wu et al., 2012) and other biophysical 
methods (Buehler et al., 2010). However, there are limitations to these techniques since 
sample preparation (i.e. preparing refractable protein crystals for crystallography) is time 
consuming and needs to be of high purity (Tereshko et al., 2008). Molecular modelling is an 
emerging discipline where state-of-art computers are used to study the theoretical molecular 
dynamics of polypeptides (Leach, 2001) in a range of successive time frames between 10
-15
 
and 10
-6 
seconds (Petrenko and Meller, 2010). Molecular dynamics (MD) simulations are 
expeditious approaches, and can yield valuable data on the supposed interactions between 
protein domains/amino acids within a protein structure. 
 
3.2 Rationale for the project 
 
Based on its known properties, hCpn10 has the potential to serve as a molecular scaffold 
where the mobile loop can be replaced with non-native peptides to mimic the functional 
binding properties of mAbs as shown in Table 3.1. MD simulations were conducted on 
hCpn10 in order to investigate, on a theoretical basis, the effect of native mobile loop 
substitution with unrelated peptides upon heptamer formation. This research focused on 
investigating molecular structure perturbations of hCpn10 due to mobile loop substitution via 
MD simulations and investigates strategies to prevent or minimise peptide loop molecular 
interactions with the β-barrel interface of hCpn10, so that heptamer formation is conserved. 
 
3.3 Research aims  
 
The aims of the research presented in this chapter are: 
 
 To investigate the potential of hCpn10 and its variants to form heptamers, using 
computational and experimental approaches; 
 To investigate the physicochemical interactions and interfaces on the molecular level, by 
using MD simulations; 
 To apply the results of MD simulations to improve the molecular stability and efficiency 
of hCpn10 variants; and 
 To establish a fundamental molecular design for hCpn10 as a molecular scaffold. 
67 
 
3.4 Materials and methods 
 
3.4.1 Protein expression, purification and characterisation 
 
All protein variants in this study were produced, purified (≥ 95 %), and characterised 
accordingly to the general materials and methods described in Chapter 2.  
 
3.4.2   Homology modelling 
 
Homology modelling of hCpn10 variants was performed in conjunction with Computist Bio-
Nanotech (Melbourne, Australia). Structural homologues based on sequences defined in this 
study (Table 1.3) were created, based on available template X-ray crystal structure of the 
chaperonin complex from Thermus thermophilus (PDB ID. 1WE3). The overall folding 
topology of chaperonin 10 is highly conserved, therefore it was highly feasible that homology 
modelling of hCpn10 variants could be performed based on the known X-ray structure of the 
related T. thermophilus Cpn10 structure of 1WE3.  
 
The conformations of the inserted sequences replacing the native mobile loop were modelled 
as close as possible to the Cpn10 conformation found in 1WE3. This conformation is a free 
energy minimum for heptameric hCpn10, while the conformation is likely not a global energy 
minimum of hCpn10 variants (i.e. mutants) structure, but only a local minimum that might 
not be stable. In order to find more stable and energetically favourable conformations, MD 
simulations to sample the accessible conformational space were performed. The N-terminus 
modelled as extended chains similarly to the template structure. The histidine residues in the 
His-tag (of the C-terminus) were simulated as uncharged side chains. The inserted E-76 
peptide (Table 3.1) was simulated with and without an intact disulphide bond (Cys23-Cys33). 
 
All models showed heptameric structure of the proteins, however, for the structural 
investigation only one monomer was chosen, that is chain “U” of 1WE3 heptamer. This 
remainder was not part of the actual simulation and figures were prepared after the simulation 
by superimposing the simulated monomer “U” onto the structure heptamer. 
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3.4.3 Molecular dynamics (MD) simulations 
 
MD simulations in this study were performed in conjunction with Computist Bio-Nanotech 
and were based on the NAMD2 program (Kale et al., 1999) combined with the CHARMM27 
force field (MacKerell et al., 1998). Generalised born implicit solvent (GBIS) method 
(Tanner et al., 2011) was applied to increase the conformational sampling time. Approximate 
dielectric effect of water treated outside of the protein as dielectric continuum, solves the 
Poisson Boltzmann equation (Fogolari et al., 2002) in order to calculate additional forces 
from solvent to protein. The van der Waals packing interactions were disregarded in 
NAMD2's implementation of the method.  
 
The monomeric form of hCpn10 protein has about 11,000 atoms and the protein is 
surrounded by a 13-15 Å thick shell of water molecules at a density of 1 g/cm
3
. The 
simulations of the monomers were performed without explicit water. However, the solvent 
effects were taken into account by using an implicit water model of GBIS method in 1 nano-
second (ns) (Tanner et al., 2011, Onufriev, 2010).  
 
A 10 ns simulation of the hCpn10 sequence was performed to test the stability and optimise 
the N-terminus of each monomer and heptamer. However, the stability of the loop 
conformations was evaluated in 1 ns duration. 
 
Primarily, all simulations were performed twice with different initial condition: (1) 
simulation with random initial velocities selected according to a Boltzman distribution at 250 
K, (2) simulation with random initial velocities at higher temperature at 310 K. The 
temperature was kept constant using "temperature scaling" method, and the entire system is 
set to the desired temperature of all velocities were periodically rescaled every 1 pico-second 
(ps). 
 
Subsequently, in addition to the methods described previously, three MD simulations for 1 ns 
were performed for each of modified sequences of CE76 and CPMyc variants (Table 3.1): (1) 
simulation in an aqueous environment ( =78.5), (2) simulation with the C-terminus His-tag 
sequence removed, and (3) simulation in cellular-like environment ( =40).  
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The conformational changes that occurred during the MD simulations of examined structures, 
were reflected as trajectory changes and were processed according to specified geometric 
descriptors of VMD program (Humphrey et al., 1996). The variations of these trajectories 
were visually examined.  
 
3.5 Results 
 
3.5.1 Mutation approaches 
 
Cpn10 is structurally conserved across several species despite the differences in amino acid 
sequences (Figure 3.1). This study focussed on hCpn10 as a potential molecular scaffold of 
human origin (Figure 3.3). As shown in Figure 3.4, the preliminary studies conducted 
assessed the stability of hCpn10 involved in the development of three mutant hCpn10 
constructs, namely: ∆L-Cpn10 (i.e. mobile loop deletion), ∆Rf-Cpn10 (i.e. roof loop deletion) 
and β-barrel (i.e. ∆Rf-∆L-Cpn10). Analytical size-exclusion HPLC revealed that the 
heptameric assembly of these hCpn10 mutants is not compromised despite these deletions 
and the apparent change in molecular weights (Figure 3.5). It can therefore be concluded 
from this data that the amino-acid residues of the hCpn10 loop regions are not critical for the 
assembly of heptameric Cpn10. 
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Figure ‎3.3  Three dimensional model of human Cpn10 
hCpn10 structure modelled based on solved structure of Thermus Thermophilus (PDB ID. 1WE3). (A) 
Top vs. side view of heptamer hCpn10; and (B) Top vs. side view of monomer hCpn10. The structure 
is shown in ribbon representations and modelled by PyMOL. 
 
 
 
Figure ‎3.4  Sequence alignments of hCpn10 and its variants  
Amino acid sequence and size of hCpn10 (wt) versus its variants; ∆Rf-Cpn10, β-barrel and ∆L-
Cpn10, illustrating mutation sites (i.e. mobile loop in blue and roof loop in red). 
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Figure ‎3.5  HPLC-size exclusion chromatograms of hCpn10 versus its mutants 
Comparison of hCpn10 with its mutants using size-exclusion HPLC and UCSF Chimera modelling. 
(A) Absorbance at 280 nm of hCpn10 (black, theoretical molecular weight 70 kDa) versus ΔRf-
Cpn10 (red, 62.3 kDa); ΔL-Cpn10 (blue, 59.5 kDa); and β-barrel only (green, 51.8k Da), respectively. 
All constructs apparently developed heptamers with various molecular sizes resulting from 
incorporation of molecular weight standards curve with known elusion retention times (detailed 
Chapter 2). (B) The side view of 3D model of the quaternary structures of each hCpn10 variants 
shown in ribbon representations (i.e. β-barrel in violet; & coil in yellow) modelled by UCSF Chimera 
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3.5.2 Molecular modelling approaches  
 
The schematic shown in Figure 3.6 outlines the integration of the experimental and 
computational (i.e. MD simulations) methodologies in order to design NMEs based on the 
hCpn10. MD simulations were conducted on multiple phases, or until the optimal model of 
hCpn10 variants could be developed and resembled into a native-like configuration. Although 
the polypeptide sequence of Cpn10 varies across all species, the protein is structurally 
conserved (Figure 3.1), therefore, three-dimensional modelling of hCpn10 in this study was 
based on the previous crystallographic solved structure of Cpn10 derived from the gram-
negative Thermus thermophilus eubacterium species PDB ID. 1WE3 (Shimamura et al., 
2004). 
 
 
 
Figure ‎3.6  An iterative guide and experimental cycle for the design and creation of NMEs based 
on the hCpn10 molecular scaffold 
 
3.5.2.1 MD simulation strategies 
 
Homology models of all hCpn10 variants sequences defined in Table 3.1 were created based 
on the template crystal structure of the chaperonin-complex from 1WE3. Although the 
conformation for heptameric hCpn10 demonstrated a free energy minimum (Figure 3.3), this 
was not observed in mutant hCpn10 structures (Table 3.1), despite the insertion of sequences 
within the mobile loop that closely resembled to the X-ray structure of the chaperonin 
In-silico design of scaffold 
based-Cpn10  
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complex of 1WE3. Therefore, in order to find more stable and energetically favourable 
conformations, molecular MD simulations were performed in order to sample the accessible 
conformational space of hCpn10 vairants. 
 
Initially, a 10 ns MD simulation of the hCpn10 monomer was performed in order to test the 
stability of the protein followed by optimization of the N-terminus in both monomeric and 
heptameric conformations with the result shown in Figure 3.7. Monomeric and heptameric 
hCpn10 had an overall degree of stability although some flexibility was observed in the β-
hairpin (roof-loop) and mobile loop (Figure 3.7, Appendix 3). In addition, the N-termini of 
each monomer, which is eleven residues in length (AGQAFRKFLPL), remained in an 
extended conformation. Since the extended N-terminus did not appear to affect the assembly 
of hCpn10 into an oligomer, it is possible to reduce the length of the N-terminus by up to nine 
residues.  
 
 
Figure ‎3.7  MD simulations of hCpn10 monomer over 1 ns duration 
Snapshots of hCpn10 shown in ribbon representations of the last 700 ps (i.e. from initial: red to final: 
blue) at intervals of 50 ps and subsequently overlaid.  
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MD simulations for hCpn10 molecules were performed twice with different initial conditions. 
In the first simulation, random initial velocities were selected according to a Boltzman 
distribution at a temperature of 250 K. The first simulation was an enhanced energy 
minimisation in order to find a more stable conformation. The second simulation was 
conducted at a higher temperature of 310 K (i.e. above room temperature for escalated 
process) where the increased kinetic energy of the atomic structure of hCpn10 allowed for a 
better sampling of the various structural changes of the protein conformations. In both 
simulations, the temperatures were kept constant using a temperature scaling method where 
all of the atom velocities in the system were periodically rescaled every 1 ps so that the entire 
system was adjusted to the set temperature. 
 
In essence, the heptameric formation of a variant hCpn10 is primarily dependent on the 
successful dimerization between adjacent monomers. However, in order for this to occur, the 
two adjacent monomers need to have a complementary surface shape and an electrostatic 
potential distribution that is conducive for dimerization. If the conditions are unfavourable, 
the binding strength of the dimer and its ability to form a self-assembling heptamer will be 
reduced (e.g. in the case of hCpn10 variant CE76, Appendix 3). 
 
A general strategy was applied in order to evaluate whether or not hCpn10 and its variants 
could develop a stable heptamer-like conformation. Explicit treatment of water molecules 
helped to assess the effects of the solvent and various ions on the hCpn10 during MD 
simulations. In essence, the hCpn10 was surrounded by a 13-15 Å shell of water molecules. 
However, this led to a significant increase in the number of atoms in this simulation. The 
hCpn10 monomer is composed of roughly 11,000 atoms whereas the heptameric form of this 
protein has an estimated of 109,000 atoms. This made it difficult to simulate the hCpn10 
heptamer as the amount of CPU power that is required to calculate the motion of bulk 
molecules is very high and subsequently time consuming. Furthermore, the assessment of 
each protein configuration such as the motion of the flexible loops was hindered as this 
requires a significant displacement of the adjacent water molecules. Nonetheless, the 
advantage of using water to assess the dynamics of a particular molecule yields more accurate 
and realistic results as a consequence of the electrostatic interactions due to the inherent polar 
nature of the water molecules as well as the van der Waals interactions between water and 
protein atoms. 
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In order to speed up the simulations and allow a faster conformational search, MD 
simulations of the monomers were also performed without using explicit water. In addition, 
the solvent effects were also taken into consideration by using an implicit water model of the 
GBIS method (Tanner et al., 2011, Onufriev, 2010, Chen et al., 2008). The GBIS is a method 
that does not use explicit water molecules or ions for molecular simulation, which 
subsequently increases the sampling speed. For hCpn10 and its variants, a simulation of 
approximately 1 ns with the GBIS method was performed which correspond to a much longer 
conformational sampling time for protein structures than in a simulation with explicit water.  
Furthermore, GBIS method utilises the Poisson Boltzmann equation as it approximates the 
dielectric (electrostatic) effect of water and treats the outside of the protein as a dielectric 
continuum (Fogolari et al., 2002, Moreira et al., 2005). Moreover, calculations of any 
additional forces from the solvent to the protein are resolved using the NAMD2 program 
(Kale et al., 1999, Phillips et al., 2005). However, the van der Waals packing interactions 
were disregarded in NAMD2's implementation of the method (Guvench and Alexander D. 
MacKerell, 2008). This approximation, on most occasions, is quite reliable as evident from 
several conducted experiments. Thus, the GBIS method was chosen, as more CPU time was 
required to see the effects on the mobile loops of the newly inserted functional peptides from 
Table 3.1. Consequently, it is important to look at the effect of replacing the mobile loop with 
a functional peptide and how this will affect the dimerisation interfaces on the monomer. This 
will be done by measuring the deviation of the surface geometry from the hCpn10 structure 
and investigating the significant changes to the electrostatic field distributions of the hCpn10 
variants.  
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3.5.2.2 MD simulations I: Molecular designing of hCpn10, CE76 and 
CPMyc variants 
 
3.5.2.2.1 Simulation of hCpn10 
 
MD simulations were performed on the β-hairpin roof and mobile loops of hCpn10. Data 
acquired from these simulations indicated that the hCpn10 was quite stable as evident from 
the 1 ns simulation snapshots shown in Figure 3.8. These images further illustrate that both 
the β-hairpin and mobile loops were flexible and did not impede heptamer formation. 
Importantly, as indicated by the MD simulations shown in Figure 3.9A, the cluster of 
conserved amino acid sequences, namely, Arg19 Ser20 Ala21 (RSA) and Gly38 Lys39 Val40 
(GKV) at the N- and the C-termini of mobile loop, respectively, was packed very tightly 
during the simulations. A second possible packing scheme was observed during the MD 
simulations where the lysines (Lys27 and Lys35) side chains pointed away from the loop and 
the polar interactions stabilised the overall extended structure of two β-strands from the 
molecule β-core. The electrostatic potentials generated by two adjacent hCpn10 monomers 
were complementary and therefore provided a greater prospect for dimerization (Figure 
3.10A). 
 
       
Figure ‎3.8  MD simulation snapshots of hCpn10 over duration of 1 ns at 310 K 
Snapshots taken of hCpn10 MD simulation: (A) Overlaid snapshots of MD simulations of the hCpn10 
monomer in ribbon representation coloured from white to dark blue. (B) Overlaid snapshots of MD 
simulations were atoms of hCpn10 mobile loop are shown as space-filling model. Both snapshots 
show monomers over 1 ns MD simulation at 310 K, in 50 ps intervals and coloured from white (350 
ps) to dark blue (700 ps), then overlaid post-MD simulations on top of the static model of the hCpn10 
heptamer.  
  
A. B. 
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Figure ‎3.9  Cluster motif RSA/GKV required for β-barrel core stabilisition   
Cluster motif to stabilise hCpn10 protein core. (A) hCpn10 clustering of conserved sequences of 
“RSA” and “GKV” shown as space-filled models and coloured blue and green, respectively, with 
strong and tight packing for β-core stabilisation. (B) CPMyc, showing the stereo model of the 
modified RSA/GKV cluster with weak packing and unstable β-barrel core. 
 
 
 
Figure ‎3.10  Figure ‎3.10  Electrostatic potential map  
Representation of the electrostatic potential on the molecular surface of hCpn10 and its variant 
obtained from 1 ns MD simulations. (A) hCpn10 (B) CE76, and (D) CPMyc. The molecular surface 
representation and the electrostatic potential distribution is colour coded as follows: Blue-Positive, 
Red-Negative and White-Neutral. The dimerisation domains are indicated by a white circle and the 
mobile loop is located below the circle. 
 
 
3.5.2.2.2 Simulation of CE76 variant 
 
CE76 is a proposed, NME created by insertion of a peptide termed E-76 which binds Factor 
VIIa, for the hCpn10 mobile loop between Ala21 and Gly38, (Table 3.1) (detailed in Chapter 
4). The E-76 peptide is stabilised with a single disulphide bond between Cys23 and Cys33. 
Molecular simulations conducted on CE76 revealed an overall stability in 1 ns MD 
 A.                                    B. 
A. B. C. 
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simulations. However, the E-76 peptide within the mobile loop region was continually 
changing conformation from the initial structure to a conformation where the E-76 peptide 
loop made contact with the surface of the protein core that formed the β-barrel like structure 
(Figure 3.11). 
        
Figure ‎3.11  MD simulations of CE76 over duration of 1 ns at 310 K 
Snapshots of MD simulations of CE76 shown in ribbon representations: (A) CE76 M1-Model, and 
(B) CE76 M2-Model with a disulphide bond between Cys23 and Cys33 in the mobile loop domain. 
Atoms of the E-76 mobile loop shown in space-filling representations: (C) M1-model showing a 
hydrophobic cluster formed (red ellipsoid) through interaction of E-76 loop with the protein core, and 
(D) M2-model showing a weaker cluster formed (yellow ellipsoid) through interactions between E-76 
loop with the protein core. The detailed descriptions of colour codes are as previously described in 
Figure 3.8. 
 
CE76 was modelled in two forms; model 1 (M1) was created as a homologous model based 
on hCpn10 (Figure 3.11A), while model 2 (M2) was created by continuing the simulation of 
model M1 but enforcing the formation of the disulphide bond between Cys23 and Cys33 
(Figure 3.11B). This allowed for the proper study of larger conformational spaces for two 
structurally similar constructs even though both models had different specifications. This was 
thought to be a necessary step given that the disulphide bond reduces the flexibility of the 
A. B. 
C. D. 
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loop and makes sampling of the conformational space slower. In the CE76 M1 model, a helix 
was formed between residues Leu32 and Gly38 in the mobile loop. A similar yet shorter helix 
was formed between residues Pro33 and Ser36 in the CE76 M2 model. However, the 
remaining regions of the mobile loop from both models folded differently as shown in Figure 
3.11. It seemed apparent that a transition between the two loop conformations could occur. 
This was, however, hindered by the disulphide bond, where Cys33 is part of the helix. This in 
turn restricted the movement of the loop and therefore, the two conformations were analysed 
separately. 
 
The newly formed helix observed in the M1 model triggered the formation of a more 
“hydrophobic cluster” that formed through the interaction of Lys39 (of E-76 loop) with 
Val100, Leu71 and Glu42 of the core region and thereby potentially preventing the 
dimerisation of the monomers (Figure 3.11C). Also, the M1 model construct showed that the 
loop came in close proximity to the core which in turn interacted with Leu82 to Lys85 
between the β-strands 4 and 5 of the protein core as part of the dimerisation interfaces (Figure 
3.11C). 
 
In the M2 model, residues Val100, Leu71 and Glu42 also formed a “weaker cluster”. 
However, polar interactions were observed between Arg30 and Asp24 of the E-76 loop, 
Glu74 of the β-barrel core; and Glu37 of the mobile-loop and Lys79 within the core of the 
protein. Due to more bending within the loop conformations, the mobile loop clashed even 
more with the turn between the β-strands 4 and 5 (Figure 3.11D). Furthermore, due to the 
distortions observed in the mutant CE76 structure relative to hCpn10, the electrostatic 
potential on both dimerisation surfaces was not completely complimentary as clearly 
illustrated in Figure 3.10B. There were two areas of negative potential that had appeared 
towards the bottom of the dimerisation site, indicating that there was a lack of electrostatic 
force in facilitating the dimerisation of the CE76 monomers. 
 
Accordingly, the collisions of the substituted mobile loop domain (E-76 peptide) with the 
protein β-barrel core and the reductions of the electrostatic complementarities of the 
contiguous monomers surfaces essentially inhibited the dimerisation of the CE76 
conformation. This in turn did not facilitate the development of a heptamer in a similar 
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structure to hCpn10. This might explain why SE-HPLC revealed the presence of numerous 
aggregates of varying sizes shown below in section 3.5.5. 
 
3.5.2.2.3 Simulation of CPMyc variant 
 
An MD simulation was conducted on another hCpn10 based NME that contained the Myc-
tag (EQKLISEEDLNG) within the mobile loop, and called CPMyc (Table 3.1). The Myc-tag 
was investigated as it is commonly utilised in conjunction with the 9E10 monoclonal 
antibody (that binds a Myc linear epitope) in protein engineering studies. The Myc peptide 
contains both charged and hydrophobic residues, and as such could be useful in investigating 
how charged and hydrophobic residues interact with the β-barrel interface. 
 
The MD simulation indicated that the CPMyc was generally stable. However, the mobile 
loop region which contained the Myc peptide was highly flexible with a continuous change in 
conformation during the 1 ns simulation time (Figure 3.12). Remarkably, the Myc-loop did 
not reach a stable conformation, which could indicate that it might be possible to form a 
heptamer if the mobile loop was able to adopt a more stable conformation. The MD 
simulations indicated that the Myc-loop was interacting with the core β-barrel protein at β-
strands 4 and 5 thereby disrupting the dimerisation interface towards the adjacent monomer, 
(Figure 3.12). Since these two β-strands seem to be necessary for the two CPMyc monomers 
to merge and form a heptamer, the assembly of this construct into an oligomer does not seem 
very likely. For future study, it might be worth it to extend the MD simulation timeframes 
(over than 1 ns) to see whether a stable conformation of the mobile loop with Myc-peptide 
might be formed eventually. 
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Figure ‎3.12  MD simulations of CPMyc over duration of 1 ns at 310 K 
Snapshots of CPMyc MD simulations: (A) Snapshots of overlaid CPMyc in ribbon representations 
and shown loop spatial extent conformations. (B) Snapshots of overlaid CPMyc shown the inserted 
Myc-loop in space-filling model. The detailed descriptions of colour codes are as previously 
described in Figure 3.8. 
 
 
The flexibility of the mobile Myc-loop was likely due to the high content of charged amino 
acids within the loop (EQKLISEEDLNG). Such flexibility and the close proximity of the 
charged side chain residues (of the loop) to the protein β-core caused a different packing 
scheme of Arg19 Ser20 Ala21 and Gly34 Lys35 Val36 motif, as previously discussed. 
Furthermore, the creation of the “polar cluster” due to the side chains of Asp82, Arg19, 
Glu70, and Lys35 led to a close alignment of β-strands 4 and 5 with RSA-sequence of the 
Myc-mobile loop (Figure 3.9B). This new “cluster” which contained residues of the β-core 
Asp82 and Glu70 could be the reason for the observed modification of the binding interfaces 
between the contiguous monomers (Figure 3.12). 
 
Due to the dramatic changes that were observed during the simulation of CPMyc, another 
MD simulation was performed. This simulation was shorter in duration (less than 1 ns) and 
conducted at high temperature at 310 K using a second CPMyc-model based on the final 
structure of the hCpn10 simulation with the “RSA/GKV cluster” as a template because of the 
observed stabilities of such template (Figure 3.9A). This simulation illustrated that β-strands 
4 and 5 were also moved towards the mobile Myc-loop similar to the movement described 
previously despite the differences in motion details. 
 
The final structure of the CPMyc simulations illustrated that the C-terminus also diverged 
from the initial configuration and interacted with the top β-hairpin roof loop which also 
B. A. 
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disrupted the second dimerisation interfaces. This distortion also caused a polarity change at 
the dimerisation sites and therefore a disparity in electrostatic potential (Figure 3.10C). 
Notably, the high flexibility of both the N- and C-termini at the polarity of the dimerisation 
sites might be easily reversible. 
 
The model of CPMyc variant illustrated in this configuration with two β-strands (4 and 5) 
moving towards the mobile loop may hinder the formation of a heptamer in similar manner as 
seen in hCpn10. This however, is clearly explained in the experimental results through the 
unfolding of CPMyc molecule where analytical SE-HPLC of CPMyc showed unstable 
molecules and the development of soluble aggregates (data not shown). 
 
3.5.2.3 MD simulations II: Molecular redesigning of CE76 and CPMyc 
variants for heptamer assembly 
 
Previous MD simulations of the hCpn10 variants of CE76 and CPMyc containing E-76 
peptide and Myc-peptide, respectively, revealed that the mobile region was highly flexible. 
This in turn hindered the proper formation of stable oligomers. Therefore, to stabilise the 
mobile loop region, several peptide-linkers were added in order to create more stabilisation 
and/or fixation within the mobile loop that could prevent any interference with the 
dimerisation region of the subunit-subunit hCpn10 monomers. The insertion positions of 
three Linker IDs including their characteristic AA sequence and various sizes are shown in 
Table 3.2. 
 
Table ‎3.2  Summary of peptide linkers used to mimic mobile loop elasticity.  
Linker ID AA Sequence AA Size Insert Positions 
P1 AAP/PAA 3/3 A21 – G38 
P2 PP/PP 2/2 A21 – G38 
E5 AAETV/EKSQG* 5/5 A21 – G38 
*Using native residues of N- & C-termini of hCpn10 mobile loop. 
 
Following the strategy outlined in the schematic in Figure 3.6, another molecular simulation 
was conducted in order to determine the ability of the linker sequences to stabilise the mobile 
loop and therefore facilitate the proper assembly of the variants into a heptamer. 
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The computational methods utilised in this second phase (II) was based on the same strategies 
used in previous simulations (Section 3.5.2.2, MD Simulation I). In addition, three simulation 
models were also run for each modified variants (as described in Tables 3.1 and 3.2, in 
conjunction). The first MD simulation was to investigate the stability and interaction of the 
inserted-loop, at the N- and C-junctures of the loop domain, and the full length monomeric 
form within an aqueous environment (i.e. dielectric constant  =78.5). The second MD 
simulation was conducted with a dielectric constant of  =78.5, and with removal of the His-
tag sequence at the C-terminus whereas His-tag was added in order to facilitate downstream 
processes for high purity protein yields. This simulation focused on assessing the stability of 
the inserted and modified loop on its own. Finally, the third simulation involved increasing 
the statistical relevance of the results by changing the dielectric condition and also to 
investigate the stability of the modified full length constructs in an environment where bulk 
water is less abundant (i.e. in an actual cellular surrounding environments) at dielectric 
constant of  =40. Each of these MD simulations ran for about 1 ns at 310 K. The final 
strategies that were applied to this second phase were to stimulate the six histidine residues of 
the C-terminus as uncharged and the inserted E-76 (of CE76) with an intact disulphide bond. 
 
Simulations of all modified constructs were conducted in their monomeric form. However, 
the snapshots illustrated in Figures 3.13 to 3.18 will often show the heptameric form of the 
crystallised wt Cpn10 of PDB. 1WE3. However, as discussed previously in section 3.2.2.2.1, 
simulation of heptameric hCpn10 (>109,000 atoms) was beyond the technical capabilities of 
the CPU and therefore, all simulation data on monomeric hCpn10 were superimposed on the 
crystal structure of 1WE3. This in turn would allow for a reasonable estimation on whether 
an inserted peptide such as E-76 or Myc- would impinge on the assembly of the hCpn10 
variants monomer of the redesigned CE76 and CPMyc, respectively. 
 
3.5.2.3.1 Simulation of CE76P1 variant 
 
The CE76P1 variant model contains the E-76-insert within the mobile loop but is separated 
from the hCpn10 β-barrel core by an Ala-Ala-Pro (P1-linker) with a single proline residue in 
each N- and C-termini loop extensions (Table 3.2). Simulation of full length CE76P1 in an 
aqueous environment ( =78.5) revealed that the β-core and the mobile loop adopted a more 
stable conformation (Figure 3.13). However, it appeared that the mobile loop had some 
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degree of mobility as this region was bending in an upward direction and could possibly 
interfere with the heptamer formation. Conversely, it is also possible that the limited 
flexibility may prevent heptamer formation of the hCpn10 variant. 
 
In the second simulation, CE76P1 was subjected to an aqueous environment with a dielectric 
constant of  =78.5. In addition, the C-terminal His-tag was removed. The additional P1-
linker, however, failed to fully stabilise the mobile loop. In fact, the last two β-sheet residues 
from Lys79 to Phe90 of the CE76P1 β-strands were lost during this simulation due to the 
strong interactions of the mobile loop residues with the protein core. This in turn could 
prevent the monomer from dimerising and then forming a heptamer. 
 
 
Figure ‎3.13  MD simulation of CE76P1 over duration of 1 ns at 310 K  
Snapshots from 1 ns MD simulations at 310
 
K shown CE76P1 variant in ribbon representation and 
overlaid onto the hypothetical hCpn10 structure (yellow), the location in a cut-out of the heptamer to 
estimate the ability of CE76P1 to form heptamer. Red ellipsoid illustrates a possible β-barrel core 
distortion by the end of the simulations. Series snapshots overlaid in 10 ps intervals from the last 100 
ps of the calculation, and coloured from light to dark blue. 
 
The E-76 peptide contains a number of polar residues which in turn are more than likely to 
influence its interaction with the β-barrel core. Therefore, a third simulation was conducted 
on full length CE76P1 monomer at a dielectric constant of  =40 in order to gain an 
understanding of the electrostatic interactions that may occur between the E-76 peptide and 
the β-core. This particular simulation will be far more realistic than the simulations that were 
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conducted in pure water as the conditions mimic the intracellular environment. Results from 
the third simulation indicated that the C-terminus His-tag had a slight interaction with the E-
76 loop which in turn stabilised its conformation. The β-core was far more stable in the third 
relative to the first simulation (Appendix 3). 
 
The electrostatic potentials of the CE76P1 protein surface were calculated in a similar manner 
as described in Section 3.5.2.2.2. The electrostatic potential generated by the CE76P1 
monomer supported dimerization as shown Figure 3.14A and furthermore, the distribution of 
the positively and negatively charged characters at the molecular surface of 
monomer/monomer interfaces appeared to vary from the original design of CE76 (i.e. CE76 
without P1-linker) and similar to the hCpn10, despite the extension and difference of the 
mobile loop conformation. It is quite possible that the P1-linker of “AAP/PAA” sequence 
could have an influence in rearranging the electrostatic configurations. 
 
 
Figure ‎3.14  Electrostatic potential maps 
Representation of the electrostatics potential at the molecular surface of hCpn10 variants obtained 
from 1 ns MD simulations of: (A) CE76P1; (B) CE76P2; (C) CE76E5; and (D) CPMycP1. Detailed 
descriptions of colour codes are as described in Figure 3.11.  
 
3.5.2.3.2 Simulation of CE76P2 variant 
 
CE76P2 was a second CE76 variant that contained the E-76 peptide within the mobile region. 
This peptide was separated from the β-core by a Pro-Pro (P2-linker) (Table 3.2) with double 
proline residues in both N- and C-termini extensions. CE76P2 underwent a simulation in an 
A. 
 
 
 
 
 
 
A. B. 
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aqueous environment at a dielectric constant of  =78.5, similar to the first simulation as 
discussed in Section 3.2.2.3.1. Simulations for the CE76P2 variant revealed that the C-
terminus His-tag was highly flexible, similar in nature to the CE76P1 variant. However, this 
tag did not appear to interact with the E-76 loop within the hCpn10 (Figure 3.15). On the 
other hand, because the C-terminus, including the His-tag, is quite extended (i.e. 
KYVDGGGGHHHHHH) it may subsequently hinder heptamer formation. This in turn will 
make computational predictions of the CE76P2 dynamics more difficult. Nevertheless, given 
the high flexibility observed in the extended C-terminus, it is likely that this region could also 
adopt a stable conformation in the multimeric structure and allow for the interaction of 
adjacent monomers to stabilise the heptamer.  However this will require wet-lab verifications. 
Another interesting observation was that the mobile loop region of CE76P2 was flexible and 
yet could adopt a number of stable conformations, none of which interfered with heptamer 
formation (Figure 3.15). In essence, the protein β-barrel core of CE76P2 was well conserved 
and showed many similarities to the hCpn10 protein core as exemplified in Figure 3.8. 
 
 
Figure ‎3.15  MD simulation of CE76P2 over duration of 1 ns at 310 K  
Snapshots from 1 ns MD simulations at 310
 
K shown CE76P2 variant in ribbon representation. The 
snapshots show the conformation of the β-core barrel and the mobile loop of the redesigned CE76P2. 
Where, red, green and purple ellipsoids show the locations of the C-terminus His-tag, the inserted E-
76 mobile loop and the last two β-strands (4 and 5) of the central β-sheet of the protein core, 
respectively. Detailed descriptions of colour codes are as described in Figure 3.13. 
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A second simulation was conducted on the CE76P2 variant whereby the C-terminal His-tag 
was removed. Simulations were conducted in an aqueous environment at a dielectric constant 
of  =78.5, and simulation analysis showed that the P2-linker can independently stabilize the 
inserted E-76 at the mobile loop domain. Furthermore, like with the first simulation, the 
structures of the β-sheets were not compromised in the N- and C-termini. However, there was 
some degree of flexibility and interaction with the β-hairpin roof loop (Appendix 3). It is 
possible that this interaction is an artefact of the simulation. Importantly, the mobile loop did 
not appear to collide with the contiguous monomers which can prove to be critical in the 
assembly of the CE76P2 heptamer as shown in Figure 3.15. 
 
The third simulation was conducted on full length CE76P2 at a dielectric medium of  =40. 
This simulation further confirmed that the P2-linker was rigid enough to create stability in the 
E-76 loop and prevent interaction with the β-Core of hCpn10. Based on the data acquired 
from these simulations it is possible that the P2-linker may be conducive to heptameric 
formation. Similar to the previous simulation, both N- and C-termini were slightly unfolded 
and interacting with the β-hairpin roof loop. However, this could once again be regarded as 
an artefact of the simulations. Nevertheless, despite the small degree of flexibility seen in the 
N- and C-termini, the remainder of the CE76P2 β-barrel core was very stable. The electrostatic 
potential that was generated by the modified CE76P2 variant illustrated that the electrostatic 
allocations supported the development of the heptamer molecule (Figure 3.14B).  
 
3.5.2.3.3 Simulation of CE76E5 variant  
 
The third variant was CE76E5 whereby the E5-linker was positioned between the inserted E-
76 loop and the protein β-barrel core (Table 3.2). Specifically, the E-76 peptide was inserted 
further downstream of the protein core by retaining five native amino acids of the native-
mobile loop, namely AAETV and EKSQG of N- and C-termini, respectively. As seen in the 
previous simulations discussed, the C-terminus His-tag of CE76E5 was highly flexible in the 
aqueous environment at a dielectric constant of  =78.5 (Figure 3.16). The first simulation 
illustrated that the His-tag did not interact significantly with the mobile loop but it folded in 
the reverse direction and disrupted the first strand of the core β-sheet. Moreover, the extended 
sequence of the histidine-tag obstructed the heptamer formation. However, given that the C-
terminus is highly flexible, it could adopt a more stable conformation at the dimerisation site, 
and subsequently allow for interaction between adjacent monomers in order to stabilise the 
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heptamer. It was apparent that the mobile loop of CE76E5 was flexible and could adopt a 
number of conformations, although none of these appeared to interfere with heptamer 
formation. Finally, the protein β-barrel core of CE76E5 was structurally well conserved as 
seen with hCpn10 despite the unfolding of both the N- and C- termini (Figure 3.16).  
 
In the second simulation, the C-terminus His-tag of CE76E5 was removed and the modelling 
was performed in an aqueous environment at 310 K ( =78.5). Similar to the first simulation, 
the E-76 loop region showed some degree of flexibility but this peptide stabilised the stem 
region of hCpn10 and did not interact with the β-hydrophobic core (see Appendix 3 for more 
detail).  
 
Figure ‎3.16  MD simulation of CE76E5 over duration of 1 ns at 310 K 
Snapshots from 1 ns simulations at 310
  
K shown CE76E5 in ribbon representation shows the 
conformations of the β-core and the mobile loop, green ellipsoid illustrated a structural distortion 
appeared toward the end of MD simulations. Detailed descriptions of colour codes are as described in 
Figure 3.13.  
 
In the third simulation, full length CE76E5 was modelled in a medium dielectric environment 
at  =40. In this simulation, the CE76E5 variant appeared to be distorted where residues Glu43 
of the E-76 loop and Glu45 of the E5-linker “PEKSQ” formed hydrogen bonds with Lys90 
and Arg102 of the protein β-barrel core (second last β-strand) (Figure 3.17A). The E5-linker 
of CE76E5 which contained polar and charged residues cannot constantly prevent the mobile 
loop from interacting with the protein core. In such circumstances, it is uncertain whether the 
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CE76E5 structure can form dimers (i.e. a prerequisite for heptamer configuration) rather than 
a heptamer as observed in hCpn10 (as seen in Figure 3.8). 
 
Electrostatic potentials were calculated for the CE76E5 variant. Despite the protein being 
more distorted in this case as shown in Figure 3.17A, the presence of electrostatic charges at 
the dimerisation interfaces and topological complementarity may be the ideal conditions to 
support dimerisation and heptamer formation (Figure 3.14C). 
 
         
Figure ‎3.17  The final structures from MD simulations of hCpm10 variants 
MD simulation final structure of hCpm10 variants. (A) CE76E5 monomer construct from simulation-3 
in medium dielectric environment ( =40), shows monomer structure distortion and rearrangement of 
the core β-barrel, central β-strands extended, and β-strands 3 and 6 lost. (B) CPMycP1 monomer from 
simulation-3 in medium dielectric environment with  =40, shows monomer structure distortion and 
the loss of the central topology of the β-stands. 
 
3.5.2.3.4 Simulation of CPMycP1 variant 
 
The modified CPMycP1 variant contained a Myc-loop domain that was stabilized with a P1-
linker at N- and C-junctures of the mobile loop (Table 3.2). It was hypothesised that the use 
of the P1-linker might bring more stability to the Myc-loop despite the inherent properties of 
the peptide. As such, similar MD simulations were performed for the redesigned 
CPMycP1that also contained extended a C-terminus His-tag. The first MD simulation was 
performed in an aqueous environment ( =78.5) where the C-terminus was highly flexible and 
the His-tag interacted loosely with the Myc-loop during certain parts of the simulation, 
(Figure 3.18). As a consequence, the slight extension of the C-terminal domain obstructed 
formation of the heptamer. However, given the high flexibility (i.e. visually of snapshots and 
numerical value of rmsf/rmsd) of this domain, interaction between adjacent monomers may 
A.                                         B. 
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stabilise the C-terminus domain and facilitate the formation of heptamers (data not available). 
Furthermore, despite the high flexibility of the Myc-loop, none of the adopted conformations 
appeared to interfere with the heptamer configuration. Like previous simulation studies, the 
β-barrel core of CPMycP1 was structurally conserved in similar topology to hCpn10 (Figure 
3.18). Moreover, a slight unfolding of the N- and C-termini domains was observed during the 
simulations and could potentially interfere with the ideal configuration of some β-strands but 
the β-strands still remained in an extended conformation. 
 
 
Figure ‎3.18  MD simulation of CPMycP1 over duration of 1 ns at 310 K 
Snapshots from 1 ns MD simulation at 310
 
K shown CPMycP1 in ribbon representation showing the 
conformational changes of the β-core and the mobile Myc-loop; yellow ellipsoid illustrates β-strands 
3 and 6 which were lost toward the end of MD simulations. Detailed descriptions of colour codes are 
as described in Figure 3.13.  
 
In the second simulation of CPMycP1, the extended C-terminus His-tag was removed and 
simulated in an aqueous environment ( =78.5). The model of CPMycP1 was distorted during 
simulation, similar to what was observed in the CE76-E5 model whereby the central β-strands 
of the CPMycP1 were extended despite the loss of two β-strands 3 and 6. On the other hand, 
no interactions between the C-terminus and the β-core were observed during the MD 
simulations and thus would not interfere with heptamer formation. The P1-linker in 
conjunction with the inserted Myc-peptide might induce an extension of the two central β-
strands, and therefore cause a distortion of the CPMycP1 variant and influence the 
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dimerisations and heptamer development which would presumably be different to the wild-
type hCpn10. 
 
The third MD simulation was on full length CPMycP1, in a biological dielectric medium of 
 =40 that resembled the intracellular environment. In this simulation, the surrounding 
conditions forced a conformational change where the extended His-tag began to fold back 
towards the vicinity of the C-terminus. Remarkably, the Myc-loop was still in an extended 
conformation and did not interact with the protein core as indicated by the third simulation 
mode. Despite that, the CPMycP1 structure was distorted and had lost the central topology of 
the two β-sheets towards the end of the MD simulations (Figure 3.17B).  
 
The distributions of the electrostatic potentials were calculated for CPMycP1 using the 
shortened molecular model without the C-terminus His-tag, despite the fact that the protein 
was distorted in this simulation (Figure 3.17B). As a consequence, this study illustrated that 
the electrostatic distributions at the potential dimerisation sites were not entirely 
complimentary and would more likely hamper dimerisation and thus heptamer formation 
(Figure 3.14D). 
 
3.5.3 Force-Mode approach (Non-MD simulations) 
 
An in vitro/wet-lab approach towards forcing heptamer formation of hCpn10-based NME 
was undertaken through a “Force-Mode” approach. In this particular technique, each hCpn10 
monomer was linked at the genetic level, whereby three glycine residues (GGG) were 
introduced between the C- and N-termini of the monomers, thus fusing all seven monomers 
together in one gene. The first step involved utilising the CE76 gene as a template where 
three glycine (Gly102 Gly103 Gly104) residues were genetically inserted from Asp101 of C-
terminus to Ala1 of adjacent monomer N-terminus (Figure 3.19). An artificial DNA encoding 
FH-CE76 (i.e. forced-heptamer design construct with 3xGly) was then transformed and 
ligated to an expression pET30a vector (i.e. pET30a-FH-CE76) using the standard molecular 
biology described in Chapter 2. The FH-CE76 was then expressed and purified from low cost 
bacterial expression systems (i.e. E. coli BL21), followed by subsequent verifications using 
optimum protein characterisation techniques, such as SDS-PAGE and analytical SE-HPLC. 
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Figure ‎3.19  Three-dimensional representation of proposed Forced Heptamer-CE76 
Representation of FH-CE76 (Top view) illustrating the location of glycine-linker in Force-Mode 
approach. The C-terminus of one monomer was linked to the N-terminus of the adjacent monomer by 
three glycine residues (Gly-Gly-Gly). FH-CE76 shown in ribbon representations (i.e. β-barrel: violet, 
coil: gray, G: glycine, N: N-terminus, and C: C-terminus) modelled by UCSF Chimera 1.5.3.   
 
The estimated molecular weight of the FH-CE76 was roughly 84 kDa and therefore due to 
the protein size and other characteristics of inserted E-76 peptide (i.e. combination of charge 
and hydrophobic residues) in comparison to native hCpn10, the expression of this protein 
resulted in the formation of inclusion bodies (IB). This is typically the case when large 
recombinant proteins are rapidly expressed in E. coli (BL21) systems. Nevertheless, the 
process is reversible and the IBs were resolubilised in 8 M of Urea and dialysed into an 
alternative optimized buffer (see Chapter 2) that facilitated the refolding of the FH-CE76.  
 
The Force-Mode approach indeed allowed for the formation of a heptamer as determined by 
SDS-PAGE (Figure 3.20). However, FH-CE76 proved to be relatively unstable during the 
purification process and resulted in a degraded product. Nevertheless, when the same method 
was applied to hCpn10 (named FH-Cpn10), this variant not only formed a stable heptamer, 
93 
 
but was also more stable during the purification process. Thus, there is potential in using the 
force-mode strategy as an alternative method for heptamer development. 
 
3.5.4 Protein expression and purification 
 
In order to test theoretical predictions by MD simulations of NME stability and heptamer 
formation, all designed hCpn10 variants that underwent MD simulations were subsequently 
synthesized, expressed in E. coli and purified. In order to assess the stability and 
oligomerisation of the hCpn10-based NME in vitro, the hCpn10 variants were designed in 
silico whereby the mobile loop was substituted with different functional peptides as described 
in Table 3.1. In addition, each hCpn10 variant contained a His-tag at the C-terminus in order 
to purify the protein at a high yield. Finally, based on the simulation-cycle schematic diagram 
in Figure 3.6, each hCpn10 variant underwent two phases of MD simulations in order to 
further optimise the construct that contained different non-native peptides and be able to 
develop heptamer configuration. 
 
Following standard expression and purification procedures (detailed in Chapter. 2), hCpn10 
and all designed variants were expressed in E. coli strains of BL21(D3) and extracted as 
soluble proteins. Following expression and E. coli cell lysis, proteins of supernatant were 
subsequently passed through Ni
2+
Sepharose column of immobilized metal affinity 
chromatography (IMAC) in order to purify the His-tagged hCpn10 variants. Purity of the 
hCpn10 variant eluants was verified through gel electrophoresis by running the sample 
through a dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (Figure 3.20). 
Eluted hCpn10 and its engineered counterparts were further purified by running the samples 
though a gel filtration Superdex
®
 200 GL column and subsequently identified using matrix 
assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF MS) 
(Figure 3.21). 
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Figure ‎3.20  SDS-PAGE analyses of hCpn10 and its variants.  
SDS PAGE analyses of hCpn10 and hCpn10 variants using a 4-12 % Bis-Tris acrylamide gel 
(NuPAGE
™
) and Coomassie stain (SimplyBlue
™
SafeStain). (A) Phase I of MD simulation (original 
construct): Lane1, Mwt marker (SeeBlue
®
Plus2, from Invitrogen
™
); Lane2, hCpn10 (control, 10 
kDa); Lane3, CE76 (12.2 kDa) from HisTrap™ FF eluate; (B) Phase II of MD simulation -details as 
before- Lane1, SeeBlue
® 
Plus2 Mwt marker; Lane2, hCpn10 (10 kDa, control); Lane3-4, CE76E5 (13 
kDa) of post-induction/purified elute; Lane5-6, CE76P1 (12.6 kDa) of post-induction/purified elute; 
Lane7-8, CE76P2 (12.5 kDa) of post-induction/purified elute; (C) Phase II of MD simulation 
(variants): Lane1, SeeBlue
® 
Plus2 Mwt marker; Lane 2, CPMycP1 (3 hrs) of 0.4mM IPTG post-
induction cell lysate extract of E. coli BL21(DE3); Lane 3, CPMycP1 (11.8 kDa) of HisTrap™ FF 
elute; (D) Force-mode Approach: Lane1, hCpn10 (10 kDa, control); Lane2, SeeBlue
® 
Plus2 Mwt 
marker; Lane3, post-induction soluble factions of FH-Cpn10 (71 kDa); Lane4, pooled of purified 
fractions from IMAC; Lane5, post-induction soluble factions of FH-CE76 (84 kDa); Lane6, pooled of 
purified fractions from IMAC.  
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Figure ‎3.21  MALDI-TOF MS comparisons of CE76 and redesigned CE76P1  
Calculated molecular weight for CE76 (left frame) and CE76P1 (right frame), as compared to observed 
molecular weight. The resolved samples were determined from SE-HPLC eluates. 
 
3.5.5 Analytical chromatography 
 
In order to verify the molecular modelling simulations of engineered Cpn10 in vitro (Table  
3.1) all proteins were subjected to an analytical size exclusion-HPLC and chromatograms 
from each run were compared with hCpn10 (Figure 3.22). 
 
The SE-HPLC chromatograms of mutant proteins from Phase-I MD simulations (i.e. 
unmodified constructs) revealed that a heptamer did not form indicating the protein to be 
unstable and subsequently degraded during the purification process. Conversely, unmodified 
CE76 only formed a tetramer (Figure 3.22). Of all the engineered constructs based on 
hCpn10, the CPMyc not only failed to form a stable heptamer but the protein also formed 
soluble aggregates that could not be analysed through SE-HPLC (data not shown).  
 
Δm/zcal  =12206 
Δm/zobs =12204 
Δm/zcal  =12685 
Δm/zobs =12683 
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Figure ‎3.22  Size exclusion HPLC chromatograms of recombinant hCpn10 variants  
SE-HPLC chromatograms of hCpn10 (red, 70 kDa, wt control) versus NME variants CE76 (brown); 
CE76P1 (blue); CE76P2 (black); and CE76E5 (green), respectively. CE76P2 and CE76E5 variants 
developed soluble aggregates. CE76E5 also developed dimers and monomers. BioRad
™ 
(dash line) 
standard combined of; 1/Thyroglobulin (670 kDa); 2/γ-globulin (158 kDa); 3/Ovalbumin (44 kDa); 
4/Myoglubin (17 kDa); 5/Vitamin B12 (1.35 kDa), used for Mwt integrations of target proteins 
(detailed in Chapter 2). 
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Clearly, the modified constructs predicated from Phase-II MD simulations (i.e. stabilised by 
various linkers from Table 3.2) predicted that a stable heptamer could be formed, albeit under 
specific conditions for some mutants (e.g. lower pH level). As the MD simulations had 
revealed, the P1- and P2-linkers were effective in restricting and stabilizing the E-76 peptide 
within the mobile loop region. This in turn prevented the interaction of the E-76 peptide with 
the β-core complex of hCpn10. Thus, the P1- and P2-linkers conferred an overall stability in 
the protein that eventually facilitated the proper formation of a heptamer (Figure 3.22). Based 
on the promising data seen with the CE76P1 and CE76P2, further stability studies were 
conducted by storing these samples at -20 °C, 4 °C, 25 °C and 37 °C at a timeframe of 1 and 
4 weeks. Analyses conducted through SDS-PAGE and SE-HPLC revealed that the proteins 
were stable under these varying storage conditions (Appendix 2). 
 
The E5-linker within the CE76E5 model was rather contrary to the observations made in the 
MD simulation which indicated that the CE76E5 would not form a heptamer based on the 
flexibility of the E-76 loop and the distortions within CE76E5. Nonetheless, the SE-HPLC 
chromatogram showed a presence of monomers, dimers and soluble aggregates, in addition to 
formation of heptamers (Figure 3.22). Despite forming heptamer, the overall stability of the 
CE76E5 model was temporary and the protein quickly degraded. Further studies were 
conducted where the P1-linker was incorporated into the CPMyc model construct. The SE-
HPLC chromatogram revealed that the CPMycP1, associated with control hCpn10 formed a 
heptamer under physiological conditions that was similar to hCpn10 (Figure 3.23). 
 
 
Figure ‎3.23  Size exclusion chromatogram of CPMycP1 versus hCpn10 
SEC chromatogram determined molecular size of recombinant proteins by gel filtration Superdex
® 
75 
column. The CPMycP1 (88 kDa) and hCpn10 (wt control, 70 kDa) showed in blue and red, 
respectively. Calculated Mwt resolved from Mwt standard curve of known proteins (detailed in 
Chapter 2).  
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3.6 Discussion 
 
There are opportunities for the development of alternative molecular scaffolds with similar 
binding capabilities as mAbs, that may have niche applications and generate novel 
intellectual property.  There are currently over fifty endogenous and non-endogenous proteins 
that have been developed as alternative scaffolds for a number of applications such as 
Affibodies, Anticalin, Monobodies, DARPins and others that have been extensively reviewed 
in Chapter 1 and elsewhere (Skerra, 2007, Koide and Koide, 2007, Stumpp et al., 2008, 
Lofblom et al., 2010). 
 
The general principle behind the success of designing an effective scaffold is to introduce a 
non-native and functional peptide(s) that will not compromise the overall stability of the 
scaffold in use. Similar to other mAb structures, many non-antibody based scaffolds possess 
flexible loop structures that can be substituted for a non-native peptide sequence such as 
Monobodies derived from human 
10
FN3, whereby random mutations of loop residues led to 
VEGFR2-antagonist as anti-angiogenesis for cancer treatment (Getmanova et al., 2006). 
Also, an immunoglobulin-CDR3 sequence was fully grafted into one of the Neocarzinostatin 
(NCS) loops for future therapeutic applications (Nicaise et al., 2004). 
 
Many of the protein scaffolds discussed in Chapter 1 have varying secondary and tertiary 
structures and consequently not all oligomeric proteins have the desirable features for 
creating new binders. Therefore, proteins with weak secondary structures are not suitable for 
the development of new molecular scaffolds. The ideal scaffold must, therefore, have a rigid 
framework with several regions that have different secondary structural conformations that 
can be substituted for numerous peptides or utilised in the development of a peptide library 
where the substituted regions are intentionally diversified. 
 
Cpn10 is an essential oligomeric mitochondrial protein that assists in folding of translated 
polypeptides or refolding of denatured proteins (Hartman et al., 1992, Martin et al., 1993, 
Pilkington and Walker, 1993, Taneja and Mande, 1999, Hartl and Hayer-Hartl, 2002, Perham 
and Wittung-Stafshede, 2007). Cpn10 is structurally conserved across many species (Hunt et 
al., 1996, Xu et al., 1997, Roberts et al., 1999, Luke et al., 2005b, Luke et al., 2005a, Numoto 
et al., 2005) and the quaternary structure (70 kDa) is composed of seven identical monomers 
as shown in Figure 3.1. Each monomer consists of a β-hairpin roof loop and a longer flexible 
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mobile loop that extends below the core of the protein. Importantly, these loops are 
interconnected by a structurally rigid hydrophobic β-barrel core (Guidry et al., 2000, 
Higurashi et al., 2003, Lin et al., 2004). Prior to forming a complex with its cognate Cpn60, 
i.e. for assisting protein folding (Shimamura et al., 2004), Cpn10 is assembled into a 
heptameric structure through a strong hydrogen bond between the β-barrels of contiguous 
monomers (Sakane et al., 2004, Sakane et al., 2007) (Figure 3.3). The mobile loop is highly 
flexible in structure and is known to play a crucial role in interacting with Cpn60 (Richardson 
et al., 2001, Lin et al., 2004).  
 
The Cpn10 core is composed of hydrophobic amino acids while the residues on the surface 
are mostly hydrophilic. In the Cpn10 protein core, the folding process is driven mainly 
through the collapse of hydrophobic residues while heptamer formation is dependent on 
hydrogen bonding between the adjacent monomer interfaces. Therefore, a well-structured 
hydrophobic core is crucial for the stability of the protein (Lazar et al., 1997, Street and 
Mayo, 1999). In addition, the protein surface plays a crucial role in its stability and for that 
reason it is important to ensure that insertion of various functional peptides does not 
compromise the core structure of the protein. In Cpn10, the main source of β-sheet stability is 
via hydrogen bonding and a subsequent alignment with adjacent antiparallel β-strands. The 
interaction between the antiparallel pairings of the β-strand interface of each monomer, and 
the inter-protein interactions govern over 75 % of the Cpn10 heptamer configuration stability 
(Guidry et al., 2003, Luke et al., 2006, Aguilar et al., 2011). Studies conducted by Sakane et 
al. (2004) determined that mutations in various residues such as Ile3 and Val95 of N- and C-
terminus, respectively, did not affect Cpn10 refolding. Interestingly, oligomeric Cpn10 is one 
of few proteins that can fold reversibly in vitro despite the introduction of various mutations 
(Perham and Wittung-Stafshede, 2007) and this is an important aspect in molecular folding 
and protein assembly for an advanced scaffold protein design. 
 
The mobile loop within Cpn10 exhibits a large variation in structural conformations as this 
region lacks a defined secondary structure. However, mobility is restricted only when the 
Cpn10 heptamer is in contact with Cpn60 (Richardson et al., 2001, Higurashi et al., 2003). 
Human Cpn10 mobile loop consists of 18 residues (AAETVTKGGIMLPEKSQG) while the β-
hairpin roof loop is composed of 12 amino acids (GSKGKGGEIQPV) (Figure 3.3). In 
general, the two loop turns (i.e. roof & mobile) that join the β-strands might play a crucial 
role, whereby modification, substitution, or mutation of any of these residues may seriously 
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affect the overall protein stability. However, in practice, the substitution or exclusion of the 
mobile loop (i.e. ΔL-Cpn10), the β-hairpin loop (i.e. ΔRf-Cpn10), or both loops ΔL-ΔRf-
Cpn10 (i.e. β-barrel) had no significant impacts on assembling of mutant-hCpn10 into 
heptamer configurations (Figures 3.4 and 3.5). 
 
As with other molecular scaffolds, loops form an extended interface that facilitates binding 
towards a specific target molecule (Chapter 1). Therefore, in these particular regions, the 
loops can be substituted or extended with a functional peptide domain which may vary in 
sequence and length. In this study, hCpn10 has been identified and proposed as an ideal 
molecular scaffold, whereby peptides and/or antibody fragments may be substituted into the 
mobile loop for various medical and biotechnological purposes (Table 3.1). 
 
Normally, information on the structure of various proteins can be acquired through X-ray 
diffraction, nuclear magnetic resonance (NMR), Förster resonance energy transfer (FRET), or 
other biophysical methods (Higurashi et al., 2003, Perham and Wittung-Stafshede, 2007, 
Buehler et al., 2010, Wu et al., 2012). These methodologies yield valuable structural 
information that can be used for various applications including drug design and anti-viral 
agents among others. Nevertheless, these methods have limitations in terms of applicability 
and time scales.  
 
MD simulation is an in silico technique that is routinely used to study biologically important 
macromolecules such as peptides, proteins, and nucleic acids at the atomic level (Su and 
Wang, 2009, Mitchell et al., 2009). These simulations are conducted at a time scale ranging 
from femto- to micro-seconds (Lindahl, 2008). The molecular dynamics are then numerically 
solved using equations of motion to follow the time evolution and thus determine the kinetic 
and thermodynamic properties of such molecules (Petrenko and Meller, 2010). The accuracy 
and level of details acquired from MD simulations are dependent on the size of the 
biomolecule and the timescale that is used. Given the advances made in computer technology 
and enhanced algorithmic design, MD simulation approaches towards complex biological 
systems (e.g. protein complexes) have become an increasingly important asset in many 
research areas. Hence, the MD simulations have altered the interplay between theory and 
experiment, providing a basis that aids in the understanding of various molecules that could 
otherwise not be obtained through other physicochemical techniques. Importantly, examining 
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the properties of biomolecules by using MD simulation is faster and more cost effective than 
synthesizing and characterizing it in a real time experiments. 
 
The experimental results in conjunction with the computer modelling data provide a basis for 
understanding the chemical machinery of various proteins. Details of the structural 
conformation and molecular interaction of hCpn10 and the scaffold-based hCpn10s needed to 
be well understood in order to stabilize the protein. Therefore, MD simulations were utilised 
in order to evaluate how mutations could affect the structural function of the mutant-proteins. 
This approach was used to identify the domain(s) and/or residue(s) of the hCpn10 that are 
most likely to accept mutations with maximum stability and thus, identify the correct 
mutation sites and cluster domains that are important for the development of other hCpn10-
based NMEs. 
 
This study was focussed on integrating the data acquired from the MD simulations as well as 
the subsequent experimental validations. The details on implementing mathematical and 
physical principles are well documented in molecular modelling literature (Leach, 2001, 
Frenkel and Smit, 2002). The choice of modelling methods was based on a practical problem, 
specifically the experimental failure of hCpn10-based variants to develop the proper 
configurations and to find out why heptamers were not formed in practice. Use of state-of-art 
simulation techniques have provided more details on the structure and dynamics of hCpn10s 
that could not be obtained from experimental analyses alone. The MD simulations of the 
hCpn10 variants provided significant insight into the dynamics of the molecules in order to 
address a number of important questions. Firstly, how the non-native peptide (in Table 3.1) 
inserted at the mobile loop domain actually behaved and transformed? Secondly, which 
residue(s) of this inserted peptide and/or of the hCpn10 molecule play a major role in 
heptamer stability? Thirdly, despite the stability of native hCpn10, why does/do certain 
mutation(s) affect the stability of the overall structure? And importantly, is there a conserved 
heptamer configuration of hCpn10-based NMEs? 
 
The MD simulations generate a number of trajectories, which are a set of atom coordinates. 
These trajectories are then used for calculations that determine the distance between atoms 
and/or residues, the prevalence of hydrogen bonds, occurrences of disulfide linkages, 
structural modifications and/or degradations (i.e. secondary, tertiary, and quaternary 
configurations), and the magnitudes of binding sites. These observations essentially provide 
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further biological insights into the molecule that was simulated (Figure 3.7). In addition, parts 
of the trajectories were highlighted by performing additional simulations in full atomic detail 
in order to shed light on the interesting parts of the hCpn10 trajectories (Figures 3.7 to 3.9). 
 
Hence, this study focussed on simulating hCpn10 and comparing its dynamics with its mutant 
variants (Table 3.1). Following the iterative guide-cycle MD simulations were performed in 
two stages (i.e. Phase I and II) based on the problem in hand (Figure 3.6). The first phase of 
the MD simulations was performed on two of the original proposed hCpn10 variants that 
contained either the E-76 or Myc- peptides at the mobile loop domains. The structures and 
kinetics of folding were studied using molecular simulations in conjunction with free energy 
and global optimization methods. A number of simulations were conducted at temperatures 
of 310 K in order to enhance the rate of hCpn10 denaturation, which in turn provided further 
insights into the forces that stabilized molecule. Furthermore, during the simulated refolding 
of hCpn10, kinetic intermediates were identified and further studied. 
 
The initial stages of folding were directly observed during the 10 ns MD simulations for 
hCpn10 (101 residues) without explicit water (Figure 3.7). This illustrated that both the top 
and mobile loops of hCpn10 were flexible at 310 K. However, none of these loops were 
flexible enough to interact with the core structure of hCpn10. These findings confirmed that 
the dimerisation interfaces of hCpn10 were not perturbed in the monomeric form of the 
protein (Figures. 3.7 to 3.9).  
 
The electrostatic potential is thought to be the second most important factor of investigative 
interest. Naturally, the electrostatic interactions play an essential role in the structure and 
function of proteins, DNA, cell membranes, and other biomolecules. One important aspect 
for understanding these interactions is that biologically active molecules are always 
surrounded by water molecules and dissolved ions, adding more degree of freedom of these 
molecules in solvent. The electrostatic potential can be projected on a molecular surface for 
the identification of possible binding sites. Also, it is important in determining the induced 
charge distribution on the molecular surface which accounts for the change in polarization 
charge across the dielectric boundary. Therefore, the electrostatic potentials of hCpn10 
monomers were determined and the electrostatic potentials generated by hCpn10 monomer 
interfaces were illustrated to be complementary and further supported the development of a 
heptamer conformation (Figure 3.10).  
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One of the major problems, of which comprehensive data is available, was the series of 
events that hCpn10 undergoes upon binding with a contiguous monomer. Studies at a 1 ns 
relaxation of the hCpn10 illustrated the kinetics of cluster motif “RSA/GKV” rebinding and 
the motion paths of the mobile loop, which in turn, added a further understanding of the 
discriminating mechanisms that could prevent dysfunctional binding of alternative sequences. 
The sequence motif “RSA” and “GKV” are located at N- and C-termini of the mobile loop, 
and were retained in a few of the hCpn10 variants (Figure 3.9). The packing of the amino 
acids within the two motifs improved during the MD simulations, indicating that the fold of 
the native mobile loop is optimal for a heptamer. The hCpn10 monomer seemed to prefer a 
tightly packed configuration where the Lys39 and Arg19 side chains can optimise the polar 
interactions within the loop as well as the hydrophobic contacts of their aliphatic chains. 
 
Phase I MD simulations were performed on hCpn10 variant termed CE76, whereby hCpn10 
mobile loop was substituted with an anticoagulant E-76 peptide. Simulation data indicated 
that CE76 failed to develop into a heptamer (Figure 3.22). MD simulation of CE76 monomer 
confirmed an overall stable molecule during the 1 ns simulation. However, the mobile loop, 
which contained the E-76 sequence (ALCDDPRVDRWYCQFVEG) and a disulphide bond 
between Cys23 and Cys33 residues, demonstrated numerous conformational changes from 
the initial model whereby the E-76 loop contacted the surface of the core protein formed by 
the β-barrel like structure. This clearly indicated that the E-76 loop would block interactions 
between different monomers and therefore, heptameric assembly. A number of critical 
interactions did occur within the E-76 loop where polar residues Arg30 and Asp24 interacted 
with Glu74 of the β-core, and residue Glu37 interacted with Lys79 of the β-core. In addition, 
weak hydrophobic interactions did occur between residues Val100, Leu71, and Gln42 of the 
β-core and the CE76. Due to the flexible nature of the E-76 loop, collision occurred more 
frequently with β-strands 4 and 5 within the β-core of the CE76 model. In addition, an 
observed distortion on the CE76, relative to hCpn10 occurred at the dimerisation interfaces 
(Figure 3.10B). A significant finding was that there were two negatively charged regions near 
the binding site, indicating a lower electrostatic potential for dimerisation of two (or more) 
CE76 monomers. Therefore, due to the collision of the E-76 loop with the protein core, and 
the reduction of electrostatic potential could possibly explain the inability of CE76 to form a 
heptamer in vitro (Figure 3.22).  
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MD simulations (I) were applied to second variant called CPMyc, which contained the Myc-
peptide within the mobile loop region of hCpn10 (Table 3.1). Although Myc-tag peptide is 
typically used for purifying recombinant proteins, it was utilised in the MD simulations as the 
peptide contained a number of charged and polar residues. Also, the success of CPMyc as 
scaffold molecule in binding to 9E10 antibody could open a future window in the design of 
vaccines, by using the avid hCpn10 to display different epitope(s) for quick immune response 
against a specific illness. Under these circumstances, the Myc-tag has been proven beneficial 
in gaining a further understanding of the dynamics of hCpn10-based variant when a peptide is 
inserted into the mobile loop. Following the same methodology used in the previous 
simulation of CE76, the CPMyc monomer was in general a stable molecule, however the 
substituted mobile loop with the Myc-tag was found to be highly flexible with a continuous 
change in conformation during 1 ns simulation (Figure 3.12). The high flexibility of the Myc-
loop was likely due to the high contents of charged residues (i.e. EQKLISEEDLNG) at the 
substituted loop domain. Furthermore, the MD simulations showed that the Myc-loop was 
interacting with the core β-barrel of contiguous CPMyc monomer where β-strands 4 and 5 of 
the protein were moving towards the mobile loop and disrupting the dimerisation interfaces 
of the adjoining monomers (Figure 3.12). Based on the simulation, the CPMyc model was 
unlikely to form full-size heptamers which was clearly confirmed through in vitro 
experiments. 
 
The second phase of the MD simulations was conducted on the modified CE76 and CPMyc 
variants. Following on from the investigations made on using hCpn10 for displaying various 
peptides, four redesigned models were evaluated in this second phase (II). The modifications 
were made by inserting the various linkers in Table 3.2 between the native hCpn10 (β-barrel 
core) and the insertion sites of the non-native peptides (at N- and C-junctures of the mobile 
loop). The inserted linkers were enriched with alanine(s)/proline(s) residues, however, in the 
case of the E5-linker used for the E-76 peptide five native loop residues were retained at the 
N- and C-termini, respectively. The key aim of using these linkers was to apply a certain 
degree of extinction and rigidity in the inserted peptide sequences, and prevent interaction 
with the β-barrel core of the hCpn10 protein. The importance of inserting linkers with 
multiple proline (Pro) residues was to impose some constraint and thereby reduce the 
entropic rate of the inserted non-native peptides, due to the nature of proline that provide 
rigidity to polypeptide chain by imposing certain torsion angles on the segment of protein 
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structure, which play crucial roles in protein folding (Ho et al., 2005, Eyles and Gierasch, 
2000, Shi et al., 2002, Bhat et al., 2003, Greenfield, 2006). 
 
Phase II of the MD simulations was performed in three different modes (as simulation 1, 2, 
and 3) for each variant. CE76P1 is the first redesigned model to be examined where the CE76 
was modified by inserting a P1-linker (Table 3.2). MD simulation 1 of the CE76-P1 indicated 
that the P1-linker could likely stabilize the E-76 loop and prevent interactions with the 
protein core (Figure 3.13). In contrast to the unmodified CE76 model, the CE76P1 core was 
more stable and no significant distortions were observed for any of β-strands 4 and 5. For 
enabling the purification process, a His-tag was C-terminally inserted. However, due to the 
high flexibility of this tag, there was a possibility of interacting with the β-barrel core which 
might hinder the heptameriztion development which is contrary to hCpn10. However, it could 
also probably prevent or reduce the interactions between the E-76 insert and the protein β-
core. The electrostatic potential generated by the CE76P1 monomer interface was not altered 
by the addition of a P1-linker, but it did support heptamerisation due to a slight compatibility 
in surface charges. Overall, the ability of the CE76P1 model to form a heptamer was apparent, 
and further verified in vitro when the CE76P1 model produced a fully functional heptamer 
following a buffer screening approach for detecting optimum conditions (i.e. CE76P1 ~ 
isoelectric point (pI) 7.1). The CE76P1 was stable and functional at low pH 5.5, which was 
resolved by UV detections of SE-HPLC (Figure 3.22) and in vitro activity determinations 
(Chapter 4). 
 
CE76P2 was a modified construct that contained a P2-linker (Table 3.2) and underwent a 
series of simulations. MD simulations on CE76P2 were performed in three environments as 
described above. These simulations verified that the P2-linker independently succeeded in 
stabilising the E-76 inserted loop. The P2-linker prevented any interaction of the inserted-
loop with the protein core and therefore allowing heptamerisation to occur in a similar format 
to hCpn10. The CE76P2 β-barrel core was stable during the MD simulations and there were 
no major distortions observed in any of the β-strands as observed in the unmodified CE76 
model. The CE76P2 was also C-terminally His-tagged, however, unlike the CE76P1, 
simulations determined that this tag did not interact significantly with the E-76 insert (Figure 
3.15). In addition, the distributions of electrostatic potential that were generated by the 
CE76P2 contiguous monomers supported heptamer formations (Figure 3.14B). Consequently, 
the P2-linker in CE76P2 model was predicted to form a heptamer. Remarkably, the CE76P2 
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was expressed and purified as a full heptamer, whereby the UV profiles of CE76P2 illustrated 
the stability of the heptamer configurations (Figure 3.22). 
 
Third examined model variant was the CE76E5 where the E-76 loop was inserted further 
downstream of the mobile loop between Val25 and Glu34 (Table 3.2). MD simulations 
illustrated that the E5-linker could not prevent interactions between the highly polar E-76 
loop and the protein β-core in all simulation conditions. An example is, in a dielectric 
environment of  =40, it did not shield the electrostatic interactions sufficiently enough to 
prevent the interactions between the polar E-76 loop and the protein β-core. The 
heptamerisation of the CE76E5 might therefore be dependent on optimising the buffering 
conditions, for example, maintaining a pH level that was utilised for the CE76P1 model. The 
E5-linker sequence “AETVT/PEKSQ”, of hCpn10 not only failed to prevent interactions 
between the mobile loop and the β-core, but furthermore, the linker sequences distorted the 
structure of the CE76E5 model that was significantly distinct from hCpn10 (Figures 3.16 and 
3.17). MD simulations of CE76E5 also illustrated that both N- and C-termini were highly 
flexible, however the His-tagged C-terminus did not interact significantly with mobile loop 
despite its high mobility. Nonetheless, the charged compatibility that was generated by the 
CE76E5 monomer interface supported heptamer formation (Figure 3.14C). Generally, the 
potential of the CE76E5 variant (pI ~ 6.65) to develop into a heptamer is not certain at this 
stage and will most likely be dependent on the protein media and storage conditions (e.g. 
adjusted pH level). In vitro studies of the CE76E5 model, however, demonstrated that the 
protein was unstable and formed soluble aggregates and other configures as clearly shown in 
its UV profile of SE-HPLC despite the medium pH was adjusted for optimum (Figure 3.22). 
 
The last redesigned model to be examined was the CPMycP1 whereby the Myc-loop was 
stabilised by single proline-linker (P1) (Table 3.2). The MD simulations of the modified 
CPMycP1 variant illustrated that the protein was stable overall with no apparent distortions in 
any of the core β-strands. MD simulations indicated that the P1-linker could independently 
stabilise and retain the inserted Myc-loop from interacting with the protein core (Figure 
3.18). This is, however, different from the simulated CE76P1 model and this is possibly due to 
the shorter size of the Myc-peptide (12 residues). Similar to other models, the MD 
simulations of both the N- and C-termini were highly elastic and the His-tag did loosely 
interact with the Myc-loop. Conversely, this might be necessary in order to stabilise the β-
barrel core. The removal of the His-tag from the C-terminus during simulations with a lower 
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dielectric constant ( =40), however, eventually distorted the CPMycP1 model. Interestingly, 
the electrostatic distributions that were generated by the CPMycP1 adjacent monomers at the 
dimerisation sites might in fact hinder oligomerisation and heptamer formation. This could be 
due to the different conformational folds of the N- and C-termini (Figure 3.14D). Generally, 
the CPMycP1 variant is likely to form a heptamer if the His-tag can adopt a conformation 
where it does not interfere with dimerisation between adjacent monomers. Yet, the 
recombinant CPMycP1 was successfully formed a heptamer as evident in the SEC profile 
measured at 280 nm, despite the unsupportive MD data of the distribution of the electrostatic 
potential (Figure 3.23). This, however, could be more relevant to the greater choice of 
buffering systems, rather than the dependent on the molecular behaviour alone for the 
development of heptamer configuration. 
 
A force-mode approach is an alternative approach and was applied in order to improve the 
development of heptamer for the scaffold based-hCpn10 variants. This method is based on 
genetically designing the hCpn10 variants with force linking six of the seven contiguous 
monomers with three glycine residues (~ 3.4 Å) from the C- to N-termini. About 3 Å is the 
distance between adjacent monomers termini. Therefore, 3xGly would have no or minor 
affect in molecular assembly. This approach was applied to the original construct of CE76 
(Table 3.1) called FH-CE76, and similarly applied to the native hCpn10 termed FH-Cpn10. 
Despite the success of this approach in forming a heptamer for both FH-Cpn10 and 
FH-CE76, there were technical drawbacks in this regard, particularly with the FH-CE76. 
Firstly, the large molecular size of 84 kDa as shown in Figure 3.19 meant that such a protein 
would more than likely to form IBs (i.e. aggregates). Secondly, extracting FH-CE76 from the 
IBs as unfolded proteins, followed by subsequent refolding via buffer exchange would 
essentially be a time consuming exercise. Lastly, the FH-CE76 was unstable and formed 
soluble aggregates following purification and therefore this protein could not be analysed via 
SE-HPLC. Therefore, a forced-heptamer approach cannot be applied for a molecule like 
CE76. However, the FH-Cpn10 was more stable with similar properties and characteristics of 
native hCpn10. Thus, the forced-heptamer approach is still applicable however in a molecular 
based manner. 
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3.7 Conclusion  
 
The aim was to establish a fundamental basis for designing a molecular scaffold based on 
hCpn10 for future therapeutic and diagnostic/analytical applications. Computational 
modelling is an advanced technology that provides the basis in understanding the kinetics and 
dynamics of various biomolecules. This is particularly important as it provides a basis to 
effectively engineer the hCpn10 NMEs with various functional peptides that will eventually 
form a heptamer in similar conformation to its wild-type counterpart. The molecular 
modelling simulations of all binders based on hCpn10 were slightly similar to the hCpn10. 
While the β-barrel architectures were retained in both native hCpn10 and its most variants, 
the mobile loop exhibited a large conformational change, most likely as a direct result of the 
side chain replacements with either charged or hydrophobic residues. This observation 
reveals remarkable structural plasticity of the inserted loops such as E-76 peptide and the 
Myc-tag which in turn prevented the dimerisation that was essential for heptamer formation. 
Remarkably, such uncontrolled plasticity of the mobile loop had been successfully retained 
and minimized through the insertions of various linkers at the N- and C-junctures of the 
inserted-loop, most likely due to the proline(s) content of those linkers. Subsequently, all 
computationally predicted models of Cpn10 based binders were synthesized and validated in 
vitro. The use of the P1- and P2-linkers, containing several alanine/proline residues, restricted 
the mobility of the inserted loop, and furthermore, facilitated the formation of a heptamer. 
The P2-linker would be more suited for higher molecular weight peptides that are inserted 
into the mobile loop. Contrary to the P1- and P2- linkers, E5- was ineffective in conferring an 
overall stability in the protein. Although the mutant hCpn10 variant of CE76E5 formed a 
heptamer, the protein rapidly degraded following purification. This could be due to 
significant alterations occurring within the protein core and the loss of the critical β-stands 
which are important for conferring stability within the molecule. This was clearly predicted 
by the MD simulations and revealed experimentally. 
 
This study showed the potential of hCpn10 to be modified with the promise to be used as 
NME scaffolds and has proven that MD simulation is a speedy and suitable tool to assist in 
such molecular design. 
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Chapter 4.  Development of a Factor VIIa Inhibitor Based on a 
High Affinity Peptide Ligand Displayed on Human 
Chaperonin-10 Molecular Scaffold. 
 
 
4.1 Introduction 
 
Advances in recombinant DNA technology have facilitated the production of large quantities 
of various peptides and proteins for the treatment of a variety of disease indications. There 
are more than two hundred approved biologics by FDA used for the treatments of various 
diseases that have been developed through recombinant DNA technology (CDER, 2014), 
including a few that are approved for in the management of the blood coagulation cascade 
including tissue factor pathway inhibitor (TFPI) and rNAPc2 (Enjyoji K et al., 1995, Bergum 
et al., 2001).  
 
At present the underpinning approach towards managing the clotting process is using small 
molecule, protease inhibitors, that directly bind to the enzymatic active site (Leung et al., 
2000). Recently, a serine protease inhibitor that selectively targets the extrinsic coagulation 
cascade (i.e. the TF-dependents) was isolated from a random peptide phage display library, 
hence heralds a new class of serine protease inhibitor, named as an E-series peptide (Dennis 
et al., 2000). E-76 peptide, derived from the parent E- series, predominantly binds to the 
exosite of Factor VIIa (FVIIa) with high affinity. This in turns causes a large conformational 
change within the active site, which subsequently prevents the activation of Factor X (FX) to 
FXa, and thus blocks the initiation of the extrinsic pathway.  
 
In general, therapeutic peptides are small in size (≤ 20 kDa), may known to have potent 
biological activity, and some with high binding affinity towards a particular molecular target 
in vitro. Nevertheless, peptides administered in vivo have a number of limitations, one of 
which is due to their small size, resulting in a shorter half-life as they are rapidly cleared by 
the renal system (Diao and Meibohm, 2013). Furthermore, peptides are highly susceptible to 
protease degradation, and as such, multiple doses of the peptide are required if there is to be 
any potent therapeutic activity in vivo (Sato et al., 2006). In order to address these limitations, 
peptide fragments can be introduced into protein scaffolds through recombinant DNA 
technology in order to increase the half-life, stability of the peptide, and thus prevent 
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proteolytic degradation. These protein scaffolds include such entities as DARPins, lipocalins, 
and others which are discussed in Chapter 1.  
 
The research described in this thesis focuses on hCpn10, an essential heptameric 
mitochondrial protein that facilitates the proper folding of translated polypeptides as a 
molecular scaffold. The hCpn10 (70 kDa) of seven identical monomers each is composed of 
two flexible loops, namely, the β-hairpin roof and mobile loop, and a rigid hydrophobic β-
barrel core. As with other molecular scaffolds, the loops have an extended interface that 
facilitates binding towards the target molecule (Korndorfer et al., 2003).  
 
Based on the properties of the hCpn10 molecule, the research described in this chapter 
focussed on utilising the hCpn10 as NME displaying the E-76 peptide (termed CE76) at the 
mobile loop site (Figure 4.1). Optimisation of CE76 with respect to stability was performed 
through molecular dynamic simulations with the insertion of a number of proline residues, as 
discussed in Chapter 3. Herein, based on experimental studies, CE76P1 was the most suitable 
structure to be further characterised. CE76P1 showed remarkable inhibitory properties towards 
FVII activation, and subsequently reduced the activation of FX, with IC50 of 6.8 nM and 1.5 
nM, respectively. Also, CE76P1 found to prolonged the TF-dependent coagulation pathway 
by 7-fold in PT assays. In significant, the NME CE76P1 possessed a potent anticoagulant 
property that could be applied as future biologics for the treatment of blood disorders. 
 
4.2 Research aims  
 
The overall aims of the work presented in this study chapter are: 
 
 To demonstrate proof of concept by designing the CE76 as a therapeutic biologics 
agent based on the hCpn10 molecule; and 
 To conduct in vitro biological activity studies on the CE76 in relation to the E-76 
peptide. 
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Figure ‎4.1  Three-dimensional model of CE76  
3D homology model of CE76 shown in ribbon representation (A) Model of full size CE76 heptamer; 
each monomer consists of main hydrophobic β-barrel core and two loops (top β-hairpin and bottom 
mobile loop). (B) Substituted mobile loop with E-76 peptide (red, 18 amino acids) between at Ala21 
and Gly38, a disulfide bond form between Cys24 and Cys34 (yellow), refer to text for full details. The 
homology model based on wt Cpn10 (PDB ID. 1WE3) as detailed in Chapter 3. This was modelled 
using PyMOL software. 
 
4.3 Materials and mMethods 
 
4.3.1 Materials 
 
Table 4.1 details the relevant materials used in the research discussed in this study and their 
manufacturer/supplier. 
 
Table ‎4.1  List of materials for the research study 
Item(s) From 
Proteins/Peptide: 
 
NovoSeven
®
RT, Factor VIIa (rFVIIa) NovoNordisk® 
Tissue Factor (rTF) Hyphen BioMed™ 
E-76 peptide (Biotin-ALCDDPRVDRWYCQFVEG) control  Auspep™
 
Antibodies: 
 
mAb-Mouse Anti-FVII Human  Sigma-Aldrich® 
HRP-Goat Anti-Mouse  Novex®, Life technologies™ 
HRP-conjugated Mouse Anti-6xHis Novex®, Life technologies™
 
A.                                              B.  
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Item(s) From 
Chemicals & Reagents:   
Thromborel
®
S SEIMENS™  
 
TriniCLOT
™ 
aPTT HS TrinityBiotech™ 
Chromozym t-PA  Roche™ 
S-2765
™
 (chromogenic substrate)   CHROMOGENIX ™
 
S-2222
™
 (chromogenic substrate)   CHROMOGENIX ™ 
3,3′,5,5′-Tetramethylbenzidine (TMB) Sigma-Aldrich® 
 
4.3.2 Protein expression, purification, and characterisations 
 
All CE76 variants in this study were expressed as soluble protein and purified (≥ 95%) 
according to Chapter 2: General Materials and Methods. 
 
4.3.3 Protein binding detections by ELISA 
 
A SpectraMax-M4 plate reader was used to measure the binding of CE76 variants in a 96-
well miroplates. A typical microtitre plate was coated overnight with 100 nM rFVIIa 
(NovoSeven
®
RT), diluted in PBS, 0.05 % (v/v) Tween 20 (PBST, pH 7.4), total of 200 µL 
per well. The ELISA plate wells were blocked by PBST, 2 % (w/v) non-fat dry milk, 
followed by three rounds of washes with PBST for removal of unbounded rFVIIa. Purified 
His-tagged CE76 and its variants (summarised in Table 4.2) were incubated in various 
concentrations (from 0.1-100 nM), and in parallel with His-tagged hCpn10 (control), and 
mAb-mouse anti-FVII human (control), all were incubated for 1 hour at 25 °C. After 
incubations, plates were washed with PBST for three rounds to confirm the removal of 
unbound proteins. The histidine-tagged proteins were detected by 1:5000 dilution (in PBST) 
of either HRP-conjugated mouse anti-6xHis antibody or HRP-goat anti-mouse antibody, and 
further incubated (in dark) for 30 min at RT, followed by three rounds of washes with PBST, 
then single wash with PBS buffer prior to developing the reaction with 100 µL of 3,3′,5,5′-
Tetramethylbenzidine (TMB, Sigma-Aldrich
®
) per well. The enzyme reaction terminated 
after 15 min with 50 µL of 1 M H2SO4. Reaction results were measured at 450 nm (A450) 
using spectrophotometer. Data of blank well (absence of rFVIIa) was used for adjusting 
background activities and data was fitted by non-linear regression from triplicate independent 
experiments. 
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4.3.4 Binding affinity and kinetic analysis by Bio-layer Interferometry 
(BLI) 
 
Binding affinity and kinetic profile measurements were conducted using BLI Octet
® 
Red 
instrument (ForteBio). The buffer contained 50 mM Tris-HCl (pH 7.6), 150 mM NaCl with 
5 mM CaCl2 and was used for all dilutions and monitoring processes. Purified His-tagged 
CE76 variants were captured via Ni-NTA biosensors, such that the response due to 
immobilization was approximately 1-2 nm. Biosensors with captured proteins were then 
dipped into multiple concentrations of rFVIIa (0, 0.1, 0.5, 1, 5, 10, 25, 50, 75, and 100 nM), 
to measure the association phase, with 1000 rpm of plate shaking. The dissociations phase 
was monitored in buffer only. All data were fit to 1:1 or 1:2 binding model of stoichiometry 
proteins by global fitting of multiple kinetic traces, and analysed by Data Analysis 7.0 
software. Data were monitored for eight different concentrations simultaneously, and zero 
nM/control trace was used for blank run and subtraction. The kinetic measurements were the 
average of triplicate measurement sets. 
 
 
4.3.5 FVII and FX enzyme activity assays 
 
The amidolytic activity of FVIIa was measured using the chromogenic substrates 
Chromozym t-PA or Spectrozyme FXa, as previously described (Andersen et al., 2012). In 
brief, a 96-well plate was blocked overnight in 200 µL Assay Buffer (AB) containing; 20 
mM HEPES (pH 7.8), 150 mM NaCl, 5 mM CaCl2, 0.1 % PEG 8000, 0.5 % BSA, at 4 °C. 
The amidolytic activity was determined in total reaction of 200 µL in AB, by incubating 50 
nM or 100 nM rFVIIa with 0.5-500 nM TF (Thromborel
®
S), for 30 min at 37 °C. 
Chromogenic substrate was added to a final concentration of either 1 mM Chromozym t-PA, 
1 mM S-2288 chromogenic substrate, or 3 mM S-2288 for assay without TF. The initial 
reaction rates for substrate hydrolysis were monitored at 405 nm for 20 min using 
Multiskan
™
 GO Microplate Spectrophotometer (Thermo Scientific
™
), at RT, and the rates 
were determined by linear regression. Similarly, incubation of TF with substrate in the 
absence of rFVIIa was used as control. 
 
FX activation by TF-FVIIa complex was also measured using chromogenic assay as 
described (Andersen et al., 2012). The activity of FX was determined by incubating 100 µL 
AB containing 200 nM FX with 100 nM rFVIIa, or with 10 nM rFVIIa and 200 nM TF 
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(Thromborel
®
S), incorporated into phospholipid as recommended (Kelley et al., 1997) of 
6 µL TriniCLOT
™ 
aPTT HS, for 1 hr at 37 °C. FX activity was impeded by adding 5 mM 
EDTA. The amount of FXa generated was measured relative to hydrolysis activity of 0.5 mM 
S-2765 chromogenic substrate, at 405 nm by using Multiskan
™
 GO Microplate 
Spectrophotometer, at RT.  
 
4.3.6 FVIIa and FX inhibition assays 
 
Inhibition of amidolytic activity of FVIIa by CE76-P1 was determined as a function of 
inhibitor concentrations, in the presence and absence of TF. In summary, a 0.001-1000 nM 
(in 10-fold series dilution in AB) of CE76P1, was incubated with 10 nM rFVIIa and 100 nM 
TF, for 10-20 min, at 37 °C, prior to adding 1 mM Chromozym t-PA or 1 mM S-2288, then 
measuring the initial reaction velocities at 405 nm by Multiskan
™
 GO Microplate 
Spectrophotometer, at RT. The linear rate of increased absorbance was expressed as 
fractional activities (Vi/V0), in which the velocity of the substrate hydrolysis in the presence 
(Vi) or absence (V0) of inhibitor CE76P1. The relative velocities (Vi/V0) were plotted against 
the CE76-P1 concentration (nM). 
 
Inhibition of FX activation by TF-VFIIa complex was performed as described (Sen et al., 
2011). FX activation by TF-FVIIa was determined as a function of CE76P1 (inhibitor) 
concentrations. A total reaction volume of 100 µl AB containing 175 nM FXa with 10 nM 
rFVIIa, and 150 nM TF was incorporated into phospholipid 6 µL TriniCLOT
™ 
aPTT HS, and 
incubated with CE76P1 (0.01–1000 nM) for 30 min at 37 °C, prior to adding 1 mM S-2765 
chromogenic substrate. Controls were made in the absence of CE76P1, rFVIIa, or FX. The 
rate of substrate hydrolysis was measured at 405 nm over 15 min by Multiskan
™
 GO 
Microplate Spectrophotometer at RT. The rate of FXa generation was expressed as fractional 
activities (Vi/V0), as previously described. All experiments were performed in triplicate 
(Appendix 4). 
 
4.3.7 Plasma clotting time (PT/aPTT) assays 
 
The prothrombin time (PT) and activated Partial Thromboplastin Time (aPTT) assays 
(detailed in Figure 4.2) were performed in pooled citrated-treated human plasma from healthy 
volunteers (n=5), as described (Lefkowitz, 2013). Clotting times were determined as a 
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function of protein concentrations at 37 °C in triplicate, using Hyland-Clotek
™
 clotting 
analyser. The recalcification time of pooled plasma was 2-4 minutes. PT and aPTT assays 
were triggered by using Thromborel
®
S (human placental thromboplastin) and 
TriniCLOT
®
aPTT HS (phospholipids mixture) for initiating coagulation of extrinsic and 
intrinsic cascades, respectively. 
 
 
Figure ‎4.2  Normal blood coagulation cascade and pathways PT/aPTT tests 
PT/aPTT tests are based on the type of initiations. The solid arrows indicate activation of a 
coagulation factor by the predecessor factor while the dotted lines indicate activation of FV and FVIII 
by thrombin. The extrinsic pathway is initiated upon vascular injury or trauma. This in turn leads to 
exposure of tissue factor (TF) that binds to phospholipids/Ca
2+
, and subsequently activates FVII (i.e. 
FVII  FVIIa). The intrinsic pathway is initiated when blood makes contact with the damaged vessel 
(i.e. exposed to negatively charged surfaces) resulting in the activation of FXII (i.e. FXII  FXIIa). 
The two pathways independently lead to the activation of FX to FXa which subsequently leads to the 
conversion of prothrombin to thrombin through a hydrolytic reaction. Fibrin polymer (i.e. fibrin-clot) 
is the end result of the blood cascade which is synthesised via thrombin-mediated conversion of the 
fibrin monomers. NME CE76 act as anticoagulant and solid arrows (red) indicate binding to both 
CE76 
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FVII and FVIIa while the dotted lines (red) indicate inhibit extrinsic activation of FX. Image adapted 
from Lefkowitz (2013). 
 
PT assay, in brief, was performed by adding 100 µL citrated plasma to a glass clotting tube 
and incubated for 10 min in the heating block of Hyland-Clotek
™
, at 37 °C. CE76 variants 
(50 µL, as inhibitors) were added in various concentrations (0.001 – 100 µM, in 10-fold 
dilutions in saline) to a final volume of 150 µL. Plasma clotting was triggered by adding 10-
100 µL Thromborel
®
S, and clotting times were determined. hCpn10, saline and heparin were 
used as controls. 
 
aPTT assay, was performed similarly to PT assay with sight modifications. A 100 µL citrated 
plasma, 100 µL TriniCLOT
®
aPTT HS, with various concentrations of CE76 variants (0.001 – 
100 µM, in 10-fold dilutions in saline), were added to glass clotting tubes, with a final 
volume of 250 µL and incubated for 2 min at 37 °C in the heating block of Hyland-Clotek
™
.
 
Plasma clotting was initiated by adding 50 µL of 2 mM CaCl2. Time prolongations of both 
PT and aPTT (in sec) were converted and plotted as folds (Ti/T0).  
 
4.3.8 Thromboelastography (TEG) 
 
Blood clotting time was measured using TEG assay. Herein, TEG were performed on pooled 
and citrated human blood from healthy donors, as described (Fischer et al., 2011). An aliquot 
blood (250-300 µL) was pipetted into warmed chambers of a dual-channel TEG
® 
5000 
Analyser. To commence coagulation, it was recalcified with 20 µL of 0.2 M CaCl2 and 20 µL 
saline, for 6-10 minutes. TEG parameters (detailed in Figure 4.3) were all measured. The 
speeds of fibrin-clot formation were determined as a function of protein inhibitor 
concentration as previously described (Fischer et al., 2011). In brief, 20 µL inhibitor (0-100 
µM, 10-fold dilutions) of CE76P1 versus E-76 peptide (control), and 10 µL of 0.2 M CaCl2 
with 2 µL clotting trigger (1:10 or 1:100 dilution), was added to TEG chamber, followed by 
280 µL citrated blood in a total reaction volume of 340 µL, made up of normal saline, and 
measured at 37 °C in duplicate. TEG assays were divided into two sections in which either 
Thromborel
®
S or TriniCLOT
® 
aPTT HS was added for the initiation of extrinsic or intrinsic 
blood coagulation cascades, respectively. The prolongations time (R) of fibrin-clot 
formations (min) were plotted in a chart versus protein/peptide inhibitor concentrations (µM).   
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Figure ‎4.3  Thromboelastography (TEG) normal scheme 
The important TEG parameters for the coagulation process are as follows: (R), the time of formation 
of the fibrin strand polymers (i.e. fibrin-colt); (K), the speed at which the clot forms; (α, alpha), the 
slope drawn from R to K; and (MA) is the strength of the clot. Diagram adapted from Galvdez and 
Cortes (2012).  
 
 
4.4 Results  
 
4.4.1 Protein expression and purification 
 
The CE76 and its variants (Table 4.2) were designed in silico by inserting E-76 peptide 
between A21 and G38 of hCpn10, and optimized for prokaryotic expression. All variants 
were expressed in E. coli BL21 (DE3) as soluble protein with up to 30 % of cellular protein 
content.  
 
Table 4.2 indicates inserted linkers (red, Italic), loop amino acids size, isoelectric point (pI), 
and monomer Mwt in kDa. Whereby, native hCpn10 mobile loop (form Ala21 to Gly38, 
blue) was substituted with E-76 peptide (back).  
 
Table ‎4.2  Mobile loop amino acid sequence of hCpn10 and its variants 
Construct Mobile Loop AA Sequence (N- to C-) ML Size pI Mwt kDaѱ 
hCpn10*  AAETVTKGGIMLPEKSQG 18 8.91 10.8 
CE76 ALCDDPRVDRWYCQFVEG 18 7.21 12.2 
CE76P1 AAPALCDDPRVDRWYCQFVEGPAA 24 7.21 12.68 
CE76P2 PPALCDDPRVDRWYCQFVEGPP 22 7.21 12.59 
CE76E5 AETVTALCDDPRVDRWYCQFVEGPEKSQ 28 6.65 13.27 
 * Wild-type. 
 ѱ Calculated Mwt in kDa per monomer. 
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Proteins were expressed with a C-terminus histidine-tag and were subjected to two steps of 
purification. It was firstly captured by affinity chromatography of IMAC (Figure 4.4), 
followed by final polishing step using gel-filtration chromatography (Figure 4.5). Proteins 
were adjusted to a working concentration of 1 mg/mL, determined by spectrophotometric and 
BCA assays. 
 
 
 
Figure ‎4.4  IMAC purification and SDS-PAGE analyses of CE76 variants 
Representative IMAC chromatogram and SDS-PGE analysis. (A) IMAC purification of CE76P1 
chromatogram showing the A280 absorbance of (1) cell lysate loading, (2) followed by a wash step 
using 10 % of 0.5 M imidazole, and (3) gradient elution to 100 % of 0.5 M imidazole (pH 7.6) 20 mM 
Tris-HCl, 150 mM NaCl. (B) SDS-PAGE of IMAC purification pooled factions, Lane1: SeeBule
® 
Plus2 Mwt std marker, Lane2: hCpn10 (10 kDa, control), Lane3: CE76 (12.2 kDa), Lane4: CE76E5 
(13.27 kDa), Lane5: CE76P2 (12.59 kDa), Lane6: CE76P1 (12.68 kDa). 
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Figure ‎4.5  Gel filtration purification and analyses of CE76 variants 
Representative GF chromatogram, form a polishing step utilised for all CE76 variants; samples were 
re-concentrated and loaded onto a HiLoad 16/600 Superdex
® 
200 PG prepacked column. (A) GF A280 
chromatogram of CE76P1 purification showing; (1) soluble-aggregates, (2) CE76P1 heptamer, and (3) 
buffer residues and contaminants. (B) SDS-PAGE analysis of all CE76 variants; Lane1: SeeBule
® 
Plus2 Mwt std marker, Line2: hCpn10 (10 kDa, control), Lanes 3 to 8 correspondingly show cell 
lysate (post-expression) and GF fractions (post-purification) of: Lanes 3-4 CE76P1 (12.6 kDa); Lanes 
5-6 CE76E5 (13.2 kDa); Lanes7-8 CE76P2 (12.5 kDa).  
 
 
Protein purity and the approximate Mwt were determined by SDS-PAGE (Figures 4.4 to 4.6). 
In addition, the native (i.e. non-denatured) Mwt for each examined variants was verified by 
SE-HPLC (Figure 4.6). Calculated Mwt of all hCpn10 variants were also compared to 
observed Mwt that was determined by MALDI-TOF mass spectrometry, summarised in 
Table 4.3. Based on the experimental data that proved CE76P1 was a highly stable molecule, 
therefore it was mostly selected for further characterisation utilising various in vitro 
assays/bioassays and other functional studies. 
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Figure ‎4.6  SE-HPLC and SDS-PAGE analyses of recombinant CE76P1 
(A) SE-HPLC A280 absorbance chromatogram of CE76P1 (88 kDa, blue) apparently forming 
heptamer in comparison to hCpn10 (control, 70 kDa, red). Mwt standards (dashed line) are: (1) 
Thyroglobulin (670 kDa); (2) Bovine gamma globulin (158 kDa); (3) Ovalbumin (44 kDa); (4) 
Myoglobin (17 kDa); (5) Vitamin B12 (1.35 kDa). (B) SDS-PAGE of CE76P1 fractions, Lane1: Mwt 
std marker, Lane2: hCpn10 (10 kDa, control), Lane3-4: CE76P1 (12.6 kDa) cell lysate and SE-HPLC, 
respectively. 
 
Table 4.3 below shows calculated versus observed Mwt of recombinant protein samples 
obtained from SE-HPLC (from Figure 4.6). Iin addition, peptide mass fingerprinting (PMF) 
from MALDI-MS revealed all CE76 variants were ≥ 82 % homologous to human Cpn10 
protein by matching observed peptide masses (subjected to trypsin digestions) to the 
theoretical masses from MASCOT protein sequence database.  
 
Table ‎4.3  Molecular weight and molecule identification of CE76 variants  
Construct 
Mass (Da) 
PMF molecule identity 
m/zcal m/zobs 
CE76 12206 12204 82 % hCpn10 
CE76P1 12685 12683 82 % hCpn10 
CE76P2 12595 12593 82 % hCpn10 
CE76E5 13278 13275 90 % hCpn10 
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4.4.2 FVIIa-CE76 binding activity 
 
The binding properties of the CE76 variants to FVIIa were first investigated using ELISA. 
CE76 variants were bound to immobilised rFVIIa, and were detected using an Anti-His-tag 
HRP conjugated antibody (Figures 4.7 and 4.8). The binding curves in Figure 4.8 are 
indicative that the CE76 variants bind strongly to rFVIIa, further suggesting that the E-76 
peptide was successfully incorporated into the mobile loop of hCpn10. In addition, the 
specificity of the CE76s were further verified by the lack of interaction observed with 
hCpn10. Also, rFVIIa was probed with anti-human FVII antibody (control) that resulted in a 
strong positive signal, comparable to the CE76 variants. It should be noted that although 
previous stability studies indicated that CE76E5 was compromised, binding with rFVIIa was 
nevertheless strong (Figure 4.8). 
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Figure ‎4.7  Quantitative measurement of CE76 variants binding to rFVIIa  
Binding of CE76 variants to immobilised rFVIIa by ELISA. (A) High protein concentration range 
(100, 50 and 12.5 nM) for designed samples CE76, CE76P1, CE76P2, CE76E5, along with controls; 
hCpn10 (Cpn10 scaffold less E76 peptide, negative control), E-76 peptide (naked E-76 peptide, 
A. 
 
 
 
 
 
B. 
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positive control) and anti-FVIIa mAb (positive control), respectively. (B) Low protein concentration 
range (10, 5 and 1 nM) for same samples. For CE76 specificity controls, no binding was observed to 
BSA, rFX or skim milk proteins (data not shown). Data represented are the mean and standard error 
of mean (n=3) measured at OD450. 
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Figure ‎4.8  CE76 variants binding to rFVIIa  
The binding of CE76 variants to rFVIIa were determined by ELISA. Protein binding to immobilised 
rFVIIa measured by microplate spectrophotometer at 450 nm, as following: CE76 (●, blue); CE76P1 
(■); CE76P2 (▲); and CE76E5 (▼) applied in series dilutions. For binding evaluation a mAb anti-
human FVII (●, black) and hCpn10 (♦), positive and negative controls, respectively, were used. Data 
represented graphically as absorbance (A450) plotted versus multiple concentrations (nM) of the 
applied proteins as mean ± standard error of mean (n=3), and curves were fitted by nonlinear 
regression. 
 
 
Further binding studies were conducted on CE76 variants and rFVIIa in order to determine 
the kinetics of CE76s to rFVIIa and obtain binding profiles through real-time BLI using an 
Octet
® 
Red system. The CE76 variants were captured onto the Ni-NTA biosensor tips and 
exposed to varying concentrations of rFVIIa, whereby up to 8 different concentrations can be 
analysed simultaneously (Figure 4.9). The observed association (ka) and dissociation (kd) 
rates of CE76 variants are summarised in Table 4.4. In essence, the calculated binding 
affinity (KD) of CE76 varied between 1 to 2-fold higher relative to the control E-76 peptide 
(Table 4.4). This further suggests that the CE76 variants have conferred binding avidity, with 
KD increased by two-fold (Table 4.4). 
 123 
   
Figure ‎4.9  Association/dissociation (BLI) trace of CE76P1 binding to rFVIIa 
Representation of a Ni-NTA biosensor (BLI, ForteBio) as following: 1. Loaded of CE76P1; 2. 
Association, and 3. Dissociation of rFVIIa, respectively. To assess non-specific binding, a Ni-NTA 
sensor without CE76P1 was tested, whereby rFVIIa did not bind; also there was no binding detected of 
rFVIIa and hCpn10, nor rFX and CE76P1. The calculated KD summarised in Table 4.4. Data analysed 
by ForteBio
®
 Data Analysis 7.0 software. 
 
Table 4.4 summarises measurement of the association and dissociation rates of CE76 variants 
and E-76 peptide (control) binding to rFVIIa. The rates obtained from triplicate experiments. 
 
Table ‎4.4  Summary of kinetic binding data determined for CE76 variants 
  
Construct  Ligand KD (nM) ka (M
-1
s
-1
)
 
kd 
 
(s
-1
)
 
hCpn10 rFVIIa -
*
 - - 
E-76 peptide  
rFVIIa 6.17 (±0.24)
a
 1.26 x10+4 (±0.88)
a 
7.79 x10
-5 
 (±0.21)
a 
CE76P1 rFVIIa 2.95 (±1.57)
a
 1.91 x10+4 (±0.42)
a 
5.63 x10
-5
 (±0.66)
a 
CE76P1 rFX -
*
 - - 
CE76P2 rFVIIa 4.72 (±0.83)
a
 2.83  x10+4 (±0.29)
a
 1.33 x10-4 (±0.24)
a
 
CE76E5 rFVIIa 5.50 (±1.59)
a 
1.87 x10
+4
 (±0.52)
a 
1.03 x10
-4 
(±0.83)
a 
 *
  No/insignificant binding activity detected.  
 a
  Errors refer to mean and ± standard error of  mean from triplicate runs. 
1 
2 
3 
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4.4.3 Inhibition of FVIIa/TF-FVIIa activity 
 
Further assays were conducted in order to determine the specific activity of CE76P1. As 
discussed previously, the CE76P1 has strong affinity towards rFVIIa and this subsequently led 
to the potent inhibition of FX, which was assessed in a dose dependent manner. Furthermore, 
CE76P1 has a calculated median inhibitory concentration of 1.5 ±0.64 nM of FX (Figure 
4.10A) that was equivalent in value to the E-76 peptide (control), as previously reported by 
Dennis et al. (2003). However, maximum inhibitory concentrations varied where 95 % of FX 
activity was inhibited by CE76P1 relative to E-76 which inhibited 90 % of FX activity, despite 
small differences in affinity between the two. Furthermore, CE76P1 was also found to be a 
potent inhibitor of amidolytic activity, which entails the hydrolysis of the small protein 
substrate Chromozym t-PA, (i.e. to determine FVII activity) with IC50 6.8 ±0.55 nM (Figure 
4.10B). Interestingly, the CE76P1 inhibited the amidolytic hydrolysis with IC50 8.4 ±0.6 nM 
despite an absence of tissue factors (Figure 4.10B). Overall, values for CE76P1 inhibition of 
FX and amidolytic activities, in the absence of TF, was 1.1 nM and 9.7 nM, respectively, 
were similar to IC50 and maximal inhibition of the original E-76 peptide. This essentially and 
illustrates that the inhibitory activity of CE76P1 works independently from the TF mediated 
triggering of the extrinsic clotting pathway. 
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Figure ‎4.10  Inhibition of TF-FVIIa catalysed activation of FX and amidolytic activity 
Representations of FX and amidolytic inhibition activities by CE76P1. (A) The IC50 value for 
inhibition of FX activation (blue) by CE76P1 was 1.5 nM. (B) The IC50 values for inhibition of 
amidolytic hydrolysis by CE76P1 in the presence (red) or absence (black) of TF were 6.8 and 8.4 nM, 
respectively. Inhibition rates of both FXa and amidolytic activity expressed as fractional rate (Vi/V0), 
and determined by nonlinear regression analysis of the data fit to a four-parameter equation for 
calculating the IC50 and maximal percent inhibitions. 
  
A. 
 
 
 
 
 
 
 
B. 
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4.4.4 Effects of CE76 on clotting times in plasma 
 
The efficacy of the CE76 variants, as summarised in Table 4.2, were assessed in further detail 
using human plasma, donated by healthy volunteers (n= 5). The inhibitory effects of all CE76 
variants were examined using two common clotting approaches, namely, a prothrombin time 
(PT) and activated partial thromboplastin time (aPTT), summarized in Figure 4.2. The PT 
assay is normally used to determine the deficiencies of Factors VII and X in the TF-
dependent extrinsic pathway while the aPTT assay is used to determine the deficiencies of 
Factors IX, X, XI, and XII in the TF-independent intrinsic pathway. 
 
Based on the ability of the CE76 variants to specifically binding to FVII, FVIIa, and/or TF-
FVIIa-complex, most CE76 variants were significantly prolonged clot formation in the PT 
assays by 4-fold compared to control E-76 peptide (Figure 4.11A). On the other hand, the 
CE76 variants (mainly CE76P1) did not prolong clot formation in any of the aPTT assays as 
expected (Figure 4.11B). This further indicates that CE76P1 had specific interactions with the 
FVII/FVIIa of the extrinsic pathway only. It is significant to note that at higher 
concentrations, the CE76P1 considerably prolonged the clot formation times, in contrast to the 
E-76 peptide that reached saturation and plateaued at 3-fold of the control hCpn10 or saline 
(i.e. non-inhibitors). It is more than likely that the extended clot formation time at higher 
concentrations is correlated with the higher avidity of the CE76P1 as there are seven binding 
sites (i.e. E-76 peptide) displayed within CE76P1 (Figures 4.1 and 4.11A).  
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Figure ‎4.11  Prolongation of PT and aPTT in human plasma 
PT and aPTT assays performed in a pool of healthy human plasma (n=5) using Hyland
™
 Clotting 
Analyser. (A) Prolongation of plasma clotting times upon initiation by Thromborel
® 
S (Human 
thromboplastin) and Ca
2+ 
in PT assays, measuring the effect of CE76 variants versus controls E-76 
peptide and hCpn10. (B) Prolongation of plasma clotting times upon initiation by TriniCLOT
® 
aPTT 
HS (Phospholipids Mixtures) in aPTT assays, measuring the effect of CE76P1 versus E-76 peptide and 
hCpn10. The uninhibited clotting times were 15 and 40 sec for the PT and aPTT, respectively, 
prolongations time (T1/T0) plotted as (fold) versus CE76 variants (µM). hCpn10 and saline were used 
in both assays as a negative control. 
  
A. 
 
 
 
 
 
 
B. 
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4.4.5 Effects of CE76P1 on human blood 
 
The anticoagulant effects of CE76P1 were further investigated via TEG in human blood. 
Citrated blood samples were acquired from healthy donors (n=3). TEG is normally used to 
monitor significant coagulopathy in patients by using whole blood. The TEG assesses the 
interaction of platelets within the coagulation cascade factors, starting from the time the 
platelet-fibrin interaction is initiated, right through to platelet aggregation, clot strengthening, 
fibrin cross linkage, and eventually clot lysis, as summarized in Figure 4.4. 
 
The focus of this research study is to determine the reaction time (R-Time) in the final 
development of a fibrin clot through both coagulation cascades when blood is exposed to 
CE76P1. In order to speed up the clotting process, the citrate-treated blood was initiated by 
either thromboplastin/Ca
2+
 for TF-dependent extrinsic factors or initiated by phospholipids 
for TF-independent intrinsic factors (Figure 4.2). Interestingly, a dose of 1 µM of CE76P1 was 
sufficient to significantly delay the development of a fibrin-clot up to three-fold compared 
with 1 µM of the original E-76 peptide, which delayed blood clotting by approximately 5 
mins (Figure 4.12). Conversely, the CE76P1 had no direct impediment effects on the 
coagulation processes of the TF-independent intrinsic factors when initiated by partial 
thromboplastin and phospholipids (Figure 4.13). Therefore, the anticoagulant effect of 
CE76P1 is only at prolonging clot formation which triggered by the extrinsic pathway factors 
in a dose dependent manner. Importantly to declare, that data obtained for this experiments 
were mostly from duplicate runs due to number of issues; first, time scale in which TEG 
cycle required about 25 to 45 min per run for two samples therefore only measuring the effect 
of CE76P1 versus three controls (i.e. E-76 peptide, hCpn10, and Heparin). Second, limited 
number of blood donor, in which TEG results were found to be more accurate from newly 
collected blood samples. 
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Figure ‎4.12  A measurement of the reaction time (R-time) for CE76P1 versus E-76 peptide 
Plot of the clotting times (R, min) versus multiple concentrations (µM) of CE76P1 and E-76 peptide. 
The R-time for uninhibited blood clotting was 2 min by hCpn10 (10 uM), while inhibited blood 
clotting by heparin (0.5 U/mL) was approximately 8 min. Citrated blood samples were from healthy 
donors (n=3), and for escalating clotting process a Thromborel
® 
S (Human thromboplastin) was used. 
The blood clotting times were measured by using TEG
® 
5000 Analyser (Thromboelastography
®
, 
HAEMONETICS
®
). 
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Figure ‎4.13  Measurement of anticoagulant activity of CE76P1 by TEG 
Graphical representation illustrated the effect of CE76P1 on R-time for the development of fibrin-clot 
of citrated human blood from healthy donors (n=3). The anticoagulant activity of CE76P1 determined 
upon initiation of extrinsic/TF-dependent pathway by Thromborel
®
S/Ca
2+
 versus initiation of 
intrinsic/TF-independent pathway by TriniCLOT
® 
aPTT HS. Shows CE76P1 (blue) was adequate to 
pause blood clotting upon initiations by TF/Ca
2+
. No significant anticoagulant effects (orange) were 
detected upon initiations by phospholipids. Heparin (0.5 U/mL, control) shows a clear anticoagulant 
activity of 8 min upon initiation of either pathways. R-time (min) measured using TEG
®
5000 
Analyser. 
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4.5 Discussion 
 
Blood coagulation is a process wherein a series of proteolytic reactions leads to the activation 
of thrombin, which plays a key role in the formation of a fibrin clot (Gray et al., 2012, 
Lefkowitz, 2013). The coagulation cascade is composed of two separate pathways, namely, 
the intrinsic and extrinsic, which are initiated by different factors (detailed in Figure 4.2). The 
extrinsic pathway commences when the circulating zymogen FVII, an inactive serine 
protease, is exposed to tissue factor (TF, a nonvascular protein) which is released upon vessel 
injury or trauma (Lefkowitz, 2013). FVII is activated upon binding to TF forming FVIIa, 
which results in the formation of the TF-FVIIa complex. This complex subsequently activates 
three important serine proteases within the cascade, and the conversion of FX, FIX and FVII 
into their active form FXa, FIXa and FVIIa, respectively. This in turn, leads to the generation 
of thrombin and eventually a fibrin clot (Gray et al., 2012, Lefkowitz, 2013). It is interesting 
to note that only 10 nM of activated FVII is required to initiate the blood coagulation process 
(Maun et al., 2003), and therefore, zymogen FVII or activated FVIIa serves as an attractive 
therapeutic target when the extrinsic pathway is initiated with the TF-FVII complex. 
 
Classical anticoagulant medications such as warfarin and heparins are widely used in 
regulating the clotting pathway (Klement and Rak, 2006). Warfarin works by impairing the 
functions of vitamin-K dependent proteins such as FVIIa, FIXa, FXa and thrombin as well as 
the activated anticoagulant proteins such as protein C and protein S (Klement and Rak, 2006). 
This is done by inhibiting the post-translational modification of these proteins, which are 
required for the interaction with the phospholipid membrane, thus leading to the disruption of 
the coagulation cascade. Heparin modulates the coagulation cascade by directly interacting 
with the plasma protein antithrombin III (ATIII) (Gray et al., 2012). This subsequently leads 
to the enhanced inactivation of a number of serine proteases, namely, FIIa, Xa and IXa. 
Heparins accelerate the ATIII that inhibit FXa and thrombin and plays an important role by 
activating the protein C pathway, in the presence of thrombomodulin (Enjyoji K et al., 1995). 
Based on the broad interaction of these drugs against a number of coagulation proteins, drug 
dosages need to be strictly monitored as it can disturb the balance between thrombosis and 
haemostasis.  
 
Based on the non-selective interaction of warfarin and heparin, a number of approaches have 
been undertaken in order to develop inhibitors that are specific towards FVII or TF-FVIIa 
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complex, which in turn will prevent activation of FX. An example is the design of a TF-
inhibitor that can block the interactions of TF and FVII, calcium, or phospholipids; or by 
interfering with the FX activity through TF-mutants, monoclonal antibodies, or synthetic 
peptide inhibitors (Paborsky et al., 1995, Kelley et al., 1997). Likewise, a FVIIa-inhibitor was 
developed from a Fab antibody, that worked by inhibiting the catalytic activity of FVIIa 
through interaction with the FVIIa-active site (Biemond et al., 1995). In addition, a naturally-
occurring inhibitor of the TF-FVIIa complex such as tissue factor pathway inhibitor (TFPI), a 
protease inhibitor with three Kuntiz-type inhibitory domains, was developed through 
recombinant DNA technology (Enjyoji K et al., 1995). At last, a recombinant NAPc2 was 
also developed that inhibits the activity of the TF-FVIIa complex by forming a canonical 
inhibitory loop within the FVIIa-active site when bound to the exosite of zymogen FX or FXa 
(Bergum et al., 2001).  
 
Recently, peptide members of a new class of serine protease inhibitor with a specificity 
towards FVIIa were successfully isolated from a random peptide library via phage display 
and were classified as an E- (Dennis et al., 2000) and A-series (Dennis et al., 2001). Studies 
conducted by Dennis et al. (2000), have reported the characterisation of the anticoagulant 
peptide, classified as E-76 (an 18 residue peptide) that binds to FVIIa, both displayed on the 
surface of filamentous phage and as a synthetic peptide, and determined that the peptide 
effectively inhibited the TF-dependent coagulation cascade, and ultimately the activity of FX. 
The interaction of TF with FVIIa is important as it facilitates the binding to FX and 
anchorage of FVIIa to cell membrane. The inhibitory properties of the E-76 peptide clearly 
resulted from its non-competitive inhibition of FX activation (Dennis et al., 2000). The 
resolved crystal structure of FVIIa-E-76 complex through X-ray crystallography revealed that 
the E-76 peptide binds to the exosite of FVIIa rather than the active site within the protease 
domain. The binding of the E-76 peptide to FVIIa caused a significant conformational change 
within the 140’s loop, which constitutes a part of the activation domain. The studies further 
indicate that the E-76 peptide may alter the way in which FVIIa binds to FX as well as 
disrupt the hydrogen bond that is linked to the oxyanion hole in the active site. Therefore, the 
E-76 peptide inhibits TF-FVIIa activity by an “allosteric switch” which in turn may give rise 
to both modes of inhibitions (steric and allosteric) for FX activation (Dennis et al., 2000). 
 
Although peptides show significant promise as potential therapeutics through in vitro 
analyses, their utility in in vivo (physiological) settings are severely limited, as they are 
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subject to either rapid protease degradation or clearance by the renal system (Diao and 
Meibohm, 2013, Sato et al., 2006). Therefore, in order to confer greater stability and to 
decrease the metabolic clearance rate so as to enhance the intended therapeutic modality, 
such peptides can be attached to various molecular scaffolds (Chapter 1), which can 
ameliorate their rapid clearance or degradation in vivo, while increasing the overall binding 
strength (or KD) through the avidity effect of multiple peptides within the molecular scaffold. 
 
Eukaryotic Cpn10 is an essential mitochondrial protein that assists in protein folding (Hartl 
and Hayer-Hartl, 2002). It is an oligomeric protein that is structurally conserved across many 
species (Perham and Wittung-Stafshede, 2007). The quaternary structure of Cpn10 is a 
heptameric fold (70 kDa) that is composed of seven identical monomers that are stabilised 
through a number of hydrogen bonds. Each Cpn10 monomer (10 kDa) consists of a rigid 
hydrophobic β-barrel core, a β-hairpin roof loop, and a mobile loop that extends below the 
core of Cpn10 (Figure 4.1). This flexible “mobile” loop region is a hallmark structure that 
plays a crucial role in interacting with its cognate Cpn60/GroEL (Lin et al., 2004). 
 
The mobile loop within Cpn10 lacks any well-defined secondary structure and is subject to 
various conformational changes (Chapter 3). The hCpn10 mobile loop consists of 18 
residues, namely, AAETVTKGGIMLPEKSQG, and substitution or a deletion (e.g. ΔL-Cpn10) 
of this region does not compromise the overall structure of the heptameric fold (Chapter 3). 
Basically, the loop domain forms an extended interface of the designed molecular scaffold, 
which facilitates binding to the target molecule. Based on the unique features of hCpn10, 
there are opportunities to design a newly and highly effective FVIIa inhibitor by substituting 
the mobile loop region with the E-76 peptide and thus create additional binding sites on par 
with hCpn10.  
 
The research reported in this study shows that the hCpn10 mobile loop domains are able to be 
substituted with the anticoagulant E-76 peptide, ALCDDPRVDRWYCQFVEG, in order to 
generate a NME based on the hCpn10, that binds FVIIa with nano-molar affinity, with 
structural stability and longer half-life than that of the E-76 peptide alone.  Furthermore, this 
research study is focussed on the optimal designing of a molecular scaffold based on the 
hCpn10, and incorporating the E-76 peptide (so-called CE76).  
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The mechanism by which the CE76 binds to FVIIa is beyond the scope of this study. 
However, extensive analyses have been reported elsewhere (Dennis et al., 2000, Dennis et al., 
2001). Furthermore, structural optimisation of CE76 was conducted through molecular 
modelling, whereby three CE76 variants were created with the insertion of a number of 
peptide linkers and designated accordingly as CE76P1, CE76P2 and CE76E5 (Chapter 3). The 
research necessitated the expression and purification of the various CE76 variants and further 
testing for their anticoagulant properties. However, due to a higher yield and perceived 
stability of the CE76P1, this variant was selected for most functional characterisation. 
 
Obtaining a high yield of CE76 proved to be challenging, however this was overcome by 
inducing high expression from the pET30a vector using IPTG inducer. CE76 variants 
included a C-terminus histidine(x6)-tag in order to facilitate purification. The CE76 variants 
were expressed in E. coli BL21 (DE3) as soluble proteins that constituted roughly 25-40 % of 
total cell proteins, as determined by the BCA assay.  
 
Maintaining the CE76 in a soluble form was also a challenge due to its low pI (≤ 7.21), which 
is close to the pI of most bacterial proteins. Furthermore, retaining the protein in a stable form 
was difficult due to the presence of a disulphide bond within the E-76 peptide. In order to 
confer more stability within the protein, multiple buffer screening trials were performed, 
whereby aggregation (leading to precipitation) for each protein was examined at 320 nm and 
390 nm (Chapter 2). CE76 variants were found to be more soluble, stable (i.e. no 
aggregation), and functional (i.e. conservation of binding to FVIIa) in 100 mM sodium 
acetate buffer pH 5.5, where pH was two units below the pI. 
 
All CE76 variants were purified from bacterial lysates through two purification stages, 
whereby the first purification step was capturing by IMAC followed by a second purification 
step of polishing by gel-filtration. The polishing step ensured that a high purity of heptameric 
CE76s could be acquired (see Figure 4.5). CE76 purity and Mwt were verified by MALDI-
TOF MS and SE-HPLC analyses (Table 4.3 and Figure 4.6, respectively). Importantly, the 
three CE76 variants, namely CE76P1, CE76P2 and CE76E5, were analysed by analytical SE-
HPLC in order not only to verify conservation of native heptameric configurations, but also 
to monitor the stability with respect to aggregation, for example the variant molecules stored 
over varying time periods at different temperatures, namely -20 °C, 4 °C, 25 °C and 37 °C. 
As predicted, two CE76 variants (i.e. both CE76P1 and CE76P2) exhibited stable and native-
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like heptameric conformations under such storage conditions as illustrated by analytical SE-
PHPLC measured at 280 nm.  
 
Since the E-76 peptide was isolated from a random peptide library against clotting Factor 
VIIa (Dennis et al., 2000), the newly synthesised CE76 was at first tested against human 
rFVIIa. Initially, the CE76 was tested for binding reactivity to rFVIIa through conventional 
ELISA. The results showed that all CE76 variants bound to rFVIIa with concentrations as 
low as 1 nM (Figures 4.7 and 4.8). In contrast, hCpn10 control (up to 1 µM) showed no 
significant binding to rFVIIa. This was to ensure that the interactions between the scaffold-
based hCpn10 and rFVIIa had not occurred independently from the E-76 peptide.  
 
The equilibrium dissociation constant (KD) was also determined for the CE76 variants in real-
time by BLI-Octet
®
. Octet is as versatile complement of commonly used Biacore
®
 but it 
operates in a more multiplexed format in order to detect and quantify the kinetics of 
molecular interactions (Abdiche et al., 2008). Each His-tagged CE76 variant was captured by 
the optical biosensors that were coated with Ni-NTA. Subsequently, the binding affinity of 
rFVIIa was measured in a concentration dependent manner. The CE76P1 had significantly 
higher affinity binding for FVIIa than other CE76 variants, with a KD 2.95 nM (Table 4.4). 
Importantly, the binding profile of CE76P1 to rFVIIa was as similar to the original E-76 
peptide (Dennis et al., 2000). Similar to the ELISA data, there was no binding detected for 
hCpn10 to rFVIIa, further confirming the specificity of CE76 variants to rFVIIa (detailed in 
Table 4.2). Importantly, in all previous detection methods, the CE76 variants required the 
presence of Ca
+2
 ions (in the form of 5 mM CaCl2) in order to enable the binding to rFVIIa, 
although TF was not as crucial. Furthermore, the CE76 variants did not hinder the interaction 
between TF to rFVIIa due to interaction of CE76s with the exosite of FVIIa. Therefore, the 
CE76 variants were only capable of binding to the coagulant FVIIa in the presence of Ca
+2
. 
In comparison, TF is only essential for activating zymogen FVII and for mounting active 
FVIIa onto the cell membrane phospholipids that results in the activation of FXa. 
 
Further characterisations of the inhibitory properties of CE76 against FVIIa were conducted. 
Accordingly, CE76P1 is the optimal candidate NME and was chosen for such characterisation. 
In comparison with the E-76 peptide (control), there was a slight improvement in the 
inhibition of TF-FVIIa mediated activation of FX in both the maximal extent of inhibition 
and the affinity of CE76P1 (Figure 4.10A). The CE76P1 inhibited roughly ~ 95 % of FX 
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activation, in addition the IC50 of CE76P1 was 1.5 nM. Furthermore, it was important to 
determine if the extension of the C-terminus tag of 4xGly/6xHis residues was required for the 
inhibition of FX activation, and therefore, a similar assay was conducted with hCpn10 that 
contained same tag. This verification was deemed necessary since charged residues like 
histidine with a pKa of 6.04 may interfere with the interaction between CE76P1 and FVIIa, 
which in turn may increase or decrease the level of FX activation. Consistent with these 
finding, the histidine extensions did not adversely affect FX activation (data not shown). 
Therefore the effect of the inserted E-76 domain was independent of the scaffold-hCpn10 
molecule of CE76P1. In addition, the CE76P1 provided no substantial improvement to the 
calculated affinity from half-maximal inhibitory concentration, in which the IC50 values of 
1.5 nM is slightly equivalent to the control E-76 peptide of 1.1 nM. 
 
Moreover, the ability of CE76P1 to inhibit the amidolytic activity, which determines FVII 
activity, was also investigated and measured using the small chromogenic substrate 
chromozym t-PA. This in turn may give further insight into assessing whether the binding of 
scaffold-designed CE76P1 could affect the enzymatic active site, of the active serine domain, 
of FVII. The data for inhibition of amidolytic activity is illustrated in Figure 4.10B. The 
amidolytic activity assays have a larger dynamic range since the maximal inhibition by 
CE76P1 at saturating concentrations was only 60 % instead of 95 % as found in the FX 
activation assays. Consistent with previous data for FX activation, a slight improvement of 
the maximal extent of inhibition by CE76P1 to 60 % was observed. Furthermore, the maximal 
inhibition of amidolytic activity at saturating concentrations by CE76P1 of TF-FVIIa and 
FVIIa-only were determined to be 60 and 62 % inhibitions, respectively (Figure 4.10B). This 
indicates that TF had no substantial effect when using the activated form of FVII, nor does 
the CE76P1 obstruct the TF binding to FVII. Importantly, within the amidolytic activity, the 
IC50 value that was determined for CE76P1 was 6.8 nM, whereas in the absence of TF, the 
IC50 value was slightly higher at a value of 8.4 nM (Figure 4.10B). 
 
The scope of this chapter is also focussed on examining the anticoagulant properties of the 
designed CE76 variants through prothrombin time (PT) of TF-dependent clotting assays in 
citrated human plasma (Kamal et al., 2007). Remarkably, the CE76P1 specifically prolonged 
the TF-dependent coagulation pathway 8-fold over normal clotting time, and thus potently 
inhibited FX activation. Furthermore, the CE76P1 illustrated its capacity to prolong clot 
formation in the PT-coagulation assays in a dose-dependent manner (Figure 4.11). This is 
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presumably due to the increased avidity of the CE76P1 as the molecule scaffolds displays 
seven E-76 peptides causing indistinct multiple binding. In comparison, the maximal PT fold-
prolongation for the control E-76 peptide plateaued at a 3-fold over normal clotting time, 
which was significantly lower than the observed in the CE76P1 as well as other CE76 variants 
(Figure 4.11A).  
 
The properties of the CE76P1 variants were assessed further through the activated partial 
thromboplastin time (aPTT) of TF-independent (Kamal et al., 2007). As evident from these 
analyses, neither the CE76P1 nor the control E-76 peptide had significant effect in prolonging 
clot formation in the TF-independent coagulation pathways (Figure 4.11B). This gives further 
credence that CE76P1 is highly specific at prolonging clot formation only in the TF-dependent 
extrinsic pathway through its interaction with the FVII/TF-FVIIa complex. In contrast and as 
expected, no anticoagulation effect was observed in either the PT or the aPTT when using 
wild-type hCpn10. It is important to observe the influence of hCpn10 molecule in the overall 
binding to any of the serine protease factors of both extrinsic and intrinsic pathways. 
 
The potent activity of CE76P1 and its specificity towards FVIIa within the extrinsic pathway 
is indeed significant. The higher avidity of the CE76P1, as evident from the extended 
prolongation within the PT assay relative to the E-76 peptide, can be attributed to the 
heptameric nature of the designed scaffold structure. However, the multiple binding sites of 
the CE76P1 towards its target FVIIa do not indicate an absolute binding of molar ratio of 1:7, 
which requires further detailed studies and is beyond the scope of this study. This observation 
does not occur when examining the control E-76 peptide with molar ratio of 1:1 binding that 
reached saturation prolongation at certain concentrations over the PT-assay (Figure 4.11A). 
 
Due to the limited access to animal models (e.g. rabbit model of venous thrombosis) for 
conducting comparative in vivo anticoagulant studies for CE76P1, an alternative in vitro 
thromboelastography (TEG) was used. TEG is normally used to monitor significant 
coagulopathy in patients by using whole blood, whereby TEG enables the assessment of 
function made from single blood sample, documenting the interaction of platelets with the 
protein coagulation cascade from the time of the initial platelet-fibrin interaction, through 
platelet aggregation, clot strengthening and fibrin cross linkage, to eventually clot lysis 
(Donahue and Otto, 2005, Martini et al., 2008, MacDonald and Luddington, 2010). Thus, the 
anticoagulant effect of CE76P1 was investigated in vitro using blood samples from healthy 
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donors. The reaction time (R), known as coagulation development time, was measured from 
the initiation of the first fibrin clot (Figure 4.3). In order to speed up the clotting processes, 
the citrated blood was triggered by thromboplastin/Ca
2+
, for initiating the clotting reactions of 
extrinsic pathway factors of FVII and FX. Yet, similar to the observation of effects on PT-
assays above, the CE76P1 significantly extended the R-time by 11-fold over the uninhibited 
blood clotting, whereas the maximal R-time prolongation for the control E-76 peptide was 
only 5 mins when clotting was initiated by thromboplastin/Ca
2+ 
(Figure 4.12). Furthermore, 
the specificity of CE76P1 towards the extrinsic pathway was evident as no inhibitory activity 
was observed through the TF-independent coagulation pathway when the clotting reactions 
were triggered by phospholipids/Ca
2+ 
for initiating of the intrinsic pathway Factors of IX, X, 
XI, and XII (Figure 4.13).  
 
4.6 Conclusion 
 
The aim of this study was to investigate the designing of a NME based on the hCpn10 
scaffold with specificity for FVIIa. The goal was to optimise the CE76 structure for stability 
and for binding capability to FVIIa. This study is not aiming to replace the classical well 
known anticoagulant drugs but rather is providing an alternative and a new class of biologic 
for specific medical applications; for example, administration post angioplasty to prevent 
platelet aggregation and thrombosis events, the latter being not an uncommon occurrence 
post angioplasty. 
 
The anticoagulant CE76 was successfully designed by displaying a functional E-76 peptide 
(targeting coagulating FVIIa) within the mobile loop between Ala21 and Gla38 of hCpn10. 
The CE76 was further optimized through the introduction of additional peptide linkers 
(detailed in Chapter 3), which conferred more stability and functionality within the overall 
protein complex.  
 
In this study, CE76 variants (CE76P1, CE76P2, and CE76E5) production, purification, and in 
vitro bioassays were performed and executed. Importantly, the CE76P1 potently inhibited the 
FVIIa-catalysed, and subsequently inhibited the activation of FX. Furthermore, the CE76P1 
significantly prolonged the clotting time of both human plasma and blood, indicating a 
potential use as a new class of biologic-based anticoagulant. The success of this approach in 
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developing a molecular scaffold-based on hCpn10 represents a framework for developing 
new molecular entities (NMEs) for multiple therapeutic and/or diagnostic purposes. 
 
Remarkably, the success of these experiments could result in CE76P1 being trialled as an 
anticoagulant biologic to balance thrombosis caused by surgery, and haemostasis caused by 
classical unspecific anticoagulant, primarily for postsurgical patients. This will be an 
extraordinary future goal. 
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Chapter 5.  The Development of a Novel Cell Surface CD44 
Detection Probe based on Displaying P7-Peptide 
Lligand on hCpn10-Molecular Scaffold 
 
 
5.1 Introduction 
 
In 2010, there were around 30 million reported new cases of cancer globally with about 1.4 
million cases reported in the United States (US) and it is forecasted that there will be around 
10.3 million cancer-related death worldwide by 2020 (Alwan, 2011, Bonvillian, 2011). A 
study conducted between 1970 and 2006 in the US has indicated that out of 100,000 patients, 
cancer mortality rates have dropped from 21 to 11 % in men, and from 12 to 6 % in women, 
which is an insignificant drop compared to other diseases (Jemal et al., 2010). In the United 
Kingdom (UK), the cancer related death rate dropped by 20 % for women and 27 % for men 
between 1990 and 2011 (Wise, 2013). This can be attributed to advances made in early 
disease detection which in turn translates to better outcomes for patients diagnosed with 
cancers of the breast, cervix, colon and rectum (Battaglia et al., 2011, Kaluna-Czaplinska and 
Jozwik, 2014, Ricci-Vitiani et al., 2007, Cappello et al., 2003, Weigel and Dowsett, 2010). 
Hence, early detection of cancer can improve patient recovery and survival  outcomes and 
ease the financial burden so often associated with cancer treatments which is estimated to be 
$US 20,000 to 100,000 per patient annually (Hassett and Elkin, 2013, Samaranayake et al., 
2009). 
 
Cancer is a very complex disease and as such conventional diagnostic methods such as  
palpation, tissue biopsy analysis, or blood tests (Seoane Leston and Diz Dios, 2010), may not 
always be conclusive. Thus, if clinicians are suspicious of potential malignancies, advanced 
techniques such as magnetic resonance imaging (MRI), digital mammography, as well as 
conducting genetic testing through either microarrays or real time polymerase chain reaction 
(RT-PCR) are then utilised (Kaluna-Czaplinska and Jozwik, 2014, Ryu et al., 2013, De Abreu 
et al., 2013, Bohndiek and Brindle, 2010, Zoon et al., 2009, Bendall et al., 2000). Despite its 
high accuracy and reliability of results, many patients have limited access to these diagnostic 
tests. 
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Cancer biomarkers are alternative tools in the diagnosis and management of cancer. 
Biomarkers are usually derived from endogenous proteins such as cell surface receptors or 
metabolites that are secreted in the circulatory system (Kaluna-Czaplinska and Jozwik, 2014, 
Weigel and Dowsett, 2010) such as the serine protease kallikrein-related peptidases 3 (KLK3, 
also known as prostate-specific antigen: PSA) that are found circulating in the blood and used 
as a biomarker for prostate cancer (Hong, 2014). Another example is the transmembrane 
growth factor receptor HER2 that is normally expressed from secretory epithelia used as 
diagnostic biomarker for breast cancer (Hicks and Tubbs, 2005). 
 
Cancer biomarkers, in general, can be detected by using less sophisticated visualising 
techniques such as immunofluorescence and confocal microscopes, or through more 
advanced techniques such as flow cytometry/fluorescence-activated cell sorting (FACS), 
array scanner or other automated advanced imaging instruments (Duan et al., 2014, Rahman 
et al., 2013, Wang et al., 2012, Moadel, 2011, Song and Naeim, 2004). These techniques are 
based on binding kinetics between, for example, antibody and antigen (Schmetzer et al., 
2012, Oshikiri et al., 2006) presumably based on the premise that an overexpressed cell 
surface biomarker is present in cancer cells. Thus, biomarkers are typically used in the 
diagnosis, treatment or monitoring of various cancers such as in the detections of HER2 in 
breast cancer patients to guide, manage and most likely identify patients that can benefit from 
anti-HER2 Herceptin
®
 antibody and assist in monitoring patients’ recovery progress  (Hicks 
and Tubbs, 2005). 
 
CD44 is a cancer biomarker that is overexpressed in different tumours such as in breast, 
prostate, colon and brain and also in leukaemia (Akisik et al., 2002, Khoursheed et al., 2002, 
Kaaijk et al., 1995, Olsson et al., 2011, Takaishi et al., 2007, Dhir et al., 1997). CD44 is a 
polymorphic membrane glycoprotein (i.e. cell surface receptor) with variant isoforms and 
Mwt that ranges from 85-250 kDa (Olsson et al., 2011, Ponta et al., 2003, Kaaijk et al., 1995, 
Eibl et al., 1995). CD44 is involved in adhesion with other cells and the extracellular matrix, 
B cell and T cell immune responses, inflammation and tumour metastases (Olsson et al., 
2011, Negi et al., 2012, To et al., 2010, Vincent and Mechti, 2004, Ponta et al., 2003).  
  
 141 
Recently, CD44 was also detected as a cell surface marker of cancer stem cells (CSCs) and is 
found to be highly expressed in several types of cancers (Balic et al., 2013, Jaggupilli and 
Elkord, 2012, Negi et al., 2012, Ishimoto et al., 2010, Hurt et al., 2008). CSCs are similar to 
normal tissue stem cells but are thought to be insensitive to chemo- and radiotherapies due to 
cells being quiescent or slow-cycling. CSCs are found to be responsible for tumour initiation 
(Hurt et al., 2008). Thus, as a cell surface protein, CD44 serves as an ideal target in the 
development of highly effective therapeutics e.g. antagonist and/or development of 
diagnostics e.g. an early detector probe for CD44. 
 
In this study, the anti-CD44 P7-peptide was displayed on hCpn10 as NMEs and developed as 
a diagnostic probe for CD44, termed CP7. The P7 peptide which was previously isolated 
using phage display screening (Park et al., 2012) was incorporated into the mobile loop of 
hCpn10 between the Ala21 and Gly38 residues. The heptameric nature of hCpn10 facilitates 
the potential display of seven loops exposing the P7 peptide (Figure 5.1). 
 
Indeed there is a growing demand for a reliable diagnostic or therapeutic probe and as such, 
hCpn10 scaffold-based CP7 was assessed in a number of in vitro bioassays to determine the 
binding efficacy of this protein against recombinant CD44 (rCD44) and its binding to breast 
adenocarcinoma, MDA-MB-486 cells, that overexpress CD44. CP7 could potentially be 
utilised as a diagnostic probe against a number of cancers with known CD44
 
overexpression. 
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Figure ‎5.1  Three-dimensional model of CP7 
Scaffold-based hCpn10 displaying CD44 specific P7 peptide. (A) 3D Model of Heptamer CP7. (B) 
Monomer CP7 highlighting the substituted mobile loop. (C) Amino acids sequence of CP7 (blue), 
mobile loop substituted with P7-peptide (green), and P1-linker (red). The 3D model of CP7 was based 
on PDB ID. 1WE3 (detailed in Chapter 3). 
 
5.2 Research aims 
 
 To design and produce a hCpn10 based scaffold (CP7) displaying a peptide recognising 
CD44 for utilisation as a diagnostic probe for cancer detection, 
 To determine the oligomeric structure of CP7 and formation of hCpn10 heptamers, and 
 To investigate the utility of CP7 as a CD44 cancer detector by determining the binding 
of CP7 to recombinant and native forms of CD44.  
  
A.                                                              B. 
 
 
 
 
 
 
 
 
 
C. 
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5.3 Material and methods 
 
5.3.1 Materials 
 
Table 5.1 details the relevant materials used in the research discussed in this study and their 
manufacturers/suppliers. 
 
Table ‎5.1  List of specific applied materials 
Item(s)  From 
Cell/Media/Reagent   
  
Breast Adenocarcinoma (MDA-MB-468) ATCC® HTB-132™ 
Gibco
®
 GlutaMAX
™
 (1x)  Life technologies™   
Gibco
®
 RPMI 1640 Medium  Life technologies™   
Gibco
®
 Fetal Bovine Serum (FBS) Life technologies™   
Corning
®
 Ultra-Low attachment cell culture flasks (250 mL/25 cm
2
) Sigma-Aldrich®  
Corning
®
 Costar
®
 cell culture plates 12-well (flat bottom) Sigma-Aldrich® 
Alexa Fluor
®
 488 Protein Labeling Kit Invitrogen™ 
VECTASHIELD
®
 Mounting Medium with DAPI Vector Lab. Inc. 
Antibodies   Label   
Mouse monoclonal anti-human Cpn10  -- abcam® 
Rabbit Anti-human Cpn10 FITC antibodies-online.com 
His (C-term) mAb Mouse (Novex
®
) FITC  Life technologies™   
Mouse monoclonal Anti-Human CD44 -- Sigma-Aldrich®
 
Rabbit Anti-Mouse IgG (H+L)  Alexa Fluor® 488 Life technologies™   
Mouse mAb Anti-Human CD44   FITC BD Pharmingen™   
Peptide/Proteins 
  
P7 peptide (HHHHHHAAPFNLPLPSRPLLR)   Biobest 
Recombinant Human CD44 (rCD44)  abcam
®
   
Recombinant Human CD44 (rCD24)  abcam
®
   
Bovine serum albumin (BSA)   Sigma-Aldrich
® 
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5.3.2 Production and purification of recombinant CP7 
 
Refer to general materials and methods in Chapter 2 for the production and purification of 
recombinant CP7. The purities of CP7 variant used in this study were ≥ 95% assessed by 
SDS-PAGE and SE-HPLC. 
 
5.3.3 Determination of CP7 binding affinity and specificity for CD44 
 
The binding affinity and specificity of the designed CP7 for CD44 was assessed using BLI-
Octet, using recombinant CD44 (rCD44) as well as rCD25 and BSA as control. Using 96-
well plate (200 µL/well), His-tagged CP7 (1, 10, and 100 nM in PBS) was immobilized and 
captured by Ni-NTA (NTA) Biosensors of BLI-Octet system for 120-180 sec, at 37 °C, with 
1000 rpm shaking. The rCD44 was applied in a concentration-dependent manner (0.01-100 
nM in PBS) for 180 sec, for binding and allowing the measurement of the association rate 
(ka). This was then washed-out for 10 min in PBS, at 1000 rpm and 37 °C to measure the 
dissociation rate (kd). Equilibrium dissociation constant (KD) of CP7 was calculated using 
Octet Version 7.0 software, with a 1:1 binding model and global fitting tools. No protein 
binding was detected for controlled rCD24 and BSA and was therefore used for subtraction. 
Binding ability of hCpn10 (His-tagged) that captured by Ni-NTA biosensor for rCD44 was 
also not detected. The average KD value reported in this study was the mean ± standard error 
of mean from three independent experiments. 
 
5.3.4 Fluorescent conjugation of CP7 
 
CP7 was covalently labelled with fluorophore DyLight 488 (DyLight™ protein label kit) 
following the manufacturers recommendation. In summary, 8 μL Borate Buffer (0.67 M, pH  
8.5) was added to 100 μL of CP7 (1 mg/mL) in PBS. It was then added to DyLight pre-
measured dye vial and was gently vortex before incubated for 1 hr at RT (in dark). 100 μL of 
protein/dye mixture was added into spin column and centrifuged at 1000xg for 1 min. 
Labelled CP7 was collected by adding 100 μL of labelling reaction to the column and 
centrifuged for 1 min at 1000xg. The labelled protein final concentration of 10 µM was 
determined by Equation 5.1. Protein absorbance was measured at 280 nm, the maximum 
absorption (Amax) of DyLight 488 dye is 493 and the correction factor (FC) is 0.147. Protein 
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molar extinction coefficient (εprotein) of CP7 is 31290 M
-1
 cm
-1
(while, ε of CP7 monomer is 
4470 M
-1
 cm
-1
). Purified 488-CP7 was stored in single-use aliquots at -20 °C. 
 
                           
               
        
                   Equation  5.1 
 
5.3.5 Cell lines and cell culture 
 
MDA-MB-468 breast cancer cells overexpressing CD44 were cultured in log-phase growth in 
20 mL Gibco
® 
RPMI 1640 Medium supplemented with Gibco
®
 GlutaMAX
™
 with 10 % Fetal 
Bovine Serum (FBS) at 37 °C in a humidified atmosphere (5 % CO2), in Corning
®
 Ultra-Low 
attachment cell culture flasks (250 mL/25 cm
2
), to a final concentration of 1 x 10
6 
cells/mL. 
 
5.3.6 Fluorescence imaging analysis 
 
Protein binding to cellular CD44 was investigated using fluorescence microscopy (EVOS
®
, 
Advanced Microscopy Group) by adding directly labelled 488-CP7 to cultured CD44 MDA-
MB-468 cells (1 x 10
6 
cells/mL) in 12-well Corning
®
 Costar
®
 cell culture plates. A 0.1, 0.5, 
1, 5, and 10 µM of 488-CP7 per well incubated for 1 hr at 4 °C, and in separate CD44
 
MDA-
MB-468 cells treated with primary antibody FITC-Mouse mAb Anti-Human CD44 (1:200 
dilution, to final concentration of 5 µg/mL) used as control. Cells were washed with PBS 
three times, were observed under fluorescence microscope and images were viewed and 
analysed using Microsoft office picture manager software. 
 
5.3.7 Immunofluorescence microscopy 
 
CD44 expressed MDA-MB-468 cells were treated with CP7 (0.1-10 µg/mL), washed with 
pre-chilled PBS twice and then fixed with ice-cold methanol (5 min). Cells were blocked 
with PBS (pH 7.4), 1 % BSA, and 0.1 % Triton X-100, for cells permeabilisation and block 
non-specific interactions. Cells were then incubated with 1-10 µg/mL secondary antibody 
FITC-Rabbit Anti-human Cpn10 (1:1000 - 1:100 in series dilutions) at 4 °C for 1 hr. MDA-
MB-468 cells were treated with 5-10 µg/mL control primary antibody Mouse mAb Human 
CD44 (1:200 and 1:100 dilution) and then followed by secondary antibody 1 µg/mL Alexa 
Fluor
®
 488 Rabbit Anti-Mouse IgG as control. Similarly cells were treated with 10 µg/mL 
hCpn10 followed by secondary 5 µg/mL FITC-Rabbit Anti-human Cpn10 antibody at 4 °C 
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for 1 hr. Cells were then finally washed with PBS three times and mounted onto microspore 
slides using antifade agent VECTASHIELD
®
 mounting medium with DAPI for nuclear 
staining, then covered using coverslips.  
 
In a direct approach, MDA-MB-468 cells were treated with labelled 488-CP7, following the 
procedures above with slight modifications. Cells were incubated with primary 0.5, 1, 5, and 
10 uM 488-CP7 at 4 °C for 1 hr, then washed with pre-chilled PBS twice, and fixed with ice-
cold methanol and blocked with PBS (pH 7.4), 1 % BSA, and 0.1 % Triton X-100. The 
control sample was treated with primary antibody FITC-Mouse mAb Anti-Human CD44 
(1:100 dilution to final concentration of 10 µg/mL). Cells were washed with PBS three times 
and mounted onto microspore slides using VECTASHIELD
®
 mounting medium with DAPI, 
and then coverslips were added. All slides were analysed using EVOS
® 
fluorescence 
microscope. 
 
5.3.8 Flow cytometry 
 
Cell surface expression of CD44 were characterised by one-colour immunofluorescent 
staining using BD Accuri
™
 C6 Flow Cytometer System (BD Biosciences). MDA-MB-468 
cells were grown as described previously, then resuspended at a concentration of 5 x10
6 
cells/mL, prior to washing with pre-chilled Flow-cytometry Buffer (FB) of: PBS (pH 7.4), 
0.1  % Sodium azide, 1 % BSA. For indirect detection approach, a 50 uL aliquot of cells 
added to equal volume of CP7 (1:2000 and 1:1000) to final concentration of 0.5-1 µg/mL and 
separately a primary Mouse monoclonal Anti-Human CD44 (1:1000, to final concentration of 
1 µg/mL), both incubated at 4 °C for 1 hr on rotation. Cells were then washed with equal 
volume of FB. Cells were then resuspended on a 50 µL FB contained fluorescein 
isothiocyanate-conjugate secondary antibody; FITC-conjugated Rabbit Anti-human Cpn10 
(1:2000 dilution) and Alexa Fluor
®
 488-Rabbit Anti-Mouse IgG (1:2000 dilution), 
respectively, and incubated at 4 °C (dark) for 30 min. Cells were then washed twice and 
resuspended in 500 µL FB containing 50 µL 4 % PFA. Negative controls consisted of grown 
cells treated identically except for primary CP7 which was replaced with hCpn10, that did not 
bind to MDA-MB-468 cells when detected with secondary FITC-conjugated Rabbit Anti-
human Cpn10. Therefore, it was used for subtraction of nonspecific binding and gating. 
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For direct detection, a 50 uL aliquot of cells were added to equal volume of fluorophore-
conjugate of 488-CP7 (1:1000 and 1:500 to final concentration of 1-2 µg/mL) and primary 
control FITC-mouse anti-human CD44 mAb (1:1000 to final concentration of 1 µg/mL), 
incubated at 4 °C for 1 hr in dark. Cells were then washed twice with FB, and then 
resuspended on 500 µL FB contained 50 µL 4 % PFA. Viable cells ≥ 10,000 analysed by 
using BD Accuri
™
 C6 flow cytometer. In this study, excitation was at 495 nm and 
fluorescence emission was detected by using the 520 nm filter for FITC/DyLight 488. Data 
were analysed using CFlow
®
 Sampler software. 
 
5.4 Results 
 
5.4.1 Preparation of CP7 - expression and purification 
 
The nucleotide sequence representative of CP7 with a C-terminus Histidine-tagged was 
cloned into the pET30a bacterial expression vector and was transformed into BL21(DE3) 
strain of E. coli. The expression of CP7 was induced by IPTG and protein expression 
conditions were further optimised as outlined in Chapter 2. The cells were harvested and 
resuspended in 50 mM Tris-HCl (pH 7.6), 0.5 M NaCl, and mechanically lysed with a single 
pass using EmulsiFlex-C5 homogeniser (at 15,000 psi). Cell lysates were recovered and 
mixed with a cocktail of protease inhibitor tablets and kept at low temperature (at 4 °C) to 
avoid protein degradation via proteases.  
 
The resulting supernatant (from 14000xg, 15 min, at 4 °C) containing soluble fractions of 
His-tagged CP7 were subsequently captured by IMAC. With the use of IMAC, soluble 
fractions of CP7 were captured by loaded onto a HisTrap
™ 
FF (5 mL) column and then eluted 
through a stepwise gradients of 10 and 100 % 0.5 M imidazole for elution. Protein fractions 
were collected and resolved by SDS-PAGE (4-12 % Bis-Tris) and visualised by staining gel 
with coomassie (Figure 5.2). The eluent of CP7 (pI 9.52) was buffer exchanged prior to 
polishing using gel-filtration chromatography. The final eluent CP7 was reconcentrated and 
stored in high homogeneity in 50 mM Tri-HCl (pH 7.6), 150 mM NaCl at working 
concentration of 1 mg/mL and stored at 4 °C for further protein characteristics.  
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CP7 was analysed by SDS-PAGE using 4-12 % Bis-Tris gels which confirmed the purity and 
expression levels of the sample (Figure 5.2). CP7 (≥ 95% purity) was further analysed for 
purity by size exclusion HPLC and exhibited a single peak that corresponded to an apparent 
molecular weight indicative of a heptamer, when compared to Mwt standards. The actual 
Mwt of hCpn10 is 70 kDa while the apparent Mwt according to the SE-HPLC chromatogram 
is between 90-100 kDa (Figure 5.3). 
 
 
 
 
    
 
 
 
 
Figure ‎5.2  SDS-PAGE analysis of CP7 production and purification 
Analysis of protein expression and purification of CP7 (A) Protein expression, Lane1, SeeBlue
®
 Plus2 
Mwt marker; Lane2, CP7 pre-induction; Lane3, CP7 (12kDa) post-induction. (B) IMAC protein 
purification, Lane1, soluble fractions cells lysed; Lane2, CP7 (12kDa) HisTrap
™
FF elute; Lane3, 
SeeBlue
®
 Plus2 Mwt marker.  
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Figure ‎5.3  Analytical SE-HPLC for recombinant CP7 versus hCpn10 
HPLC-based size analysis of CP7 and wild-type hCpn10. The elution time of each protein was 
detected in mAU at 280 nm wavelength. The dashed line indicates the elution time of various proteins 
in a Mwt standard mix and corresponds to: (1) Thyroglobulin (670 kDa); (2) BGG (158 kDa); (3) 
Ovalbumin (44 kDa); (4) Myoglobin (17 kDa); and (5) Vitamin B12 (1.35 kDa). These standards 
were used to determine the apparent Mwt of CP7 (Blue, 88 kDa) and hCpn10 (Red, 70 kDa). 
 
5.4.2 Characterization of CP7 for CD44 binding 
 
The specificity and binding affinity of CP7 and CD44 were assessed in vitro using the BLI-
Octet technology which is a label-free technique that analyses real-time interaction between 
various molecules (Figure 5.4). The use of the BLI-Octet system has many advantages over 
traditional ELISA methods as it is more accurate, can be easily replicated and only requires a 
small sample size. Furthermore, the Octet system can determine the binding kinetics which 
cannot be achieved through conventional ELISA. 
 
The CP7 variant has a potential use as a detection probe for certain cancers overexpressing 
CD44. The binding characteristics against rCD44 as well as rCD24 and BSA, which acted as 
a control, were assessed in further detail. The binding affinity of CP7 to rCD44 was 
determined to be 1.32 x10
-9 
M (± 0.08), (Figure 5.4). 
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Figure ‎5.4  Kinetic analysis of CP7 binding to rCD44 determined by BLI-Octet 
The binding curves depict the capture of His-tagged CP7 by Ni-NTA biosensors and the association 
of rCD44 at series concentrations (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 25, 50, 75, 100 nM). The determined 
KD of CP7 was 1.32 x10
-9
 (± 0.08) M while the association (ka) and dissociation (kd) rates calculated 
from binding curves were 4.29 x10
5
 (± 0.16) M.s
-1 
and 5.66 x10
-4
 (± 0.19) s
-1
, respectively. Controls 
rCD24 and BSA were used to evaluate non-specific binding. Coloured curves represent experimental 
data and red curves represent the statistical fitting of the curves using 1:1 binding model. Octet Data 
Analysis 7.0 software was used for the kinetic and data analyses. 
 
In addition, the binding characteristics of CP7 were further assessed in MDA-MB-468 breast 
cancer cell that overexpress CD44 through immunofluorescence microscopy using direct and 
indirect approaches. In the indirect approach, CP7 interaction with endogenous CD44 was 
detected by probing the complex with secondary rabbit anti-human Cpn10 antibody 
conjugated to FITC. A green fluorescein staining was observed after the cells were fixed with 
4 % PFA followed by a series of intensive washes with PBS (Figure 5.5). A negative control 
of cells was probed with hCpn10 followed by the secondary FITC-rabbit anti-human Cpn10 
antibody which showed no detection of fluorescence. In order to compare with the two 
positive controls, P7 peptide and anti-human CD44 antibody, the cells were incubated with 
His-tagged P7 peptide followed by FITC-Mouse anti-His (C-term) while monoclonal mouse 
anti-human CD44 antibody was detected by secondary Alexa Fluor
®
 488-Rabbit anti-mouse 
antibody. Both controls were visualised under the fluorescence microscopy (Figure 5.5). 
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Figure ‎5.5  Immunofluorescence images of CD44
 
MDA-MB-468 cancer cells 
Immunofluorescence images show breast cancer cells detected indirectly by fluorescein 
isothiocyanate-conjugate secondary antibodies. (A) Unlabelled cells only and counterstained with 
DAPI (blue) for nuclei staining. (B) Control P7 peptide, followed by FITC-mouse anti-His6 (green, 
2
secondary
) and nuclear stain, DAPI (blue). (C) Control hCpn10, followed by FITC-rabbit anti-Human 
Cpn10 mAb (green, 2
secondary
), and nuclear stain, DAPI (blue). (D) Designed CP7, followed by FITC-
rabbit anti-Human Cpn10 mAb (green, 2
secondary
), and nuclear stain, DAPI (blue). (E) Control mouse 
anti-human CD44 mAb, followed by Alexa Flour
®
 488-rabbit anti-mouse IgG (green, 2
secondary
), and 
nuclear stain, DAPI (blue). Using EVOS
®
 fluorescence microscopy and white bar shows scale of 
100µm. 
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The binding of CP7 to CD44 was also detected directly by conjugating fluorescein DyLight
®
 
488 to CP7 using DyLight
®
 protein labelling kit for 488-CP7 (Figure 5.6). The binding of the 
fluorescently labelled 488-CP7 to MDA-MB-468 cells was also examined under the 
fluorescence microscopy (Figures 5.7 and 5.8). As previously described, cells were fixed with 
4 % PFA and incubated with labelled 488-CP7. After incubation, the cells were visualised 
and there appeared to be low fluorescence intensity in relation to the control of FTIC-Mouse 
anti-human CD44 mAb (Figure 5.7). However, this could be due more to the technical 
challenges of directly conjugating fluorophore to CP7. The fluorescein-488 did not affect the 
inserted P7 peptide from binding to targeted CD44 nor did it affect intermolecular stability of 
CP7 which was confirmed by SE-HPLC. 
 
Dylight-
488 
 CP7 
(Heptamer) 
 Labelled    
488-CP7 
(Monomer) 
Labelled                             
488-CP7                 
(Heptamer) 
 
 
+ 
 
= 
 
 
 
  Top view  Side view Top view 
Figure ‎5.6  Labelling scheme for CP7 with fluorescein DyLight
® 
488 
Process of labelling and possible conjugation sites at the N- and C-termini of CP7 using DyLight
®
 
protein labelling kit. 
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Figure ‎5.7  Immunofluorescence images of MDA-MB-468 cancer cells  
Immunofluorescence images of CD44 MDA-MB-468 cancer cells using primary-conjugated CP7. 
(A) Unlabelled cells only and counterstained with DAPI (blue) for nuclei staining. (B) Labelled 488-
CP7 (green, 1
primery
), and nuclear stain, DAPI (blue). Showing low fluorescence intensity due to 
labelling preparation optimization, despite confirmed binding to cells using FACS. (C) Control FITC-
Mouse mAb anti-human CD44 (green, 1
primery
), and nuclear stain, DAPI (blue), using fluorescence 
microscopy (white bar shows scale of 100 µm).  
 
FITC DAPI Emerge 
   
 
Figure ‎5.8  Immunofluorescence images of MDA-MB-468 cancer cells by confocal microscopy 
Immunofluorescence images of CD44 MDA-MB-468 cancer cells directly detected by labelled 488-
CP7 (green, 1
primery
), and nuclear stain, DAPI (blue), using confocal microscopy (white bar shows 
scale of 5 µm). 
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Prior to conducting the immunofluorescence assays of CP7 against the MDA-MB-468 cells 
(from both indirect and direct approaches), the interaction of the CP7 molecules with the 
breast cancer cells was assessed using flow cytometry in order to evaluate the specificity and 
binding efficiency of CP7 against CD44 on the cell surface. The same approaches of direct 
and indirect probing discussed above was conducted in the flow cytometry analyses and a 
similar observation was made whereby CP7 had a stronger binding affinity to the CD44 
MDA-MB-468 cells relative to the anti-human CD44 antibody (Figure 5.9). Overall, the 
unlabelled CP7 and fluorescently labelled 488-CP7 both clearly showed a strong binding 
affinity to CD44 in both the experimental protocols (Figures 5.9 and 5.10). 
 
              
                 
 
Figure ‎5.9  Flow cytometric analyses of CD44 expression on MDA-MB-468 cell surface 
Overlay histograms of MDA-MB-468 cells indirectly detected by secondary fluorescein 
isothiocyanate-conjugate antibodies using Accuri
™
 C6 Flow Cytometer. Fluorescence intensity was 
expressed as a 4-decade log scale plotted versus cells number. (A) Cells incubated with CP7 (1
primary
), 
followed by FITC-Rabbit anti-Human Cpn10 (blue, 2
scondary
). (B) Cells incubated with Mouse mAb 
anti-CD44 Human (control antibody, 1
primary
) followed by Alexa Flour
® 
488-Rabbit Anti-Mouse IgG 
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(red, 2
scondary
). (C) Cells incubated with hCpn10 (1
primary
), followed by FITC-Rabbit anti-Human 
Cpn10 (orange, control, 2
scondary
). Unlabelled Cells (green) used for illustrating the non-specific 
binding and also for gating. (D) Cells incubated with P7 peptide (control, 1
primary
), FITC-Mouse Anti-
His6 (green, 2
secondary
). Data are representative of one from three separate experiments. Acquisition of 
> 5,000 events was performed. 
 
 
            
 
Figure ‎5.10  Flow cytometric analyses of CD44 expression on MDA-MB-468 cell surface 
Overlay histograms of CD44
 
MDA-MB-468 cells stained with primary detectors using Accuri
™
 C6 
Flow Cytometer. (A) Cells directly detected by labelled 488-CP7 (blue, 1
primary
); and (B) Cells directly 
detected by FITC-Mouse mAb anti-CD44 Human (red, 1
primary
, control); unstained cells (Black) 
illustrating the non-specific binding and gating. Samples were prepared in similar manner as of Figure 
5.9. 
 
5.5 Discussion 
 
By 2020, it is expected that the total number of cancer-related deaths will be over 30 million 
worldwide (Jayamohan et al., 2013, WHO, 2002). One of these types of cancer is breast 
cancer which is a serious disease affecting 1.3 million people worldwide and accounts for an 
annual mortality of over 500,000 (Zoon et al., 2009, Hortobagyi et al., 2005). Survival rates 
of cancer sufferers have, however, improved significantly as advancements have been made 
in early detection of this cancer. This is not only important for breast cancer, but also for all 
types of cancers where an early diagnosis during Stages I or II can ensure a higher five-year 
survival rate over 50 % (Walters et al., 2013, Wise, 2013, Jemal et al., 2010, WHO, 2002). 
Relapses of cancer patients due to poor prognosis are responsible for the decrease of the 
survival rates of breast cancer patients from 80 to 60 % with local recurrence, and from 80 to 
10 % for metastatic cancer (To et al., 2010, Jaggupilli and Elkord, 2012). 
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Much research has been invested in the discovery and detection of a number of candidate 
biomarkers as they have the potential to aid clinicians in the management of various cancers 
whereby staging, progression and potential regression of the tumour can be monitored. CD44 
is a cell surface protein that is vital for a number of cellular functions such as cell adhesion, 
migration, interaction with the endothelium and subsequent progression towards metastasis 
(Zoeller, 2011, Naor et al., 2002). CD44 has been identified as a biomarker where high 
expression levels have been observed in breast, prostate, colon, leukaemia, head and neck, 
and brain cancers (Trapasso and Allegra, 2012, Jaggupilli and Elkord, 2012, Negi et al., 
2012, Akisik et al., 2002, Khoursheed et al., 2002, Kaaijk et al., 1995, Olsson et al., 2011, 
Takaishi et al., 2007, Dhir et al., 1997).  
 
Importantly, CD44
 
was also found to be highly expressed in cancer initiation cells of CSCs of 
several solid tumours (Ishimoto et al., 2010, Hurt et al., 2008). Thus, the detection of CD44
 
cancer cells is crucial as CD44 CSCs are responsible for initiation of tumours post chemo- 
and radio-therapies due the inherent resistant nature of CSCs and have quiescent or slow-
cycling properties (Balic et al., 2013, Negi et al., 2012, Ishimoto et al., 2010, Hurt et al., 
2008). Studies conducted by To et al. (2010) have determined that CD44 is expressed at high 
levels in a population of CSCs in breast cancer and as such, this protein serves as a promising 
marker for detection of cancer.  
 
Recent work conducted by Park et al. (2012) using phage display technology resulted in the 
isolation of a peptide P7, with high affinity and specificity towards CD44. This study 
focussed on enhancing the binding properties of the P7 peptide by engineering P7 into the 
mobile loop of hCpn10, generating a NME designated CP7 (Figure 5.1). Utilising P7, the 
development of CP7 described in this research, with specificity towards CD44, would have 
utility as a diagnostic probe, as this could provide an opportunity to detect, for example 
cancer during its early stages and improve therapeutic outcomes. The design of CP7 was 
initially optimized in silico through MD simulation studies, which indicated on a theoretical 
basis that P7 could be stabilised within the hCpn10 scaffold using a P1-linker for CP7, as 
discussed in Chapter 3. Therefore, all results and discussions of studies refer to the optimized 
CP7CD44-P1, and designated CP7. 
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CP7 was designed and modelled in silico by incorporating P7 peptide (FNLPLPSRPLLR, 12 
residues) into the mobile loop of hCpn10 and produced using recombinant DNA technology. 
The P7 peptide was inserted between Ala21 and Gly38 with the addition of a P1-linker (i.e. at 
the N- and C-junctures of the loop) for the stabilization of the inserted non-native P7 
oligopeptide (Figure 5.1). Also, a C-terminus histidine-tag was incorporated into CP7 to 
facilitate a high purity yield of this variant (Figure 5.2). CP7 was produced as a soluble 
protein and assembly into a heptamer, which was confirmed by SE-HPLC (Figure 5.3). 
 
The functional characteristics of CP7 were further verified for their potential utility as a 
diagnostic probe for CD44/biomarker. However, in order to be effective, CP7 must first have 
a higher binding affinity and avidity towards CD44 and furthermore, the CP7 variant must be 
highly stable under various harsh laboratory conditions. The binding kinetics of CP7 with 
human rCD44, were initially measured using a BLI-Octet system at various concentrations 
(Figure 5.4). CP7 exhibited higher affinity towards rCD44 in the nanomolar range (1.32 x10
-9 
M), compared to that of P7 peptide alone. Also, CP7 illustrated high specificity towards 
rCD44 by lacking interactions with rCD24 and BSA (Figure 5.4). 
 
Two general methods are regularly applied to detect biomarkers, based on a direct or indirect 
approach. The direct method involves the use of a conjugated antibody/protein such as a 
FITC-labelled mAb that recognizes a specific antigen. The method is simple and fast as it 
involves just one step and less number of wash procedures. However, the sensitivity of the 
primary-labelled antibody/protein is low due to low signal amplification. Indirect methods 
involve probing the target antigen with an unlabelled antibody/protein followed by incubating 
the bound antibody with a labelled secondary antibody that recognizes the primary 
antibody/protein. In contrast to the direct approach, this approach is more sensitive and 
produces higher signal intensity. Both direct and indirect approaches were then applied to 
CP7 variant to assess its interaction with endogenous CD44 in cancer cells. 
 
In this study, the efficacy of CP7 variant was assessed further using the adenocarcinoma 
breast cancer cells MDA-MB-468, that is known to overexpress the transmembrane CD44. 
Other cell lines, such as MCF7 breast cancer cells, may require treatment with radiation to 
enrich the expression of CD44 (Lagadec et al., 2010, Phillips et al., 2006). In fact, it has been 
reported that radiation was found to result in a doubling of CD44 expression. In this study, 
co-localization of CD44 and CP7 variant was observed in untreated MDA-MB-468 cells 
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(i.e. no radiation were required). The immunofluorescence imaging and flow cytometry 
approaches both revealed that CP7 variant was specific to CD44 in MDA-MB-468 cells, as 
evidenced by a higher fluorescence intensity detected in both analyses (Figures 5.5 to 5.10). 
 
Initially, the indirect approach was applied when MDA-MB-468 cells were probed with CP7 
and stained with a rabbit anti-human Cpn10 mAb that was conjugated to FITC. The results of 
the immunofluorescence assay and flow cytometry reveal that CP7 bound with high affinity 
to CD44 (Figures 5.5 and 5.9). Furthermore, CP7 had higher fluorescence intensity relative to 
both controls, the P7 peptide (AAPFNLPLPSRPLLR) and mouse monoclonal anti-human 
CD44 antibody, possibly due to two reasons. Firstly, CP7 variant contains seven identical 
monomers and consequently seven binding sites with displayed P7 peptides, which in turn 
increases the avidity of CP7 for binding to CD44 on the cell surface; secondly, it is highly 
probable that the secondary mAb of FITC-rabbit anti-human Cpn10 bound to one or more 
subunits of the CP7 variant, and is actually one of the seven identical subunits.  
 
In the direct approach, CP7 was directly conjugated to a DyLight 488 fluorophore, called 
488-CP7. The DyLight 488 was coupled at the lysine residues of CP7 (Figure 5.6) and was 
subsequently used as a primary probe for CD44 but with less washing steps. The interactions 
were verified through flow cytometry and immunofluorescence microscopy imaging, as 
previously discussed. Despite the binding detection, the signal intensity of labelled 488-CP7 
was low in relation to the indirect approach described above (Figures 5.7, 5.8 and 5.10). This 
could be due to the sub-optimization of the conjugation conditions of the fluorophore 488 to 
CP7 variant or due to the low number of free lysine residues that are found in both N- and C-
termini of the CP7. This step, however, will require further optimisation in the future before 
in vivo studies can be conducted in order to assess the efficacy of directly labelled CP7’s 
binding to CD44 for example of breast, brain, colon, leukaemia, or prostate cancers. 
 
5.6 Conclusion 
 
CD44 has emerged as a promising biomarker for the potential detection of different type 
cancers as well as of CSCs. This study focused on designing a diagnostic probe by 
incorporating the P7 peptide into the mobile loop of hCpn10 to detect endogenous CD44, 
overexpressed on MDA-MB-468 cells. The in vitro results indicated that CP7 is a stable 
NME, can be potentially utilised as a low cost diagnostic probe for cancer cells, and can be 
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used as an alternative to antibodies in various immunologically-based assays. Nevertheless, 
further validation of CP7 variant is required in order to determine whether this NME has 
potential clinical value. 
 
The hCpn10 scaffold could have a variety of applications across a broad spectrum, including 
environmental monitoring, medical diagnostics, purification reagents and therapeutics. Naked 
peptides have generally low affinity, and the bestowing of avidity through incorporation into 
the mobile loop of hCpn10 could render previously known peptides useful for the above 
applications. 
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Chapter 6.  Preliminary Results of Anti-Aangiogenic Candidates 
 
 
6.1 Introduction 
 
Angiogenesis is a mechanism whereby new blood vessels form by branching out from pre-
existing ones. This process is highly regulated by a number of pro- and anti- angiogenic 
factors, that can for example, be triggered in response to physical trauma in order to facilitate 
proper wound healing. In addition, angiogenesis can be artificially stimulated in order to treat 
myocardial and peripheral perfusion (Bridoux et al., 2012, Atluri and Woo, 2008).  
 
Vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor 
(FGFR) are receptors involved in a number of diseases and are therefore novel targets for 
biopharmaceutical development with the intention of managing various cancers. A number of 
strategies have been pursued in order to develop anti-angiogenic therapeutics for the 
treatment of cancer. This is based on the premise that any absence of new blood vessels 
would prevent further tumour malignancy and reduce the chances of metastasis (Figure 6.1). 
Nevertheless, balancing between physiological and pathological angiogenesis is a significant 
challenge. In hypoxic conditions, malignant tumours secrete a number of growth factors such 
as VEGF or FGF in order to trigger the formation of new blood vessels that will eventually 
vascularise the tumour and facilitate the growth and potentially initiate tumour metastasis 
(Hummers et al., 2009, Teicher, 2010). Indeed, inhibiting angiogenesis is a major part of 
cancer treatment, for example, Avastin
®
 is used to treat lung cancer by inhibiting 
angiogenesis (Ferrara et al., 2005).  
 
VEGF is a pro-angiogenic factor and is well known for its role in activating angiogenesis in 
the vasculature. VEGF bind to three receptors, namely; VEGFR1, VEGFR2, and 
neurophilin1 (NR1). VEGF interacts primarily with VEGFR2 in triggering endothelial 
proliferation, migration and survival (angiogenesis signalling). Creating a VEGFR2 receptor 
antagonist with high affinity would hinder the interaction between VEGF and VEGFR2. This 
in turn would prevent phosphorylation and the subsequent initiation of angiogenesis through 
the mitogen activated protein kinase (MAPK) pathways (Tarrega et al., 2010).  
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The FGF family is composed of more than twenty-three signalling molecules that induce cell 
proliferation, differentiation and migration through interactions with the FGF receptors 
(FGFR1 to 4) on cell surface (Coutts and Gallagher, 1995). Basic FGF (bFGF) is a member 
of FGF family with high expression levels, along with its cognate receptors, are implicated in 
malignancy, angiogenesis and metastasis (Yamazaki et al., 1997, Giri et al., 1999).  As such, 
bFGF serves as a potential target for cancer therapy whereby an anti-bFGF binder can 
effectively inhibit endothelial cell proliferation in vivo (Hori et al., 1991, Asano et al., 1995) 
and thus prevent bFGF-induced angiogenesis. Bevacizumab (Avastin
®
), an anti-VEGF 
monoclonal antibody that was approved by the FDA, is currently used in the clinic for the 
management of cancer whereby angiogenesis is inhibited (Cohen et al., 2007). Other small 
molecule drugs that are reported to have anti-angiogenic activity are sorafenib (BAY 43-
9006) (Greenwald et al., 2013) and sunitinib (SU11248) (Baumann et al., 2012), which target 
the receptor tyrosine kinases. Nevertheless, these drugs have severe side effects due to their 
broad spectrum reactivity against a number of receptors kinases. 
 
bFGF and VEGF are critical in promoting tumour angiogenesis and their high expression 
levels were correlated with vascularity and malignancy (Gacche and Meshram, 2014). VEGF 
promotes mitogenic activity on the endothelial cells, while bFGF synergistically enhances the 
mitogenic effect of VEGF. Both molecules have a direct effect on stimulating endothelial and 
tumour cell proliferation. In essence, this blocker could then potentially terminate the 
endothelial cell survival, proliferation and migration (Figure 6.1). In this study, two peptides 
designated P11 and R2 were identified that bind bFGF and VEGF receptors, respectively.  
These peptides were substituted for the mobile loop of hCpn10, to create NMEs designated 
CP11bFGF-P1 and CR2VEGF1-P2. The research reported in this chapter details the expression and 
purification of CP11bFGF-P1, and includes some limited characterisation. 
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Figure ‎6.1  The role of angiogenesis factors in stimulating tumour growth 
The premature tumour cell development for obtaining a vascular supply. (A) The beginning of the 
tumour mass is small and can obtain nutrients and oxygen from existing blood vessels. (B) The 
tumour grows beyond the capacity of nearby blood vessels and then releases soluble pro-angiogenic 
factors (e.g. bFGF and VEGF) which promote the development of new blood vessels from major 
vessels. (C) The new sprouting blood vessels will provide more nutrients and oxygen for tumour to 
grow beyond 3 mm in size. (D) Two proposed and designed anti-angiogenic candidates named 
CP11bFGF-P1 and CR2VEGF1-P2 are currently under development and can be applied for stopping and 
preventing further angiogenesis sprouting and thus causing tumour growth diminutions.  
 
6.2  Materials and methods 
 
6.2.1 Protein expression and purification 
 
Following the standard methodology of recombinant protein expressions and purifications 
described in Chapter 2, the variant CP11bFGF-P1 was designed in silico by inserting P11 
peptide between A21 and G38 of hCpn10, expressed in E. coli BL21 (D3) as soluble protein, 
and purified by IMAC (≥ 90%) as determined by SDS-PAGE and GF.  
 
A.                        B.                                 C. 
D. 
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6.2.2 Protein characterisation  
 
Native Mwt of CP11bFGF-P1 was determined by Size-exclusion (SEC) using high-resolution 
Superdex
® 
200 10/300 GL column following standard methodology of gel filtration 
chromatography (Section 2.7.2.3, Chapter 2).  
 
6.3 Results and discussion 
  
Given that both FGFR and VEGFR2 are potential target receptors for cancer treatment, two 
receptor antagonists were designed using hCpn10 as a molecular scaffold. The P11 peptide 
(Li et al., 2012), which is reactive to FGFR and the R2 peptide (Vicari et al., 2011), which is 
reactive to VEGFR2, were incorporated into the mobile loop region of hCpn10 to create 
CP11bFGF-P1 and CR2VEGF1-P2, respectively. Based on previous studies where hCpn10 was 
assessed as a potential scaffold for peptide display, it was hypothesised that CP11bFGF-P1 and 
CR2VEGF1-P2, would be more potent than the naked peptides, in preventing the interactions of 
bFGF and VEGF with their cognate receptors (Figure 6.1). 
 
NME CR2VEGF1-P2 is part of research study reported elsewhere (Recinos and Mahler, 
unpublished). Herein, CP11bFGF-P1 is only reported. The NME CP11bFGF-P1 was successfully 
expressed in E. coli BL21 (DE3) as soluble proteins. His-tagged CP11bFGF-P1 (11.6 kDa) was 
purified using IMAC, and was then subsequently characterised using the standard 
methodology of SDS-PAGE outlined in Chapter 2 (Figure 6.2). SEC chromatography 
indicated that NME CP11bFGF-P1 with the insertion of stabilizer P1-linker (i.e. proline-linker 
as detailed Chapter 3) at the N- and C-junctures of the mobile loop was successfully 
assembled into a native heptamer-like configuration in comparison to hCpn10 (Figure 6.3).  
 
CP11bFGF-P1 and CR2VEGF1-P2 are proposed as NMEs with anti-angiogenic activity, whereby 
they are able to block FGFR and VEGFR2 receptors which promote the development of new 
blood vessels from major vessels. In another therapeutic scenario, CP11bFGF-P1 and CR2VEGF1 -
P2 could be utilised in combination at a 1:1 ratio, targeting both receptors simultaneously. The 
mechanism of action could work in a similar manner as that proposed for the novel dual 
VEGF-R2/bFGF-R inhibitor Brivanib, which is currently in clinical development (Dempke 
and Zippel, 2010).  
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Figure ‎6.2  SDS-PAGE of CP11bFGF-P1 expression and purification 
Representative SDS-PAGE analyses of CP11bFGF-P1. (A) CP11bFGF-P1 (11.6 kDa) expression in E. coli 
BL21(D3), detail as following; Lane1: SeeBlue
®
 Plus2 Mwt std marker, Lane2: pre-expression cell 
lysate (soluble), Lane3: CP11bFGF-P1 post-expression cell lysate (soluble), Lane4: pre-expression cell 
lysate (insoluble), Lane5: CP11bFGF-P1 post-expression cell lysate (insoluble). (B) CP11bFGF-P1 (11.6 
kDa) IMAC fractions, Lane1: SeeBlue
®
 Plus2 Mwt std marker, Lane2: pre-load, Lane3: column 
unbound proteins flow-through, Lanes4-7: 10 % washed 0.5 M imidazole, Lanes8-13: 100 % 0.5 M 
imidazole purification fractions. 
 
 
Figure ‎6.3  Analytical size-exclusion and SDS-PAGE of recombinant CP11bFGF-P1 
Representative SEC analysis of CP11bFGF-P1. (A) SEC chromatogram of CP11bFGF-P1 (blue, 75.5 kDa) 
and hCpn10 (red, 70 kDa) determined by Superdex
® 
200 10/300 GL prepacked column. Notably, 
CP11bFGF-P1 apparently formed heptamer-like configuration in comparison to hCpn10 (control). (B) 
SDS-PAGE of SEC fractions; Lane1: SeeBlue
®
 Plus2 Mwt std marker, and Lane2-3: reduced and 
non-reduced CP11bFGF-P1 (11.6 kDa), respectively.  
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6.4 Future directions   
 
CP11bFGF-P1 and CR2VEGF1-P2 were successfully expressed and purified.  Both NMEs were 
confirmed to form a native-like heptamer by SEC-chromatography. Further characterisation 
studies associated with the activity and potency of CP11bFGF-P1 and CR2VEGF1-P2 are required. 
These studies could include in vitro assays using traditional methods such as ELISA and real-
time BLI to assess the binding between the NMEs and FGF and VEGF receptors and to 
determine binding parameters (ka, kd and KD). Additional studies can be conducted in order to 
assess anti-tumour activity through methylthiazole tetrazolium (MTT) colorimetric assays 
(Nawa et al., 2012). The inhibitory effects on cell cycle progression can be assessed through 
flow cytometry or by measuring the inhibition of MAPK activation (Tarrega et al., 2010). 
The anti-angiogenic effects can be assessed on chick embryo chorioallantoic membrane 
(CAM) (Li et al., 2007, Martinez-Madrid et al., 2009), by studying the level of 
neovascularisation that is either enhanced by bFGF or VEGF versus inhibited by CP11bFGF-P1 
or CR2VEGF1-P2. Further studies could to be conducted in vivo using xenograft models to 
investigate the delay in tumour development. In summary the production of CP11bFGF-P1 and 
CR2VEGF1-P2 has laid the groundwork for further research and development of these two 
NMEs as biologic drugs for cancer treatment. 
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Chapter 7.  Conclusion and Future Directions 
 
 
The research outcomes presented in this thesis have made a valuable contribution in the area 
of molecular scaffolds, and has indeed shown that human Cpn10 is another molecular 
scaffold capable of presenting and displaying peptides in a fashion that allows binding of the 
peptides to target proteins. As has been pointed out, monoclonal antibodies are nature’s 
scaffold for presenting peptides through the CDR loops, that are able to bind to a myriad of 
antigenic determinants found in nature. Antibodies are established therapeutic and diagnostic 
agents, and there are now around 35 approved globally and 100s in clinical trials for 
treatment of disease indications, predominantly chronic diseases such as cancer and 
inflammatory diseases. Antibodies are the key reagents in diagnostic test kits and other forms 
of immunoassays. Although antibodies are very successful as therapeutic and diagnostic 
agents, the intellectual property landscape is complex and is a hurdle in the development of 
new antibody-based NMEs. 
 
The discovery of other molecular entities that are capable of behaving like antibodies in 
“beyond antibody” approaches has opened up a new area in protein therapeutics and 
diagnostics, and has led to the development of novel intellectual property. The common 
attribute of molecular scaffolds is that they possess domains (typically loop structures, but 
also flat structures, inherent in the DARPins (ankyrins), for example) where the endogenous 
loop peptide can be substituted with other peptides. These peptides are typically preselected 
to bind to an antigenic determinant (for example, from a peptide phage display library), in the 
same way that antibodies may be selected that bind to antigenic determinants on proteins 
through antibody phage display technology. Some of the more successful scaffolds include 
the Fibronectin (Monobody) and lipocalins (Anticalins), both which have candidate NMEs in 
clinical development. More recently another novel molecular scaffold has been reported 
termed FynomAb, derived from the human Fyn SH3 domain that is highly conserved among 
different species (Brack et al., 2014). FynomAb have two loops within the molecule, and 
peptides can be substituted within these loops that bind to an antigen of choice. FynomAb 
have no cysteine residues, are of small size (7 kDa) and are highly stable.   
 
Human Cpn10 is a chaperone protein and is associated with protein folding, but has also been 
reported to have anti-inflammatory properties (Chapter 1). Regardless of the endogenous 
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activity of hCpn10, the loop structures within the monomer (mobile loop and roof loop) can 
potentially be substituted with peptides that have been preselected to bind to an antigenic 
determinant. The mobile loop was chosen in this study, as it has been previously shown that 
the loop can be deleted without compromising assembly of heptamer from monomer, and 
preliminary data had suggested that the loop could be substituted with other peptide sequence 
(Mahler, personal communication). Like FynomAb, hCpn10 does not contain any cysteine 
residues, which can have some advantages when expressing in E. coli. Also like FynomAb, 
hCpn10 is soluble when expressed in E. coli, which simplifies production. An added 
advantage of hCpn10 as a molecular scaffold is that the monomer assembles into a stable 
heptamer. The heptameric structure has seven peptides displayed, and so will impart an 
avidity which considerably increases the apparent affinity of heptamer over monomer, in the 
same way that avidity contributes to the apparent affinity of the pentameric IgM 
immunoglobulin.   
 
The development of hCpn10 as a molecular scaffold has not been without technical 
challenges, and initial studies showed simple loop substitution did not always lead to 
heptamer formation. Indeed with some examples, ideal heptamer assembly did not occur and 
resulted in dimers, trimers, tetramers and other higher order oligomers and aggregates. The 
mixed oligomers and aggregates were partitioned between soluble and insoluble (inclusion 
body) fractions. In order for hCpn10 to function as a molecular scaffold, stable heptamer 
formation upon generic peptide substitution is required. To this end, molecular modelling 
studies revealed the propensity for some peptides within the mobile loop to interact with 
residues of the β-barrel interface through salt bridging, for example, and disrupt stable 
heptamer formation. The insertion of alanine/proline linkers at the N- and C-terminal 
junctions of the mobile loop was effective in spatially orienting the mobile loop away from 
the β-barrel interface, facilitating stable heptamer formation. Although some further 
optimisation of the hCpn10 molecular scaffold may be required, the research outcomes have 
demonstrated that the mobile loop can indeed be substituted with non-native peptides, to 
create NMEs with binding activity to other proteins. Thus in a “beyond antibody” approach, 
the hCpn10 molecular scaffold has been utilised to create NMEs of potential therapeutic and 
diagnostic utility. 
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7.1 Molecular modelling and simulations 
 
Molecular modelling and simulations sought to gain a fundamental understanding of the 
molecular structure of hCpn10 and the molecular dynamics of the mobile loop, so as to 
understand and assess the potential utility to display various peptides within the mobile loop 
region. Accordingly studies were conducted to determine if non-native peptides could be 
inserted into the mobile loop without compromising monomer structure and assembly into 
heptamer (Chapter 3).  
 
MD simulations of wild-type hCpn10 and its variants revealed that the β-barrel core was 
highly rigid and stable, whereas the mobile loop with substituted peptides exhibited large 
conformational change from its native configurations due to the nature of the amino-acid side 
chains. Removal of the mobile loop did not affect the assembly of the hCpn10 monomer into 
heptamer (as discussed in Chapter 3), providing further insight into the utility of this protein 
as a molecular scaffold.  
 
MD simulation studies were conducted on hCpn10 containing non-native peptides within the 
mobile loop region. As a consequence, the assembly of the hCpn10 variant was compromised 
in some cases. However as mentioned previously, insertion of multiple alanine/proline linkers 
(P1 and P2) at the N- and C-junctures of the mobile loop stabilised the loop (of the non-native 
peptides) of the hCpn10 variants. Based on these simulation studies, it was apparent that such 
linkers constrained the inserted peptide loop into native-like conformation in order to better 
mimic the variants hCpn10 heptamer and facilitate the proper assembly of the recombinant 
designed protein (Chapter 3).  
 
Structural predictions as a result of the MD studies were verified through expression and 
purification of the NMEs candidate based on hCpn10, followed by characterisation including 
the use of SE-HPLC to verify the native heptamer formation. The observed results were 
consistent with the hypothesis that these peptide linkers are important for the stabilisation of 
these hCpn10 variants. Thus, the success of this approach in developing a molecular scaffold 
based on hCpn10 represents a new framework for the development of NMEs for therapeutic 
and/or diagnostic purposes.  
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7.2 Development of an anticoagulant biologic  
 
Blood coagulation is a process in which multiple proteolytic reactions lead to the activation 
of thrombin, a key protein involved in the formation of a fibrin clot. There are two pathways 
in the coagulation cascade, namely, intrinsic and extrinsic. Factor VII is responsible for the 
activation of the coagulation cascade via the extrinsic pathway and therefore serves as an 
attractive target for the development of biologic anticoagulants.  
 
Studies have been conducted using phage display technology to isolate peptides that can act 
as serine protease inhibitors. One such peptide was previously isolated and showed 
preferential reactivity to FVII/FVIIa and subsequently inhibited FXa of the extrinsic TF-
dependent coagulation cascade. This peptide, subsequently termed E-76, was incorporated 
into the mobile loop region of hCpn10 for potential therapeutic applications. The 18 residues 
within the native mobile loop region were substituted with the E-76 peptide between Ala21 
and Gla38 to form a new scaffold molecule called CE76 (Chapter 4). Introducing the E-76 
peptide within the loop of hCpn10 potentially results in an extended half-life compared to 
that of E-76 naked peptide due to a larger size, and also potentially protects the peptide from 
proteolysis. In addition, the introduction of this peptide into the mobile loop of hCpn10 
further increased the binding avidity of this peptide as seven copies of the E-76 peptide were 
displayed (Chapter 4). 
 
The anticoagulant CE76 was successfully expressed and purified from E. coli cells as a 
soluble protein and was further characterised. SE-HPLC studies indicated that a number of 
CE76 variants, namely, CE76P1, CE76P2, and CE76E5 formed a stable heptamer with the 
introduction of the multiple linkers as indicated through the MD simulation studies, with the 
exception of CE76E5 that had a short-term stability profile (Chapter 4).  
 
CE76P1 demonstrated the highest affinity towards FVIIa using biolayer interferometry (BLI). 
Furthermore, the in vitro studies indicated that the CE76P1 protein was a potent inhibitor of 
FVIIa and subsequently FX activity that delayed clot formation in citrated plasma and human 
blood, as well as based on the measurements of enzymatic activity. The results obtained from 
these analyses indicate that CE76P1 may have potential utility as a biologic-based 
anticoagulant (Chapter 4). CE76P1 could be used to effectively regulate the coagulation 
cascade and prevent haemostasis or thrombosis, based on the specificity of CE76P1 towards 
the extrinsic pathway. Moreover, CE76P1 could be used for patients experiencing post-
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surgical thrombosis and reduce the incidence of haemostasis which are typically observed 
with the use of standard anticoagulants such as warfarin or heparin.  
 
Further characterisation of CE76P1 is required, including investigating the mode of action in 
vivo of CE76P1 inhibiting FVIIa activity. Furthermore, the half-life of CE76P1 should be 
examined in vivo in relation to the E-76 peptide, which is essential for any future study. Most 
importantly, conducting in vivo studies, for example using rabbit models of venous 
thrombosis, can provide further insight on the utility of CE76P1 as a potential biologic 
anticoagulant.  
 
7.3 Development of a cancer diagnostic probe 
 
Biomarkers are utilised to diagnose and assess disease indications. Implicit in investigating 
biomarkers is the need to develop diagnostic reagents that have specificity for the target 
biomarker. CD44 is a cell surface glycoprotein that is found to be overexpressed in a number 
of cancers such as breast, prostate, colon and ovarian, as well as CSCs in a number of solid 
tumours, therefore, is an ideal biomarker for diagnosis or targeted treatment.  
 
In this facet of the research, hCpn10 was utilised as a scaffold whereby the mobile loop was 
replaced with the anti-CD44 P7 peptide, creating an NME designated CP7 (Chapter 5). 
Experimental binding studies by BLI confirmed that the CP7 bound to rCD44. Furthermore, 
CP7 bound to MBA-MB-468 breast cancer cells which overexpress CD44, with higher 
fluorescence intensity compared to that generated when using a mAb anti-CD44 antibody, as 
observed through fluorescence microscopy imaging and flow cytometry. Also, labelled 488-
CP7 bound to MBA-MB-468 in a comparable manner. Thus, in vitro studies indicate that 
CP7 could be utilised as a probe for cancer diagnosis (Chapter 5).  
 
Furthermore, CP7 could be conjugated with radiolabels such as 
99m
Tc-, 
64
Cu-, 
68
Ga- and used 
as a probe for in vivo cancer detections and to monitor patient’s response to therapy. The 
design of NMEs with diagnostic potential based on hCpn10 molecular scaffold may translate 
to more advanced detection methods, better prognosis, and improved therapeutic outcomes 
for various cancers. 
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7.4 Future directions and applications for scaffold based-hCpn10 
 
hCpn10, as a molecular scaffold, meets the important requirements in biologics development 
in terms of size, molecular and thermal stability, production scalability, and has advantages as 
previously described. The viability of using hCpn10 as a molecular scaffold has been 
demonstrated by substituting peptides E-76 (binds Factor VIIa), P7 (binds CD44), P11 (binds 
FGFR) and R2 (binds VEGFR2) for the mobile loop region of hCpn10, while maintaining 
native heptameric structure. The success of displaying the E-76 peptide within the mobile 
loop of hCpn10 for use as an anticoagulant and the display of the P7 peptide as a diagnostic 
probe is indicative that hCpn10 can serve as peptide display platform for the development of 
various biologics and diagnostic agents with a higher binding avidity towards different 
biological targets, compared to naked peptides.   
 
In other applications, hCpn10 could be utilised in vaccine development whereby an antigen 
of choice can be incorporated into the scaffold in order to induce an effective immune 
response. Other applications could involve utilising hCpn10 as a multivalent biologic against 
a variety of biological targets; for example, cross-linking cell surface receptors, or inducing a 
cytotoxic T-cell response against a malignant cell. hCpn10 can be used to develop a platform 
technology for the discovery of new biologic binders using phage display technology. In 
essence, a library of hCpn10 binders could be developed by introducing sequence diversity 
within the mobile loop and displaying this molecule on the surface of filamentous phage. For 
managing autoimmune diseases, hCpn10 can be used as a decoy molecule by displaying 
peptide fragments that are target of auto-antibodies. Regardless of its application, hCpn10 is 
easily scalable for production as a soluble protein in prokaryotic production systems, which 
generally have favourable process economics compared to mammalian cell production 
systems.  
 
An open question is the potential immunogenicity of hCpn10 variants with potentially 
antigenic peptides within the mobile loop. hCpn10 has been shown to be non-immunogenic, 
supported by data that was acquired from Phase I and II clinical trials, where hCpn10 was 
tested for therapeutic efficacy against rheumatoid arthritis and multiple sclerosis (Chapter 1). 
However substituting non-endogenous peptides would likely change the immunogenicity 
profile, and each NME based on hCpn10 would need to be evaluated for immunogenicity 
through clinical trials. 
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Appendix 1  
 
Amino acid sequences and theoretical pI/Mwt for all protein candidates used in this study:  
1.  hCpn10  
        10         20         30         40         50         60  
MAGQAFRKFL PLFDRVLVER SAAETVTKGG IMLPEKSQGK VLQATVVAVG SGSKGKGGEI  
 
        70         80         90        100  
QPVSVKVGDK VLLPEYGGTK VVLDDKDYFL FRDGDILGKY VD  
Theoretical pI/Mwt: 8.89 / 10931 Da (per monomer) 
 
2. ∆L-Cpn10  
        10         20         30         40         50         60  
MAGQAFRKFL PLFDRVLVER SAGKVLQATV VAVGSGSKGK GGEIQPVSVK VGDKVLLPEY  
 
        70         80  
GGTKVVLDDK DYFLFRDGDI LGKYVD  
Theoretical pI/Mwt: 8.96 / 9260 Da (per monomer) 
 
3. ∆Rf-Cpn10 
        10         20         30         40         50         60  
MAGQAFRKFL PLFDRVLVER SAAETVTKGG IMLPEKSQGK VLQATVVAVG GGVKVGDKVL  
 
        70         80         90  
LPEYGGTKVV LDDKDYFLFR DGDILGKYVD  
Theoretical pI/Mwt: 7.94 / 9733 Da (per monomer) 
 
4. β-barrel (∆Rf-∆L-Cpn10)  
        10         20         30         40         50         60  
MAGQAFRKFL PLFDRVLVER SAGGKVLQAT VVAVGGGPVS VKVGDKVLLP EYGGTKVVLD  
 
        70  
DKDYFLFRDG DILGKYVD  
Theoretical pI/Mwt: 7.98 / 8402 Da (per monomer) 
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5. CE76 
        10         20         30         40         50         60  
MAGQAFRKFL PLFDRVLVER SALCDDPRVD RWYCQFVEGK VLQATVVAVG SGSKGKGGEI  
 
        70         80         90        100  
QPVSVKVGDK VLLPEYGGTK VVLDDKDYFL FRDGDILGKY VD  
Theoretical pI/Mwt: 6.21 / 11287 Da (per monomer) 
 
6. CE76P1 
        10         20         30         40         50         60  
MAGQAFRKFL PLFDRVLVER SAAAPLCDDP RVDRWYCQFV EPAAGKVLQA TVVAVGSGSK  
 
        70         80         90        100  
GKGGEIQPVS VKVGDKVLLP EYGGTKVVLD DKDYFLFRDG DILGKYVD  
Theoretical pI/Mwt: 6.21 / 11765 Da (per monomer) 
 
7. CE76P2 
        10         20         30         40         50         60  
MAGQAFRKFL PLFDRVLVER SAPPLCDDPR VDRWYCQFVE PPGKVLQATV VAVGSGSKGK  
 
        70         80         90        100  
GGEIQPVSVK VGDKVLLPEY GGTKVVLDDK DYFLFRDGDI LGKYVD  
Theoretical pI/Mwt: 6.21 / 11675 Da (per monomer) 
 
8. CE76E5 
        10         20         30         40         50         60  
MAGQAFRKFL PLFDRVLVER SAAETVTLCD DPRVDRWYCQ FVEPEKSQGK VLQATVVAVG  
 
        70         80         90        100        110  
SGSKGKGGEI QPVSVKVGDK VLLPEYGGTK VVLDDKDYFL FRDGDILGKY VD  
Theoretical pI/Mwt: 5.43 / 12358 Da (per monomer) 
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9. FH-Cpn10  
        10         20         30         40         50         60  
MAGQAFRKFL PLFDRVLVER SAAETVTKGG IMLPEKSQGK VLQATVVAVG SGSKGKGGEI  
 
        70         80         90        100        110        120  
QPVSVKVGDK VLLPEYGGTK VVLDDKDYFL FRDGDILGKY VDGGGAGQAF RKFLPLFDRV  
 
       130        140        150        160        170        180  
LVERSAAETV TKGGIMLPEK SQGKVLQATV VAVGSGSKGK GGEIQPVSVK VGDKVLLPEY  
 
       190        200        210        220        230        240  
GGTKVVLDDK DYFLFRDGDI LGKYVDGGGA GQAFRKFLPL FDRVLVERSA AETVTKGGIM  
 
       250        260        270        280        290        300  
LPEKSQGKVL QATVVAVGSG SKGKGGEIQP VSVKVGDKVL LPEYGGTKVV LDDKDYFLFR  
 
       310        320        330        340        350        360  
DGDILGKYVD GGGAGQAFRK FLPLFDRVLV ERSAAETVTK GGIMLPEKSQ GKVLQATVVA  
 
       370        380        390        400        410        420  
VGSGSKGKGG EIQPVSVKVG DKVLLPEYGG TKVVLDDKDY FLFRDGDILG KYVDGGGAGQ  
 
       430        440        450        460        470        480  
AFRKFLPLFD RVLVERSAAE TVTKGGIMLP EKSQGKVLQA TVVAVGSGSK GKGGEIQPVS  
 
       490        500        510        520        530        540  
VKVGDKVLLP EYGGTKVVLD DKDYFLFRDG DILGKYVDGG GAGQAFRKFL PLFDRVLVER  
 
       550        560        570        580        590        600  
SAAETVTKGG IMLPEKSQGK VLQATVVAVG SGSKGKGGEI QPVSVKVGDK VLLPEYGGTK  
 
       610        620        630        640        650        660  
VVLDDKDYFL FRDGDILGKY VDGGGAGQAF RKFLPLFDRV LVERSAAETV TKGGIMLPEK  
 
       670        680        690        700        710        720  
SQGKVLQATV VAVGSGSKGK GGEIQPVSVK VGDKVLLPEY GGTKVVLDDK DYFLFRDGDI  
 
 
LGKYVD  
Theoretical pI/Mwt: 9.18 / 76653 Da (per heptamer) 
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10. FH-CE76 
        10         20         30         40         50         60  
MAGQAFRKFL PLFDRVLVER SALCDDPRVD RWYCQFVEGK VLQATVVAVG SGSKGKGGEI  
 
        70         80         90        100        110        120  
QPVSVKVGDK VLLPEYGGTK VVLDDKDYFL FRDGDILGKY VDGGGAGQAF RKFLPLFDRV  
 
       130        140        150        160        170        180  
LVERSALCDD PRVDRWYCQF VEGKVLQATV VAVGSGSKGK GGEIQPVSVK VGDKVLLPEY  
 
       190        200        210        220        230        240  
GGTKVVLDDK DYFLFRDGDI LGKYVDGGGA GQAFRKFLPL FDRVLVERSA LCDDPRVDRW  
 
       250        260        270        280        290        300  
YCQFVEGKVL QATVVAVGSG SKGKGGEIQP VSVKVGDKVL LPEYGGTKVV LDDKDYFLFR  
 
       310        320        330        340        350        360  
DGDILGKYVD GGGAGQAFRK FLPLFDRVLV ERSALCDDPR VDRWYCQFVE GKVLQATVVA  
 
       370        380        390        400        410        420  
VGSGSKGKGG EIQPVSVKVG DKVLLPEYGG TKVVLDDKDY FLFRDGDILG KYVDGGGAGQ  
 
       430        440        450        460        470        480  
AFRKFLPLFD RVLVERSALC DDPRVDRWYC QFVEGKVLQA TVVAVGSGSK GKGGEIQPVS  
 
       490        500        510        520        530        540  
VKVGDKVLLP EYGGTKVVLD DKDYFLFRDG DILGKYVDGG GAGQAFRKFL PLFDRVLVER  
 
       550        560        570        580        590        600  
SALCDDPRVD RWYCQFVEGK VLQATVVAVG SGSKGKGGEI QPVSVKVGDK VLLPEYGGTK  
 
       610        620        630        640        650        660  
VVLDDKDYFL FRDGDILGKY VDGGGAGQAF RKFLPLFDRV LVERSALCDD PRVDRWYCQF  
 
       670        680        690        700        710        720  
VEGKVLQATV VAVGSGSKGK GGEIQPVSVK VGDKVLLPEY GGTKVVLDDK DYFLFRDGDI  
 
 
LGKYVD  
Theoretical pI/Mwt: 6.62 / 79140 Da (per heptamer) 
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11. CPMyc  
        10         20         30         40         50         60  
MAGQAFRKFL PLFDRVLVER SAEQKLISEE DLGKVLQATV VAVGSGSKGK GGEIQPVSVK  
 
        70         80         90  
VGDKVLLPEY GGTKVVLDDK DYFLFRDGDI LGKYVD  
Theoretical pI/Mwt: 5.39 / 10446 Da (per monomer) 
 
12. CPMycP1  
        10         20         30         40         50         60  
MAGQAFRKFL PLFDRVLVER SAAAPEQKLI SEEDLPAAGK VLQATVVAVG SGSKGKGGEI  
 
        70         80         90        100  
QPVSVKVGDK VLLPEYGGTK VVLDDKDYFL FRDGDILGKY VD  
Theoretical pI/Mwt: 5.39 / 10924 Da (per monomer) 
 
13. CP7CD44-P1 
        10         20         30         40         50         60  
MAGQAFRKFL PLFDRVLVER SAAAPFNLPL PSRPLLRPAA GKVLQATVVA VGSGSKGKGG  
 
        70         80         90        100  
EIQPVSVKVG DKVLLPEYGG TKVVLDDKDY FLFRDGDILG KYVD  
Theoretical pI/Mwt: 9.52 / 11144 Da (per monomer) 
 
14. CP11bFGF-P1 
        10         20         30         40         50         60  
MAGQAFRKFL PLFDRVLVER SAAAPPLLQT LGGGSPAAGK VLQATVVAVG SGSKGKGGEI  
 
        70         80         90        100  
QPVSVKVGDK VLLPEYGGTK VVLDDKDYFL FRDGDILGKY VD  
Theoretical pI/Mwt: 8.96 / 10663 Da (per monomer) 
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15. CR2-VEGF1-P2 
        10         20         30         40         50         60  
MAGQAFRKFL PLFDRVLVER SAPPITMQIM RIKPHQGQHI GEMSFPPGKV LQATVVAVGS  
 
        70         80         90        100        110  
GSKGKGGEIQ PVSVKVGDKV LLPEYGGTKV VLDDKDYFLF RDGDILGKYV D  
Theoretical pI/Mwt: 9.26 / 12114 Da (per monomer) 
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Appendix 2 
 
 
  
Representation example shows PCR product of hCpn10 (+ve, control), CE76, CE76P1, and FH-CE76, 
respectively, using HyperLadder
™ 
100 bp standard. Red ovals illustrate a correct bp size. 
 
 
 
 
Representation example shows cPCR of transformed cells with ligated product. (A) cPCR product 
of CE76P1 (from 1-13 colony), and (B) cPCR product of CPMycP1 (from 1-10 colony). Using 
HyperLadder™ 100 bp standard. Yellow ellipses were (+ve) controls and red ellipses illustrated 
colony with positive oligonucleotide sizes. 
 
 
  L  +ve  1   2    3    4   5    6   7    8   9   10 11 12  13 
L  +ve 1    2   3   4    5    6    7    8   9  10   
       L          +ve         1    2    3     1    2    3      1     2    3  
bp 
500— 
300— 
 
100— 
bp 
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300— 
 
100— 
bp 
500— 
300— 
 
100— 
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Example of protein expression of CE76 induced by 0.04 mM IPTG during log-phase and confirmed 
by SDS-PAGE. M: SeeBlue
®
 Plus2 Mwt standard, T0: pre-induction, T1-T3: post-induction.   
 
      
Example of protein expression of FH-CE76 induced by 0.04 mM IPTG during log-phase and 
confirmed by SDS-PAGE. M: SeeBlue
®
 Plus2 Mwt standard, T0: pre-induction, T1-T3: post-induction.   
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Example of SE-HPLC stack chromatograms of CE76P2 stored for 30 days at -20, 4, and 25 °C, 
respectively. By using Agilent
™
 1200 HPLC system and Tosoh
™ 
TSK column and chromatograms 
were stacked to illustrated protein CE76P2 solubilities, stabilities, and degradations.   
 
 
Respresination of CE76P1 denaturing and refolding study by DSC. This is a preliminary result 
from a single run and not verified.  
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Appendix 3  
 
 
Snapshots of hCpn10 MD simulations over 1 ns duriation. Show overlaid monomer protein backbone 
during last 700 ps simulation taken every 50 ps. The monomer structures range from initial (red) to 
the final structure (blue), showing in two different views. 
 
 
Snapshots of CE76 MD simulations over 1 ns duriation. Show overlaid monomer protein backbone 
during last 700 ps simulation taken every 50 ps. The monomer structures range from initial (red) to 
the final structure (blue), showing in two different views. 
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Snapshots of CE76 over 1 ns duriation MD simulations. Show only initial and final of CE76 monomer 
in space-filling during last 700 ps simulation.    
 
 
Snapshots of CPMyc over 1 ns duriation MD simulations. Show only initial and final of CPMyc 
monomer in space-filling during last 700 ps simulation.  
  
Initial  Final  
Initial  Final  
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Sanapshots of CMyc over 1 ns duration MD simulation. Shows overlaid monomer backbone of the 
last half of 700 ps simulation taken every 50 ps. The monomer structures range from initial (red) to 
the final structure (blue). 
 
 
Overlaied wt Cpn10 X-ray monomer “U” from PDB ID. 1WE3 and the final structure of CE76 form 1 
ns MD simulations. CE76 is coloured according to secondary structure (red: helix, yellow: strands, 
and green: loops), and wt Cpn10 (1WE3, cyan).  
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MD simulation of CE76P1 full length in ε=78.5 over 1 ns duration. The CE76-P1 monomer simulated is 
shown in a coloured ribbon representation: the β-sheet of the protein core is show in yellow, turns are 
shown in cyan and random conformations are show as a white ribbon. A wt Cpn10 (1WE3) monomer 
is shown in red and is located in an orientation and position necessary for a wt Cpn10 or it variant to 
form heptamer. The mobile loops are located towards the bottom of the figure. The red protein was 
not included in the simulation.  
 
MD simulation of CE76P1 with the His-tag removed in ε=78.5 over 1 ns duration. The CE76P1 
simulated monomer is shown in ribbon representation as a series of snapshots from the simulation in 
40 ps intervals. The snapshots are coloured according to simulation time red (start) to blue (end). 
CE76P1 was overlaid onto a hypothetical heptameric wt Cpn10 (1WE3) structure which was not 
included in simulation. CE76P1 monomer is located in a cut-out of the heptamer to estimate the ability 
to form heptamers.  
 207 
 
MD simulation of CE76P1 in ε=40 over 1 ns duration. The CE76P1 simulated monomer is shown in 
ribbon representation as a series of snapshots from the last 100 ps simulation in 10 ps intervals. The 
snapshots are coloured according residue number: green (N-terminus) to blue (C-terminus).  
 
 
MD simulation of CE76P2 in ε=78.5 with His-tag removed over 1 ns duration. The CE76P2 simulated 
monomer is shown in ribbon representation as a series of snapshots from the last 100 ps simulation in 
10 ps intervals. The snapshots are coloured according to simulation time from light to dark blue.  
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MD simulation of CE76P2 full length in ε=40 over 1 ns duration. The CE76P2 simulated monomer is 
shown in ribbon representation as a series of snapshots from the last 100 ps simulation in 10 ps 
intervals. The snapshots are coloured according to simulation time from light to dark blue.  
 
 
MD simulation of CE76P2 in ε=40 over 1 ns duration. Same as above Fig., but the protein is rotated by 
90° around the horizontal axis to allow a view from “bottom” the potential hexameric structure.  
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MD simulation of CE76E5 in ε=78.5 over 1 ns duration. The CE76E5 simulated monomer is shown in 
ribbon representation as a series of snapshots from the last 100 ps simulation in 10 ps intervals. The 
snapshots are coloured according to simulation time from white to dark blue.  
 
 
MD simulation of CE76E5 in ε=78.5 over 1 ns duration. Similar to above Fig., but the protein is 
rotated by 90° around the horizontal axis to allow a view from “underneath” the potential hexameric 
structure. 
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MD simulation of CE76E5 in ε=78.5 without His-tag over 1 ns duration. The CE76E5 simulated 
monomer is shown in ribbon representation as a series of snapshots from the last 100 ps simulation in 
10 ps intervals. The snapshots are coloured according to simulation time from light to dark blue.  
 
 
MD simulation of CE76E5 in ε=40 over 1 ns duration. The CE76E5 simulated monomer is shown in 
ribbon representation as a series of snapshots from the last 100 ps simulation in 10 ps intervals. The 
snapshots are coloured according to simulation time from light to dark blue.  
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MD simulation of CPMycP1 in ε=78.5 without His-tag over 1 ns duration. The CPMycP1 simulated 
monomer is shown in ribbon representation as a series of snapshots from the last 100 ps simulation in 
10 ps intervals. The snapshots are coloured according to simulation time from light to dark blue.  
 
 
MD simulation of CPMycP1 in ε=40 over 1 ns. The CPMycP1 simulated monomer is shown in ribbon 
representation as a series of snapshots from the last 100 ps simulation in 10 ps intervals. The 
snapshots are coloured according to residue sequence number time from green (N-terminus) to blue 
(C-terminus).  
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Appendix 4 
 
 
Anticoagulant Effect of CE76P1 vs E-76 peptide (control) on the clot generation time (R-time) by TEG 
using human blood. Blood clotting initiated by Thromborel
® 
S and Ca
2+
. Uninhibited clotting times 
were 100 sec.  
 
 
 
Chromogenic assays for determination the CE76P1 median inhibition concentration (IC50) for FX.  
CE76P1 IC50 = 1.4994 ±0.4763 nM. 
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